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Worldwide, over 403.000 individuals were diagnosed with kidney cancer in 20181. This 
accounts for 2-3% of all newly diagnosed cancers, which makes kidney cancer the 14th most 
common cancer in the world. The incidence of kidney cancer is twice as high in men as in 
women2, 3. In addition, the incidence increases steadily with age, with the peak incidence 
at approximately 75 years2. The age-standardised incidence rate (according to the World 
standard population; ASR) of kidney cancer is reported to be particularly high in more 
developed regions (9.4 per 100.000), including The Netherlands, when compared to less 
developed regions (ASR <1 per 100,000)1.
 
More than 90% of malignancies in the kidney are comprised of carcinoma of the renal 
parenchyma or renal cell carcinoma (RCC). The ASR of RCC in The Netherlands has been 
increasing steadily from 6.0 per 100,000 in 1989 to 7.3 per 100,000 in 2007 and has since 
stabilised (7.3 per 100,000 in 2017)4. The initial rise in incidence has largely been attributed 
to the more widespread use and the improvement of imaging techniques such as computed 
tomography (CT) and ultrasonography5-7.
Tumour histology
Renal cell carcinoma can be classified into several histopathological entities with distinct 
pathological and genetic characteristics. Clear cell RCC (ccRCC; 70-80%) and papillary 
RCC (pRCC; 10-17%) account for the majority of all RCC occurrences8. The other RCCs are 
comprised of chromophobe RCC (chRCC; 5-8%), and various other less frequent subtypes 
(<1%)8, 9. 
 
Clear cell RCC is thought to arise from epithelial cells in the proximal convoluted renal tubule 
and are characterised by their optically clear cytoplasm10. Clinically, the prognosis of ccRCC 
is largely dependent on the clinical characteristics at diagnosis. This is often exemplified by 
the TNM Classification of Malignant Tumours (TNM), in which information on tumour size 
and extension (T), lymph node involvement (N) and distant metastasis (M) can be used to 
classify tumours by anatomical stage. Stage I ccRCC has a 5-year survival of 86%, while 
stage IV ccRCC has a 5-year survival of 18%11. In addition, other features such as tumour 
grade, necrosis, sarcomatoid/rhabdoid differentiation and microvascular invasion can be used 
as prognostic parameters to predict the cancer-specific survival of patients12. 
Papillary RCC is thought to have a better 5-year survival rate and, in turn, a lower malignant 
potential, when compared to ccRCC10, 13, 14. Papillary renal cell carcinoma is generally 
subdivided into two morphologically distinct subtypes, type 1 and type 2 pRCC. Type 1 
pRCC is often multifocal and further characterised by papillae and tubular structures, covered 
with small cells containing pale cytoplasm and small, uniform, oval nuclei15. Type 2 pRCC 
is characterised by papillae covered with large cells containing eosinophilic cytoplasm and 
large, spherical nuclei15. Clinically, type 1 pRCC generally presents with a lower tumour 
grade and stage compared to type 2 pRCC, and is thought to have a better overall survival 
and a less aggressive nature14-16. However, understanding the prognostic implications of the 
distinction between type 1 and type 2 pRCC remains challenging as results on the prognosis 






Tumour genetics of ccRCC
Cancer is caused by the gradual accumulation of DNA damage in an individual cell during 
a person’s life. As such, these particular mutations are not transmitted from one generation 
to the other, but transmitted to all cells descending from the mutated cell18. This provides 
cancer researchers the opportunity to use DNA mutations as a marker to identify the steps 
that contributed to the development of cancer. Mutations in driver genes may lead to the 
reprogramming of cell growth, the breakdown of genomic maintenance systems and the 
reprogramming of cell metabolism, which may result in abnormal cell growth19.
The most characteristic features of ccRCC are the functional loss of VHL, and the loss of the 
short arm of chromosome 3 (3p), with an incidence of over 90% in primary ccRCC20. VHL 
was originally identified through studies on the hereditary von Hippel-Lindau syndrome21. 
In this syndrome, the inactivation of the remaining copy of VHL through somatic mutations, 
gene silencing or deletion, in addition to an already present germline mutation of the other 
allele, was discovered as a characteristic factor in the development of ccRCC21. Due to the 
presence of a germline VHL mutation, only a VHL mutation in the remaining allele in any 
of the proximal epithelial cells of the kidney suffices to initiate the development of ccRCC. 
Thus, 90% of the individuals with the von Hippel-Lindau syndrome tend to develop renal 
tumours before the age of 65, with a mean age of RCC development of approximately 40 
years22-24. Mutations in VHL have also been implicated in sporadic ccRCC25. In keeping 
with Knudson’s two-hit hypothesis, sporadic RCC requires the inactivation of both parental 
VHL alleles26-28. However, not all individuals with sporadic ccRCC have a mutation in VHL, 
which suggests that involvement of other genes may also be involved in the aetiology of 
ccRCC8. Indeed, other tumour suppressor genes present on chromosome 3p besides VHL, 
namely PBRM1, BAP1 and SETD2, have been implicated in the development of ccRCC15. 
Furthermore, several other genetic alterations have been detected in various pathways, 
including the VHL/HIF-, and mTORC1-pathways and the SWI/SNF-complex29-31. 
Risk factors
Environmental exposures are thought to affect the somatic mutation rate32. By reducing the 
exposure to environmental factors that may enhance the mutation rate the probability that 
driver genes will become mutated may be reduced32. Therefore, identifying (modifiable) risk 
factors poses an opportunity for primary prevention strategies against cancer.
A multitude of modifiable risk factors has been investigated in relation to the overall risk of 
RCC. However, few risk factors have been consistently associated with RCC. Established 
modifiable risk factors for RCC include cigarette smoking, obesity and hypertension2, 31. 
Interestingly, while alcohol consumption is generally thought to increase cancer risk, it has 
been inversely associated with the risk of RCC31, 33. Overall, the effect estimates associated 
with these risk factors are often modest. However, due to the high prevalence of these risk 
factors in the population, the attributable risks are often sizable34.
Large meta-analyses evaluating the role of tobacco and cigarette smoke exposure have 
concluded that there is a clear indication of an association with RCC risk. Evidence from 
a meta-analysis, including evidence from 38 case-control studies and 22 cohort studies, 




current smokers 1.36 (1.19-1.56), when compared to non-smokers35. An earlier meta-analysis 
reported a strong dose-dependency in the RCC risk increase in both men and women, as well 
as a reduction in RCC risk with increasing duration of smoking cessation36. 
 
Being overweight or obese has also been indicated as major risk factor for RCC as well. 
Evidence from a dose-response meta-analysis, combining information from 21 cohort 
studies, indicated that overweight (Body Mass Index (BMI); between 25 and <30 kg/m2) was 
associated with an increased risk of developing RCC (pooled RR 1.28 (95%CI 1.24-1.33)), 
while the association of obesity (BMI ≥ 30 kg/m2) with the risk of RCC was stronger (1.77 
(95%CI 1.68-1.87), when compared to normal weight37.
 
There is a large body of evidence regarding the association between having a history of 
hypertension and the risk of RCC, although some controversy exists regarding the role of 
antihypertensive medication in this relationship38. Based on findings from a meta-analysis, 
which included 12 prospective studies, a positive association between hypertension and 
the risk of RCC was reported (pooled RR 1.67 (95%CI 1.46-1.90)38. Multiple studies 
have attempted to disentangle the effect of antihypertensive medication from the effect of 
hypertension39. One study reported an association between hypertension and kidney cancer, 
independent of antihypertensive use39. Another study reported that a positive association of 
antihypertensive use with RCC risk was only detected in combination with poorly controlled 
blood pressure39. Whereas, one study reported an increased risk in individuals who used 
antihypertensive medication40, others indicated that the effect of antihypertensive medication 
disappeared after correction for hypertension41, 42. These discrepancies highlight that there 
are still some knowledge gaps regarding the relationship between hypertension and the risk 
of developing RCC.
 
In strong contrast to most cancers, moderate alcohol consumption has been reported to be 
inversely associated with the risk of developing RCC (pooled RR 0.79 (95%CI 0.72-0.86))33. 
However, no further benefit was attained for levels above moderate alcohol consumption33. 
In fact, one meta-analysis reported that the beneficial reduction in RCC risk may already be 
attained at one alcoholic beverage per day43. Although the mechanisms behind this association 
are poorly understood some hypotheses regarding the effects of alcohol on insulin sensitivity, 
or its diuretic effect have emerged in the literature33, 44, 45.
While these factors have been associated in a plethora of epidemiological studies, the 
evidence for multiple other risk factors from prospective cohort studies is limited or lacking. 
As a result, many risk factors and their role in RCC carcinogenesis remain poorly understood.
Aside from these established and consistently associated risk factors multiple other potential 
risk factors have been implicated in the aetiology of RCC. As a result, potential opportunities 
for the prevention of RCC remain underrepresented in scientific literature. Among those 
risk factors are type 2 diabetes mellitus, kidney stones, physical activity and dietary factors, 
e.g. the intake of vegetables and fruits. The knowledge gap resides partially in the lack of 
extensive prospective cohort studies that have assessed these factors in relation to RCC, and 
partly in the difficulty of adequately assessing these risk factors. Evidence from large-scale 
prospective cohort studies on these potential risk factors may, therefore, provide additional 





mechanisms driving this cancer.
Aetiologic heterogeneity
In recent years, the aetiology of renal cell carcinoma is more often analysed by stratifying by 
histological subtype. Based on the aforementioned distinct clinical, pathological and genetic 
differences, it has been speculated that the RCC subtypes may possess distinct aetiologies. 
While the current evidence remains sparse, there are some indications for such aetiologic 
heterogeneity across RCC subtypes. The most prominent heterogeneity has been observed 
for BMI. Current evidence suggests a positive association between BMI and ccRCC, but 
no association was observed with pRCC46, 47. Furthermore, differences in the prevalence of 
ccRCC and pRCC have been found in current smokers48. However, other studies observed 
no etiologic heterogeneity regarding cigarette smoking46, 47. Moreover, based on the currently 
available scientific literature, no clear etiologic heterogeneity has been indicated for history 
of hypertension across ccRCC and pRCC risk46, 47. While no heterogeneity has been observed 
for hypertension, a potential heterogeneity exists regarding the use of antihypertensives49. In 
particular, pRCC was associated with long-term diuretics use and calcium channel blockers, 
while the reported associations for ccRCC were weaker49. These findings highlight the need 
for further research to bolster the evidence base for future preventative measures against 
RCC.
Molecular Epidemiology and RCC
Molecular epidemiology aims to establish the relationship between biomarkers on the one 
hand, and exposures, susceptibility and disease on the other18. In RCC, multiple molecular 
methods are being employed to learn more about the aetiologic makeup of RCC and its 
subtypes, and the mechanisms that drive the occurrence or prognosis of RCC. In this thesis, 
we have used information on germline variants, in addition to information on environmental 
exposures, to investigate gene-environment interactions and ccRCC risk.
Germline single nucleotide polymorphisms (SNPs)
As stated before, epidemiologic observations have implicated environmental factors 
in the development of cancer50. However, the exposure to environmental factors can not 
entirely explain cancer risk, indicating that there is a crucial role of genetic susceptibility 
among similarly exposed individuals50. This notion has led to the use of gene-environment 
interaction approaches, in which epidemiologists try to obtain better estimates of disease 
risks by accounting for the joint effect of genes and environmental exposures51, 52. One way 
to study this is by using single nucleotide polymorphisms (SNPs). SNPs are commonly 
occurring genetic variations present in the germline. When SNPs are present in a regulatory 
region of a gene they may affect the gene’s function or its expression level, which may 
lead to increased disease susceptibility51. The effects of these SNPs may be amplified upon 
interaction with a specific environmental exposure. These gene-environment interactions 
play a role in a large fraction of cancer cases in a population, due to the high frequency of 
their occurrence50. In (cc)RCC, multiple gene-environment interactions have already been 
identified that convey additional risk. For instance, such interactions have been observed 
for (cc)RCC risk regarding ADH7 and alcohol consumption53; AGTR, AGT and ACE and 
sodium and hypertension54; RXRA and calcium and vitamin D intake55; NAT2, CYP1A1 and 




the continuous detection of new susceptibility loci, more gene-environment interactions can 
be expected to be found. This may potentially lead to more insight in the population-based 
differences in cancer risk and into the mechanisms of carcinogenesis.
Somatic mutations
Large efforts have been made using next-generation sequencing techniques to characterize 
the genomic landscape of RCC of which the data is widely accessible using large open 
databases, such as The Cancer Genome Atlas (TCGA), the Catalogue of Somatic Mutations 
in Cancer (COSMIC) database and cBioportal16, 58-60. 
Through these efforts, a wealth of information is available on, among others, the occurrence of 
somatic mutations in ccRCC. Data generated by these large scientific collaborations indicates 
that VHL is the most frequently mutated gene in ccRCC (~52% mutated)29, 58. In addition to 
VHL, somatic mutations in other genes have also been implicated in ccRCC, namely PBRM1 
(30-33%), SETD2 (12-13%), BAP1 (10-13%), KDM5C (7%), MTOR (6-7%), TP53 (2-7%), 
and multiple less frequently mutated genes (<5%)29, 58. There are indications that somatic 
mutations also play a role in the prognosis of (cc)RCC61-66. For instance, somatic mutations in 
PBRM1 have been associated with a better overall survival for ccRCC66. Moreover, mutations 
in BAP1, SETD2, KDM5C and TP53 have been associated with an unfavourable prognosis 
of ccRCC61-63. 
The implications of the use of large databases in ccRCC research
There is a need for future research regarding the involvement of various mutations and 
pathways in ccRCC as there are some limitations involved in the use of large databases, such 
as the TCGA and COSMIC. For instance, information available in the TCGA is assembled 
mainly from a convenience sample of cancer patients, and although strict criteria were in 
place for eligibility, there appear to be differences in the general population with regards to 
age, race/ethnicity and clinical characteristics for the majority of cancers67. For renal cell 
carcinoma, an overrepresentation of stage 3 and 4 tumours and an underrepresentation of 
stage 1 tumours was observed, when compared to the U.S. population. This is likely related 
to the stringent inclusion criteria67. In addition, TCGA samples are primarily provided by 
U.S. academic institutions and, in part, derived from research and trials in these academic 
centres68, 69. As a result, this may limit the generalisability of findings to all patients as 
individuals treated in these institutions are generally younger, compared to the average 
cancer patient67. As the COSMIC database is largely built upon the sample information 
provided by the TCGA, a lot of the current scientific knowledge is driven by results from the 
TCGA58. Lastly, the TCGA was not originally designed to study risk factors or to perform 
survival analyses. Consequently, the completeness and accuracy of the information available 
on these factors is lower than in traditional epidemiologic studies and may warrant additional 
caution when interpreting results. Therefore, it is of great importance to further the current 
knowledge by using information from population-based prospective cohort studies with a 
long follow-up to obtain an accurate representation of the genomic landscape of cancer cases 
at the population-level.
 
In conclusion, the many aetiological mechanisms present in the development of RCC make 
it a complex disease to analyse. Furthermore, evidence from large prospective cohort studies 





histologic subtypes is currently lacking. Additional insight into the interplay of environmental 
factors and the genetic make-up may open up avenues for future research into the mechanisms 
driving the development of this cancer.
Rationale of this thesis
Using information from a large prospective cohort study we aimed to identify whether various 
environmental and genetic risk factors are differentially associated with the risk of specific 
subgroups of renal cell carcinoma. In addition, we investigated whether somatic mutations 
were associated with the prognosis of clear cell renal cell carcinoma.
Study design 
All studies within this thesis were conducted using information obtained through the 
NLCS. The NLCS was initiated in September 1986 with the inclusion of 120,852 men and 
women aged 55-69 years from 204 Dutch municipal population registries70. At baseline, all 
participants completed a mailed, self-administered questionnaire on dietary habits and other 
risk factors for cancer, including lifestyle factors, medical conditions and anthropometry. The 
questionnaire included a 150-item food frequency questionnaire that focused on habitual food 
consumption during the year preceding baseline. In addition to the baseline questionnaire, 
approximately 90,000 participants provided toenail clippings, which have shown to be a 
valid source of DNA for the genotyping of germline genetic variants71.
In the NLCS, a case-cohort design was used for efficiency in data processing, genotyping 
and follow-up for vital status. Cases were derived from the entire cohort, while a randomly 
selected subcohort of 5,000 participants was used to estimate person-time for the entire 
cohort70. Follow-up for cancer occurrence for all participants was conducted by computerised 
record linkage with the Netherlands Cancer Registry (NCR), the Dutch pathology registry 
(PALGA), and the causes of death registry maintained by Statistics Netherlands (CBS). The 
follow-up for vital status of the subcohort was nearly 100% complete after 20.3 years. The 
completeness of cancer follow-up is estimated to be over 96%72.
During the 20.3 years of follow-up, 608 RCC cases were identified. Cases with histologically 
confirmed epithelial RCC were eligible for the collection of formalin-fixed paraffin-embedded 
(FFPE) tumour tissue. In total 454 FFPE tumour blocks were collected from ~50 pathology 
laboratories throughout the Netherlands. Two experienced pathologists revised the tumour 
histology according to the WHO-classification of RCC tumours73. Further information on 
the clinical characteristics, such as age at diagnosis and tumour size, were obtained from 
pathological reports and the Netherlands cancer registry. Information on survival time was 
accomplished by record linkage with municipal population registries and the causes of death 
registry maintained by Statistics Netherlands (CBS). The identification of somatic mutations 
was performed using a targeted sequencing protocol for a panel of 42 genes implicated in 
ccRCC on DNA isolated from FFPE tumour blocks of 252 cases.
Thesis outline
In chapter 2 we describe the association of type 2 diabetes and its treatment with renal cell 
cancer risk. In chapter 3 and 4 we assessed the heterogeneity of associations across ccRCC 




between established risk factors for RCC and histologic subtypes of RCC, including cigarette 
smoking, body mass index, alcohol consumption and history of hypertension. Chapter 4 
details the association between kidney stones and ccRCC and pRCC risk. In addition, we 
describe the association between kidney stones at various localisations of upper tract urothelial 
carcinoma. In chapter 5, we studied the association between four germline polymorphisms 
on (cc)RCC risk. In addition, we assessed potential gene-environment interactions, gene-
gene interactions and the association between SNPs and VHL promoter methylation status. 
In chapter 6, we created a seven-gene mutational profile and assessed whether somatic 
alterations in these genes affected the cause-specific survival of RCC, taking into account 
patient characteristics and the co-occurrence of mutations. Lastly, in chapter 7, we discuss 
the implications of our results in light of the current literature and discuss future perspectives 
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At present, mostly case-control and retrospective studies have investigated the association 
between etiologic risk factors and the development of histologic subtypes of renal cell 
carcinoma (RCC). Therefore, we assessed the heterogeneity between body mass index (BMI), 
cigarette smoking, alcohol consumption and hypertension across clear-cell RCC (ccRCC) 
and papillary RCC (pRCC) risk in the prospective Netherlands Cohort Study on diet and 
cancer (NLCS). In 1986, 120,852 participants aged 55-69 completed a self-administered 
questionnaire on diet and other risk factors for cancer. Participants were followed-up for 
cancer through record linkage. Tumor histology was assessed through centralized revision by 
two experienced uropathologists. After 20.3 years of follow-up, 384 histologically verified 
RCC cases, including 315 ccRCC and 46 pRCC cases, and 4144 subcohort members were 
eligible for case-cohort analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) 
were estimated by multivariable-adjusted proportional hazards models. Overall, BMI was 
associated positively with ccRCC risk, but inversely with pRCC risk. Cigarette smoking was 
associated with an increased ccRCC, but a decreased pRCC risk. Alcohol consumption was 
inversely associated with both ccRCC and pRCC risk. Hypertension was associated with an 
increased risk of both ccRCC and pRCC. Statistically significant etiologic heterogeneity was 
observed for BMI, BMI change since age 20, and smoking duration in current smokers across 
ccRCC and pRCC risk. In conclusion, we observed potential heterogeneity for BMI, BMI 
change and smoking duration across ccRCC and pRCC risk.





Kidney cancer consists primarily of adenocarcinomas that arise in the renal parenchyma, 
commonly referred to as renal cell carcinomas (RCC) 1. RCC is comprised of various entities 
defined by a distinct tumor histology, chromosomal alterations and molecular pathways 2. 
The most common subtypes are clear cell (approximately 70% of all RCC) and papillary 
renal cell carcinoma (10-15%) 2.
 
Established modifiable risk factors for RCC include cigarette smoking, excess body weight and 
hypertension 3-8. Furthermore, alcohol consumption has been associated with a decreased RCC 
risk in multiple prospective epidemiological studies 9, 10. Even though histological subtypes 
of RCC have been formally recognized for more than two decades 11, data on etiologic risk 
factors linked to these subtypes remains sparse 1. Previous studies have found evidence for a 
potential heterogeneity between the risk of ccRCC and pRCC for body mass index 12-15, and 
antihypertensive medication 16. At present, no histological heterogeneity has been found in 
relation to cigarette smoking or hypertension status 12, 14. Lastly, to our knowledge, no studies 
have directly assessed the etiologic risk heterogeneity between alcohol consumption and 
histologic RCC subtypes yet. The current available evidence on the heterogeneity between 
histologic RCC subtypes for these modifiable risk factors is solely based on information from 
(nested) case-control studies 12-14, 16 and three retrospective studies 15, 17, 18. Additional evidence 
from large-scale prospective cohort studies may aid in uncovering potential heterogeneity 
between these established risk factors and ccRCC and pRCC development.
In the Netherlands Cohort Study (NLCS) on diet and cancer, a large nationwide prospective 
cohort study, we were able to assess tumor histology through a centralized revision by two 
experienced pathologists. With this information, we aimed to investigate the heterogeneity 
of associations between ccRCC and pRCC for the main established etiologic risk factors of 
RCC, namely BMI, cigarette smoking, alcohol consumption and hypertension.
Methods
Study population
The NLCS is a nation-wide prospective cohort study initiated in September 1986 with the 
inclusion of 58,279 men and 62,573 women between the ages of 55-69 years. The study 
design has been described in detail elsewhere 19. In short, the study is a prospective cohort 
study initiated to investigate the association between diet and cancer risk. A case-cohort 
design was used for efficiency in follow-up for vital status and data processing. A subcohort 
of 5000 participants, of which 2411 men and 2589 women, was randomly sampled from the 
full cohort at baseline to estimate person-time at risk for the entire cohort. All participants 
were followed up by computerized record linkage with the Netherlands Cancer Registry 
(NCR), the Netherlands Pathology Registry (PALGA), and cause of death from Statistics 
Netherlands (CBS). In addition, participants were regularly followed up for migration and 
vital status. Follow-up for vital status of the subcohort was nearly 100% complete after 20.3 
years and the completeness of cancer follow-up through record linkage is estimated to be 
over 96% 20. The institutional review boards of Maastricht University (Maastricht) and the 
Netherlands Organization for Applied Scientific Research TNO (Zeist) approved the NLCS. 
The NLCS was conducted in accordance with the Declaration of Helsinki. By completing 




In total, 608 RCC cases were identified within the NLCS between 1986 and 2006. 
Histologically confirmed RCC cases were eligible for the collection of formalin-fixed 
paraffin-embedded (FFPE) tumor tissues. Overall, FFPE tumor tissues were collected for 
454 (79.8%) of the 568 eligible cases 21. Tumor histology was revised by two experienced 
pathologists according to the WHO-classification of RCC tumors 2. Of the 454 RCC cases, 
366 (80.6%) were clear-cell (cc)RCC cases, 60 (13.2%) papillary (p)RCC cases, 15 (3.3%) 
chromophobe RCC cases, and 13 (2.9%) other or undefined RCC cases. Further classification 
of pRCC cases resulted in 35 (7.7%) type 1 pRCC, 24 (5.3%) type 2 pRCC, and 1 (0.2%) 
undefined pRCC. To maintain sufficient power in the analyses, type 1 and type 2 pRCC were 
combined into one category. Chromophobe RCC and other or undefined RCC cases were not 
assessed due to the insufficient number of cases.
Cohort members with prevalent cancer at baseline, except skin cancer, and incomplete 
or inconsistent information on exposure variables and a priori selected confounders were 
excluded from analyses. In total, 515 RCC cases (International Classification for Oncology 
3: C64.9) and 4144 subcohort members were included in the analyses. Of the 384 included 
RCC cases with confirmed tumor histology 315 (82.0%) were ccRCC cases and 46 (12.0%) 
were pRCC cases.
Exposure assessment
All participants completed a mailed, self-administered questionnaire at baseline on dietary 
habits and other risk factors for cancer. By completing and returning the baseline questionnaire, 
individuals agreed to participate in the NLCS. From this questionnaire information was 
derived on anthropometric measures, smoking habits, dietary habits and medical conditions.
Baseline BMI (kg/m2) was calculated using weight at baseline and the self-reported height 
squared. To calculate the BMI at age 20, the self-reported weight at age 20 was used in 
combination with the self-reported height at baseline. Change in BMI since age 20 
was calculated by subtracting the BMI at age 20 from the BMI at baseline. In addition, 
men reported their trouser size and women reported their skirt size as a proxy for body 
composition 22. Questions on cigarette, cigar and pipe smoking were used to assess smoking 
status, smoking quantity and smoking duration. Questions on beer, red wine, white wine, 
sherry, fortified wines, liqueur, and liquor were used to assess the consumption of alcohol. 
Participants who consumed alcoholic beverages less than once a month were considered 
non-users. Standard glass sizes were defined as 200 ml for beer, 105 ml for wine, 80 ml 
for sherry, and 45 ml for both liqueur and liquor 23. These values corresponded to 8, 10, 11, 
7 and 13 grams of alcohol, respectively. Mean daily alcohol consumption was calculated 
by multiplying the consumption frequency and the standardized item unit of each alcoholic 
beverage. Information from the questionnaire was also used to define stable abstainers and 
stable users of alcohol. Stable abstainers were defined as participants that reported no alcohol 
consumption 5 years before baseline. Stable users were defined as participants who reported 
that they drank equal amounts of alcoholic beverages 5 years before baseline. The diagnosis 
of hypertension was derived from a question on whether the participant was diagnosed with 
hypertension preceding baseline by a physician. In addition, participants were asked to report 
the use of any drugs for a period longer than 6 months. From this information, the use of 
antihypertensive medication was extracted.





Cox proportional hazard models were used to estimate sex-adjusted and multivariable-adjusted 
Hazard Ratio’s (HRs) and 95% confidence intervals (CIs). Stata statistical software: release 15 
(StataCorp., 2017, College Station, TX) was used for all analyses. Analyses were adjusted for 
smoking status (never/former/current), smoking duration (y, continuous, centered), smoking 
frequency (cig/d, continuous, centered), pipe and/or cigar smoking (never/former/current), 
alcohol consumption (g/d, continuous), body mass index (kg/m2, continuous), diabetes status 
(no/yes) when applicable. Analyses on BMI change were additionally adjusted for BMI at 
age 20. As proposed by Leffondré et al. 24, smoking duration and smoking frequency were 
centered to avoid multicollinearity with smoking status. Analyses on smoking cessation 
were additionally adjusted for cigarette-years, calculated by multiplying smoking frequency 
with smoking duration, to resolve multicollinearity between smoking duration and smoking 
cessation. Fruit consumption, vegetable consumption and use of antihypertensive medication 
were included in models as potential confounders if they altered HRs for RCC risk by more 
than 10%. None of these potential confounders satisfied this condition, and were, therefore, 
not included in models as a confounding factor. The use of antihypertensive medication was 
studied as a potential risk factor based on findings from previous studies 5, 25.
Person-years at risk were calculated from baseline until registration of RCC or until date of 
censoring by death, emigration, loss to follow-up or end of follow-up, whichever occurred 
first. The proportional hazards assumption was tested with scaled Schoenfeld residuals and 
log-log curves. The proportional hazard assumption was violated for age, BMI and smoking 
frequency when using time-on-study as timescale. To resolve this issue, age-on-study was 
used as timescale with smoking frequency as a time-varying covariate. Standard errors 
were calculated using the robust Huber-White sandwich estimator, similar to the variance-
covariance estimator by Barlow 26, to account for additional variance introduced by sampling 
a subcohort from the full cohort.
Test for heterogeneity of associations were performed to evaluate differences between 
ccRCC and pRCC risk for all etiologic risk factors using the competing risks procedure in 
Stata. P-values were calculated with a method developed for the case-cohort design based on 
bootstrapping. This procedure has been described in more detail elsewhere 27, 28. All tests were 
performed two-sided and P-values <0.05 were considered statistically significant.
Results
The age at baseline of RCC cases was slightly lower, compared to the subcohort (Table 
1). In addition, RCC cases were predominantly men, had a slightly increased mean BMI 
at baseline, BMI at age 20 and trouser and skirt size, were more often current and former 
smokers, consumed more alcohol and more often reported a diagnosis of hypertension and 
anti-hypertensive medication use, compared to the subcohort. Compared to ccRCC cases, 
papillary RCC cases, were more often men, had a lower BMI at baseline, had a lower trouser 
and skirt size, were more often former cigarette smokers and pipe or cigar smokers, had a 
higher cigarette smoking duration and frequency, and consumed less alcohol.
 
Overall, results between sex-adjusted and multivariable-adjusted cox-regression models 




supplements (Supplementary Tables 1.1 – 1.4).
Table 1 - Baseline characteristics of the subcohort and Renal Cell Carcinoma cases in the 
Netherlands Cohort Study on diet and cancer, 1986-2006
Subcohort Renal Cell Carcinoma
Baseline characteristics: Overall ccRCC pRCC
Total, (n) 4144 515 315 46
Age at baseline, (years) 61.3 (4.2) 60.9 (3.9) 60.7 (3.9) 61.1 (3.9)
Male sex, (n, %) 2039 (49.2) 337 (65.4) 200 (63.5) 40 (87.0)
Body Mass Index at baseline, (kg/m2) 25.0 (3.1) 25.4 (3.0) 25.5 (3.0) 24.6 (2.2)
Body Mass Index at age 20, (kg/m2) 21.5 (2.6) 21.7 (2.6) 21.9 (2.7) 21.7 (2.1)
Trouser size in men at baseline, (size) 51.5 (4.3) 52.1 (3.1) 52.2 (3.4) 51.6 (2.7)
Skirt size in women at baseline, (size) 43.5 (3.0) 44.3 (3.0) 44.2 (2.7) 42.8 (1.8)
Cigarette smoking status, (n, %)
Never smokers 1524 (36.8) 136 (26.4) 85 (27.0) 10 (21.7)
Former smokers 1466 (35.4) 219 (42.5) 136 (43.2) 22 (47.8)
Current smokers 1154 (27.9) 160 (31.1) 94 (29.8) 14 (30.4)
Ever cigarette smokers only
Smoking duration, (years) 31.8 (12.2) 32.1 (12.0) 31.7 (11.9) 36.5 (10.6)
Smoking frequency, (cig/d) 15.4 (10.3) 17.1 (12.2) 16.5 (11.5) 18.0 (12.0)
Pipe and/or cigar smoking
Never pipe or cigar smoker, (n, %) 3559 (85.9) 414 (80.4) 248 (78.7) 32 (69.6)
Former pipe or cigar smoker, (n, %) 308 (7.4) 66 (12.8) 43 (13.7) 10 (21.7)
Current pipe or cigar smoker, (n, %) 277 (6.7) 35 (6.8) 24 (7.6) 4 (8.7)
Alcohol intake, (g/d)a 13.5 (15.1) 15.2 (15.3) 15.0 (15.0) 13.8 (12.3)
Diagnosis of hypertension, (n, %) 1093 (26.4) 161 (31.3) 99 (31.4) 16 (34.8)
Use of antihypertensive medication, 
(n, %) 856 (20.7) 124 (24.1) 80 (25.4) 11 (23.9)
Abbreviations: ccRCC: clear cell Renal Cell Carcinoma, pRCC: papillary Renal Cell Carcinoma
a In consumers only.
BMI
In multivariable-adjusted analyses, a positive association was observed between BMI and 
RCC risk (Table 2). Furthermore, we observed an U-shaped association between BMI at age 
20 and RCC risk. BMI change per one kg/m2 increment since age 20 was associated with a 
non-statistically significantly increased RCC risk. Trouser and skirt size were associated with 
an increased risk of RCC across increasing size categories (p-trend: 0.02, 0.005 for trouser 
and skirt size, respectively).
In general, an increasing ccRCC risk was observed across increasing BMI categories. The 
strength of the associations was slightly elevated compared to associations observed for 
overall RCC risk. In addition, a statistically significantly increased risk was found per one kg/
m2 increase (HR 1.04, 95%CI 1.01-1.08). For pRCC risk, associations became increasingly 
inverse across increasing BMI categories. A borderline significant inverse association was 
found for pRCC per kg/m2 increase (HR 0.91, 95%CI 0.82-1.00). We observed statistically 
significant heterogeneity across ccRCC and pRCC for baseline BMI (per kg/m2; pheterogeneity: 
0.02). Furthermore, an U-shaped association was found between BMI at age 20 and ccRCC, 




while no clear association was found for pRCC. Furthermore, an increase in change in 
BMI since age 20 was associated with an increase in risk for ccRCC, and a decrease in 
pRCC risk. These differences in BMI change since 20 were statistically significant in tests 
for heterogeneity (pheterogeneity: 0.03). Trouser size in men was associated with a statistically 
significantly increased ccRCC risk per size increase, while no association was found with 
pRCC risk. However, no heterogeneity of associations was observed (pheterogeneity: 0.18). No 
analyses were performed for skirt size in pRCC, because of the limited number of female 
pRCC cases (n=5).
Table 2 - Multivariable-adjusted Cox proportional hazard models with age as timescale for 
the association between Body Mass Index (BMI) and risk of clear-cell Renal Cell Carcinoma 
and papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and cancer, 
1986-2006
clear-cell Renal Cell 
Carcinoma








years No. HR 95% CI No. HR 95% CI
hetero-
geneityb
BMI at baseline (kg/m2)
<23 16723 55 1 Ref. 11 1 Ref.
23-<25 21298 90 1.14 (0.81-1.63) 18 0.92 (0.42-2.04)
25-<27 16372 81 1.30 (0.90-1.86) 10 0.60 (0.24-1.48)
≥27 15477 89 1.61 (1.13-2.30) 7 0.50 (0.19-1.33) 0.62 f
p trend 0.005 0.09
Cont. 
(per kg/m2) 69871 315 1.04 (1.01-1.08) 46 0.91 (0.82-1.00) 0.02
BMI at age 20 (kg/m2) c
<20.0 15384 61 1.39 (0.93-2.09) 6 0.75 (0.26-2.17)
20.0-<21.5 14576 45 1 Ref. 9 1 Ref.
21.5-<23 14558 67 1.50 (1.01-2.23) 10 1.08 (0.42-2.83)
≥23 15549 85 1.76 (1.21-2.57) 8 0.77 (0.29-2.04) 0.56
p trend 0.05 0.98
Cont.
(per kg/m2) 60067 258 1.05 (1.00-1.10) 33 1.01 (0.90-1.13) 0.70
BMI change since age 20 (kg/m2) d
<1.5 14892 60 1 Ref. 8 1 Ref.
1.5-<3.5 16693 73 1.08 (0.75-1.57) 16 1.31 (0.50-3.43)
3.5-<5.5 13659 58 1.15 (0.77-1.72) 7 0.69 (0.22-2.14)
≥5.5 14823 67 1.34 (0.89-2.02) 2 0.16 (0.03-0.82) 0.80
p trend 0.15 0.005
Cont. 
(per kg/m2) 60067 258 1.03 (0.99-1.08) 33 0.89 (0.75-0.98) 0.03




Table 2 - Continued
clear-cell Renal Cell 
Carcinoma









years No. HR 95% CI No. HR 95% CI
hetero-
geneityb
Trouser size - Men
<50 4745 26 1.16 (0.68-1.99) 8 1.86 (0.62-5.59)
50-<52 6736 32 1 Ref. 6 1 Ref.
52-<54 10137 63 1.31 (0.84-2.04) 12 1.13 (0.42-3.07)
54-<56 5553 41 1.54 (0.95-2.51) 8 1.46 (0.51-4.17)
≥56 2756 24 1.90 (1.09-3.33) 3 0.98 (0.23-4.11) 0.94
p trend 0.03 0.57
Cont. 
(per size) 29928 186 1.06 (1.01-1.12) 37 1.00 (0.95-1.05) 0.18
Skirt size - women e
<42 7012 15 0.87 (0.45-1.69) 1 -
42-<44 9372 24 1 Ref. 1 1
44-<46 10272 31 1.16 (0.67-2.01) 3 -
46-<48 6529 27 1.52 (0.87-2.67) 0 -
≥48 3774 17 1.55 (0.81-2.98) 0 - -
p trend 0.04 -
Cont.
(per size) 36958 114 1.07 (1.01-1.13) 5 - -
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered) smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/current), 
hypertension status (no/yes), alcohol consumption (g/d, continuous), diabetes (no/yes), models included 
a time-varying covariate for smoking frequency because of a potential violation of the proportional 
hazards assumption
b Based on multivariable-adjusted models
c Analysis with BMI at age 20 have a restricted number of cases due to missing values
d Additionally adjusted for BMI at age 20
e Not adjusted for pipe and/or cigar smoking due to unstable estimates for these confounding factors
f Models failed to converge more than 10 times during heterogeneity analyses (1000 replications). 
Models and intrinsic standard errors are based solely on successful bootstraps.
Cigarette smoking
In multivariable-adjusted models, cigarette smoking status was associated with an increased 
risk of RCC (Table 3). Associations persisted after adjustment for smoking frequency and 
duration. Restricting analyses to exclusively cigarette smokers strengthened associations 
in current cigarette smokers. No clear association was found with smoking duration and 
smoking frequency. Smoking cessation was associated with a decreased RCC risk in 
categorized analyses.
Similar to RCC overall, an increased ccRCC risk was found in both former (HR 1.26, 
95%CI 0.91-1.74) and current smokers (HR 1.41, 95%CI 1.01-1.97). Associations remained 
similar after adjusting for smoking frequency and duration, and when restricting analyses 




to exclusively cigarette smokers. No clear association was found between smoking status 
and pRCC risk. However, when restricting analyses to exclusively cigarette smokers, an 
inverse association with pRCC risk was found in former (HR 0.66; 95%CI 0.22-1.98) and 
current smokers (HR 0.46, 95%CI 0.11-1.90). Heterogeneity tests between ccRCC and 
pRCC risk were not able to provide reliable estimations for analyses on smoking status. No 
clear association was found between smoking frequency and smoking duration and ccRCC 
risk. An increased pRCC risk was observed in cases with increasing smoking frequency and 
duration, although not statistically significant. Statistically significant heterogeneity was 
observed for smoking duration in current smokers per 5-year increment (pheterogeneity: 0.04), 
but not in former smokers (pheterogeneity: 0.17). While there were indications for a decreased 
ccRCC and pRCC risk with increasing categories of duration of smoking cessation, solely 
analyses on pRCC risk suggested a potential inverse association per 5 years increase. Tests 
for heterogeneity did not show statistically significant differences across ccRCC and pRCC 
for smoking cessation (pheterogeneity: 0.98).
Table 3 - Multivariable-adjusted Cox proportional hazard models with age as timescale for 
the association between cigarette smoking and risk of clear-cell Renal Cell Carcinoma and 
papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and cancer, 1986-
2006
clear-cell Renal Cell 
Carcinoma









years No. HR 95% CI No. HR 95% CI
hetero-
geneityb
Unadjusted for cigarette smoking frequency and duration
Cigarette smoking status
Never 27409 85 1 Ref. 10 1 Ref.
Former 24499 136 1.26 (0.91-1.74) 22 0.84 (0.35-2.02)
Current 17963 94 1.41 (1.01-1.97) 14 1.08 (0.47-2.51) 0.73g
p trend 0.05 0.78
Never 27409 85 1 Ref. 10 1 Ref.
Former 24499 136 1.26 (0.90-1.78) 22 0.97 (0.39-2.46)
Current 17963 94 1.39 (0.98-1.97) 14 0.65 (0.24-1.77) 0.75g
p trend 0.06 0.39
Adjusted for cigarette smoking frequency and duration c
Cigarette smoking status
Never 26090 73 1 Ref. 9 1 Ref.
Former 19102 93 1.37 (0.95-1.97) 10 0.66 (0.22-1.98)
Current 15348 82 1.54 (1.07-2.22) 13 0.46 (0.11-1.90) 0.71g
p trend 0.02 0.28




Table 3 - Continued
clear-cell Renal Cell 
Carcinoma









years No. HR 95% CI No. HR 95% CI
hetero-
geneityb
Solely in exclusive cigarette smokers
Smoking frequency d
>0-<20 cig/d 21689 102 1 Ref. 10 1 Ref.
≥20 cig/d 12761 73 1.01 (0.72-1.42) 13 1.67 (0.68-4.10) 0.18
Cont. 
(per 5 cig/d), 
former smoker
19102 93 1.03 (0.92-1.16) 10 1.10 (0.83-1.47) 0.42
Cont. 
(per 5 cig/d), 
current 
smoker
15348 82 1.03 (0.93-1.14) 13 1.22 (0.91-1.64) 0.27
Smoking duration e
>0-<30 yrs 13701 65 1 Ref. 2 1 Ref.
≥30 yrs 20749 110 0.90 (0.62-1.32) 21 4.96 (1.19-20.7) -h
Cont. 
(per 5 yrs), 
former smoker
19102 93 1.03 (0.92-1.14) 10 1.67 (1.04-2.67) 0.17
Cont. 
(per 5 yrs), 
current 
smoker
15348 82 0.96 (0.85-1.08) 13 1.26 (0.63-2.51) 0.04
Number of years of smoking cessation f
Current 
smoker 15348 82 1 Ref. 13 1 Ref.
>0-<15 10444 53 0.91 (0.65-1.29) 7 0.76 (0.30-1.94)
≥15 8657 40 0.88 (0.59-1.33) 3 0.44 (0.12-1.64)






(per 5 yrs), 
former 
smokers
19102 93 0.98 (0.86-1.11) 10 0.87 (0.58-1.31) 0.98
a Additionally adjusted for: pipe and/or cigar smoking (never/former/current), Body Mass Index 
(continuous), hypertension status (no/yes), alcohol consumption (g/d, continuous), diabetes (no/yes), 
models included a time-varying covariate for smoking frequency because of a potential violation of the 
proportional hazards assumption
b Based on multivariable-adjusted models
c Additionally adjusted for cigarette smoking duration (years, centered) and cigarette smoking frequency 
(cig/d, centered)
d Additionally adjusted for smoking duration (years, centered)




e Additionally adjusted for smoking frequency (cig/d, centered)
f Additionally adjusted for cigarette-years
g Models failed to converge more than 10 times during heterogeneity analyses (1000 replications). 
Models and intrinsic standard errors are based solely on successful bootstraps.
h Estimates were unstable due to limited sample sizes in subcategories.
Alcohol
In multivariable-analyses, alcohol consumption was associated with a seemingly non-linear 
decreased risk of RCC, although not statistically significant (Table 4). In stable users and 
abstainers, associations were mostly inverse. The inverse association with RCC risk was 
the strongest in the category 5-<15 g/d, when compared to abstainers, in both analyses with 
all alcohol users and analyses with stable users and abstainers. HRs attenuated in categories 
above 15 g/d.
Associations were slightly stronger in analyses on ccRCC risk, compared to associations 
found for RCC overall. A non-linear association with ccRCC risk was found for alcohol 
consumption in stable alcohol users and abstainers. In analyses on pRCC risk, a seemingly 
non-linear association was observed with an increased pRCC risk at alcohol consumptions 
<15 g/d and a decreased pRCC risk at higher alcohol consumptions, when compared 
to abstainers. In stable alcohol users and abstainers, an inverse association was observed 
between alcohol consumption and pRCC risk. However, these analyses were performed on a 
very limited number of participants. Tests for heterogeneity of associations between ccRCC 
and pRCC were not able to provide reliable estimations for categorical analyses on alcohol 
consumption. No heterogeneity was observed between ccRCC and pRCC risk in continuous 
analyses (pheterogeneity range: 0.85-0.86).
Hypertension
In multivariable analyses, self-reported hypertension and the self-reported use of 
antihypertensive medication were associated with an increased RCC risk (table 5). Risk 
estimates were elevated in participants who reported both hypertension and the use of 
antihypertensive medication.
Similar to analyses on RCC overall, hypertension and the use of anti-hypertensive 
medication risks were consistently associated with an increased risk for both ccRCC and 
pRCC. The observed associations were the strongest with pRCC. Participants who reported 
both hypertension and the use of antihypertensive medication had a strongly elevated risk 
of both ccRCC and pRCC. Overall, tests for heterogeneity indicated no differences between 
ccRCC and pRCC risk regarding the self-reported hypertension and use of anti-hypertensive 




Table 4 - Multivariable-adjusted Cox proportional hazard models with age as timescale for 
the association between alcohol and risk of clear-cell Renal Cell Carcinoma and papillary 
Renal Cell Carcinoma in the Netherlands Cohort Study on diet and cancer, 1986-2006
clear-cell Renal Cell 
Carcinoma













Abstainer 16613 76 1 Ref. 7 1 Ref.
>0-<5 20731 79 0.77 (0.56-1.07) 13 1.42 (0.55-3.66)
≥5-<15 15589 64 0.71 (0.50-1.00) 14 1.48 (0.57-3.84)
≥15-<30 10810 63 0.86 (0.59-1.25) 8 0.89 (0.32-2.46)
≥30 6127 33 0.77 (0.49-1.23) 4 0.67 (0.19-2.36) 0.62 d
p trend 0.37 0.32
Cont. 
(per 5 g/d) 69871 315 0.98 (0.94-1.03) 46 0.94 (0.86-1.04) 0.85
Alcohol consumption among stable abstainers/users (g/d) c
Abstainer 12986 57 1 Ref. 7 1 Ref.
>0-<5 11867 46 0.86 (0.57-1.28) 6 0.81 (0.27-2.42)
≥5-<15 9435 42 0.87 (0.57-1.34) 6 0.86 (0.27-2.73)
≥15-<30 5832 38 1.09 (0.67-1.77) 3 0.58 (0.15-2.30)
≥30 3287 20 1.00 (0.55-1.83) 2 0.75 (0.14-3.93) - d
p trend 0.82 0.57
Cont. 
(per 5 g/d) 43407 203 1.00 (0.94-1.05) 24 0.99 (0.85-1.15) 0.86
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered), smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/current), 
hypertension status (no/yes), body mass index (kg/m2, continuous), diabetes (no/yes), models included 
a time-varying covariate for smoking frequency because of a potential violation of the proportional 
hazards assumption
b Based on multivariable-adjusted models
c Stable abstainers were defined as participants that reported no alcohol consumption 5 years before 
baseline. Stable users were defined as participants who reported that they drank equal amounts of beer 
or other alcoholic beverages 5 years before baseline.
d Models failed to converge more than 10 times during heterogeneity analyses (1000 replications). 
Models and intrinsic standard errors are based solely on successfull bootstraps.




Table 5 - Multivariable-adjusted Cox proportional hazard models with age as timescale 
for the association between hypertension and risk of clear-cell Renal Cell Carcinoma and 
papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and cancer, 1986-
2006
clear-cell Renal Cell 
Carcinoma













No 51868 216 1 Ref. 30 1 Ref.
Yes 18002 99 1.32 (1.02-1.69) 16 1.95 (1.03-3.67) 0.67
Use of antihypertensive medication
No 56463 235 1 Ref. 35 1 Ref.
Yes 13408 80 1.45 (1.10-1.91) 11 1.47 (0.70-3.08) 0.82
Hypertension status & use of antihypertensive medication
No hyp or no 
med 59848 251 1 Ref. 35 1 Ref.
Hyp and med 10023 64 1.56 (1.16-2.09) 11 2.41 (1.15-5.01) 0.62
Abbreviations: hyp: Hypertension status, med: use of medication.
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered), smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/
current), alcohol consumption (g/d, continuous), body mass index (kg/m2, continuous), diabetes (no/
yes), models included a time-varying covariate for smoking frequency because of a potential violation 
of the proportional hazards assumption





In this large-scale prospective cohort study we investigated the etiologic heterogeneity 
between BMI, smoking, alcohol consumption and hypertension across ccRCC and pRCC risk. 
We observed statistically significant heterogeneity of associations across ccRCC and pRCC 
for BMI, BMI change since age 20 and smoking duration in current smokers. We observed no 
heterogeneity across histologic subtypes for alcohol consumption and hypertension.
There is a growing body of evidence regarding a potential subtype-specific association 
between BMI and RCC risk. In multiple studies, an association with obesity was observed 
with ccRCC, and not with pRCC risk 12, 14, 29. In contrast, one study found no difference in 
BMI across the development of ccRCC and pRCC 15. Other studies, which only reported 
differences between the occurrence of clear-cell RCC versus other histologic RCC subtypes 
combined, also reported potential histologic differences related to obesity 13, 30, 31. In our 
study, we found evidence for heterogeneity across ccRCC and pRCC risk in continuous 
analyses for BMI at baseline, as well as for BMI change since age 20. Even though we did 
not observe statistically significant heterogeneity in categorical analyses, large differences 
in estimates were observed for BMI categories across ccRCC and pRCC risk. We report 
a similar association, compared to previous studies, between BMI and ccRCC risk. For 
pRCC risk, however, we observed consistent inverse associations regarding BMI, while 
previous studies found no association 12, 14, 29. This may due to the limited power of our pRCC 
analyses, as we report results with wide confidence intervals for pRCC. The consistent report 
of heterogeneity across multiple studies, does provide an indication of etiologic differences 
across RCC subtypes regarding BMI.
Several plausible mechanisms may explain the observed association between BMI and 
ccRCC risk specifically. Clear-cell RCC commonly harbors somatic mutations in the von 
Hippel-Lindau (VHL) tumor-suppressor gene 32. Inactivation of VHL leads to upregulation 
of the type 1 insulin-like growth factor receptor (IGF1R) in RCC cells 33. Obesity has been 
related to hormonal changes in the body, including an increase in circulating levels of 
insulin-like growth factor-1 (IGF-1) 34. IGF-1 strongly stimulates cell proliferation, inhibits 
apoptosis, and can enhance angiogenesis 35. Therefore, the inactivation of VHL in ccRCC 
and the obesity-related increase in IGF-1 may amplify the process of tumorigenesis. Another 
hypothesized mechanism may be the relationship between hypoxia and the development 
of ccRCC 36. Physiologically, the kidney is sensitive to perturbations in oxygen levels due 
to the activation of the VHL-HIF1A pathway 37. Somatic mutations in this pathway are 
known to lead to carcinogenesis due to defects in the hypoxia sensing mechanism, which is 
characteristic of ccRCC development 37. Therefore, it is hypothesized that chronic hypoxia 
may exert similar effects due to the repeated activation of the hypoxia sensing mechanisms 
36. Obesity may achieve this due to the link to obstructive sleep apnea, which causes a state 
of hypoxia during sleep 38. Therefore, the presence of hypoxia due to obstructive sleep apnea 
could, in part, explain the observed relationship between obesity and ccRCC in particular 39. 
However, verification of the association between obstructive sleep apnea and ccRCC risk 
should still be addressed in future studies.
To our knowledge, three studies have investigated the potential for heterogeneity between 
cigarette smoking and the risk of histologic subtypes of RCC 12, 14, 17. In these studies, no 




heterogeneity of associations was found across ccRCC and pRCC for tobacco smoking 
status 12, 14, 17. In our study, a positive association was observed between cigarette smoking 
status and ccRCC risk, but no clear association was found with pRCC risk. Patel et al. 17 
investigated the heterogeneity between smoking frequency, duration and pack-years across 
ccRC C and pRCC in detail and found no evidence for heterogeneity. Similarly, we found 
no heterogeneity of associations for cigarette smoking frequency and smoking cessation. We 
observed a statistically significant heterogeneity for smoking duration in current smokers 
(pheterogeneity: 0.04). However, this may be a chance finding as we observed a very skewed 
distribution of cigarette-smoking patterns in pRCC cases, which may have affected the 
heterogeneity estimates between ccRCC and pRCC.
The current evidence suggests that alcohol consumption is inversely associated with the 
risk of RCC 9, 10, 40, 41. As of yet, the potential for histologic heterogeneity regarding alcohol 
consumption has remained unexplored. In our study, we observed inverse associations 
between alcohol consumption and both ccRCC and pRCC risk. No heterogeneity was found 
across ccRCC and pRCC in either overall alcohol consumers or stable users and abstainers. 
However, these findings need to be validated in future studies.
Previous research has indicated that patients with hypertension more often present with 
non-clear cell histology 42. Even though slightly stronger associations were found between 
hypertension and pRCC, when compared to ccRCC, we observed no statistically significant 
heterogeneity of associations, which is in line with findings from Purdue et al. 12. A previous 
study by Colt et al. 16 has indicated potential drug- and histology-specific associations 
between hypertension and RCC. In their study pRCC, but not ccRCC, was associated with 
long-term use of diuretics and calcium channel blockers 16. In our study, we observed similar 
point estimates between antihypertensive medication use and ccRCC risk and pRCC risk. 
Unfortunately, due to the limited number of pRCC cases, we were unable to assess the risk 
related to different types of antihypertensive medication. 
The present study had several strengths, including the prospective design, the detailed 
assessment of exposures and confounders at baseline, and the long duration of cancer follow-
up. Our results for overall RCC, as detailed in the supplementary materials (Supplementary 
Tables 2.1-2.4), were in line with evidence from large-scale meta-analyses on obesity 43, 
smoking 3, 8, alcohol consumption 9, 41 and hypertension 7, which strengthens the credibility 
of our results. Furthermore, the differentiation between histological subtypes was based on 
the centralized revision by two experienced uropathologists, which improved the accuracy 
of the information on histologic RCC subtypes. However, our study also was subject 
to some limitations. Firstly, information on anthropometry and exposure status was self-
reported by the participants at one single time point. Consequentially, there may have been 
measurement error due to self-report. Moreover, changes in exposure status during follow-
up were not recorded. Secondly, we had a limited number of cases with a tumor histology 
other than ccRCC. As a result, we were unable to assess the etiologic heterogeneity in more 
detail for exposures (e.g. anti-hypertensive medication subtypes), histologic subtypes (e.g. 
chromophobe RCC) and to further categorize the pRCC subtypes (e.g. type 1 and type 2 
pRCC). In particular, the inability to further stratify pRCC may have influenced results as 




possess molecular and clinicopathologically distinct characteristics 2, 44. It may be possible 
that type 1 and type 2 pRCC are distinctly associated to the risk factors included in our 
analyses. Lastly, due to the low number of pRCC cases, we were not able to obtain reliable 
estimates in all heterogeneity tests.
In conclusion, the results of our study are suggestive of the presence of an etiologic 
heterogeneity regarding RCC subtypes. In particular, we observed that the association 
between BMI and ccRCC and pRCC differs. These results highlight the need for more detailed 
subtype-specific analyses when investigating risk factors for RCC. Evidence from studies on 
specific tumor histologies may help uncover mechanisms that play a role in the process of 
tumorigenesis for RCC by uncovering etiologic similarities and differences between tumor 
subtypes.
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Supplementary Table 1.1 - Sex-adjusted Cox proportional hazard models with age as 
timescale for the association between Body Mass Index (BMI) and risk of clear-cell Renal 
Cell Carcinoma and papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet 
and cancer, 1986-2006
clear-cell Renal Cell Carcinoma papillary Renal Cell Carcinoma
Characteristics Subcohort Cases Sex-adjusted Cases Sex-adjusted
person-
years No. HR 95% CI No. HR 95% CI
BMI at baseline (kg/m2)
<23 16723 55 1 Ref. 11 1 Ref.
23-<25 21298 90 1.18 (0.83-1.67) 18 1.04 (0.48-2.22)
25-<27 16372 81 1.36 (0.95-1.94) 10 0.70 (0.29-1.67)
≥27 15477 89 1.69 (1.19-2.40) 7 0.63 (0.24-1.65)
p trend 0.002 0.21
Cont. 
(per kg/m2) 69871 315 1.05 (1.01-1.09) 46 0.93 (0.84-1.03)
BMI at age 20 (kg/m2) a
<20.0 15384 61 1.42 (0.95-2.13) 6 0.82 (0.29-2.31)
20.0-<21.5 14576 45 1 Ref. 9 1 Ref.
21.5-<23 14558 67 1.49 (1.01-2.20) 10 1.11 (0.45-2.75)
≥23 15549 85 1.80 (1.24-2.62) 8 0.87 (0.34-2.25)
p trend 0.05 0.89
Cont.
(per kg/m2) 60067 258 1.05 (1.00-1.10) 33 1.02 (0.90-1.14)
BMI change since age 20 (kg/m2) b
<1.5 14892 60 1 Ref. 8 1 Ref.
1.5-<3.5 16693 73 1.11 (0.77-1.61) 16 1.45 (0.57-3.69)
3.5-<5.5 13659 58 1.18 (0.79-1.75) 7 0.80 (0.27-2.37)
≥5.5 14823 67 1.41 (0.95-2.09) 2 0.22 (0.04-1.14)
p trend 0.08 0.02
Cont. 
(per kg/m2) 60067 258 1.04 (1.00-1.09) 33 0.89 (0.78-1.01)
Trouser size - Men
<50 4745 26 1.14 (0.66-1.95) 8 1.92 (0.66-5.57)
50-<52 6736 32 1 Ref. 6 1 Ref.
52-<54 10137 63 1.29 (0.83-2.01) 12 1.25 (0.46-3.37)
54-<56 5553 41 1.51 (0.93-2.44) 8 1.54 (0.53-4.49)
≥56 2756 24 1.85 (1.06-3.23) 3 1.10 (0.27-4.43)
p trend 0.03 0.69
Cont. 
(per size) 29928 186 1.06 (1.01-1.12) 37 1.00 (0.95-1.06)
Skirt size - women
<42 7012 15 0.84 (0.44-1.63) 1 -
42-<44 9372 24 1 Ref. 1 1
44-<46 10272 31 1.18 (0.68-2.03) 3 -
46-<48 6529 27 1.62 (0.93-2.85) 0 -
≥48 3774 17 1.71 (0.90-3.24) 0 -
p trend 0.01 -
Cont.
(per size) 36958 114 1.09 (1.03-1.15) 5 -
a Analysis with BMI at age 20 have a restricted number of cases due to missing values
b Additionally adjusted for BMI at age 20




Supplementary Table 1.2 - Sex-adjusted Cox proportional hazard models with age as 
timescale for the association between cigarette smoking and risk of clear-cell Renal Cell 
Carcinoma and papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and 
cancer, 1986-2006
clear-cell Renal Cell 
Carcinoma
papillary Renal Cell 
Carcinoma
Characteristics Subcohort Cases Sex-adjusted Cases Sex-adjusted
person-
years No. HR 95% CI No. HR 95% CI
Unadjusted for cigarette smoking frequency and duration
Cigarette smoking status
Never 27409 85 1 Ref. 10 1 Ref.
Former 24499 136 1.30 (0.95-1.77) 22 0.95 (0.43-2.12)
Current 17963 94 1.29 (0.93-1.78) 14 0.96 (0.41-2.12)
p trend 0.15 0.94
Adjusted for cigarette smoking frequency and duration a
Cigarette smoking status
Never 27409 85 1 Ref. 10 1 Ref.
Former 24499 136 1.30 (0.94-1.80) 22 1.06 (0.45-2.46)
Current 17963 94 1.27 (0.91-1.78) 14 0.59 (0.22-1.61)
p trend 0.15 0.27
Exclusively cigarette smoking
Never 26090 73 1 Ref. 9 1 Ref.
Former 19102 93 1.36 (0.94-1.95) 10 0.87 (0.19-1.72)
Current 15348 82 1.50 (1.04-2.14) 13 0.41 (0.10-1.70)
p trend 0.02 0.22
Solely in exclusive cigarette smokers
Smoking frequency b
>0-<20 cig/d 21689 102 1 Ref. 10 1 Ref.
≥20 cig/d 12761 73 1.06 (0.76-1.48) 13 1.50 (0.63-3.60)
Cont. 
(per 5 cig/d), 
former smoker
19102 93 1.05 (0.95-1.17) 10 1.08 (0.80-1.46)
Cont. 
(per 5 cig/d), 
current smoker
15348 82 1.03 (0.93-1.15) 13 1.11 (0.89-1.38)
Smoking duration c
>0-<30 yrs 13701 65 1 Ref. 2 1 Ref.
≥30 yrs 20749 110 0.90 (0.62-1.32) 21 4.61 (1.10-19.27)
Cont. 
(per 5 yrs), 
former smoker
19102 93 1.02 (0.92-1.14) 10 1.67 (1.02-2.71)
Cont. 
(per 5 yrs), 
current smoker
15348 82 0.96 (0.85-1.08) 13 1.27 (0.71-2.28)
Number of years of smoking cessation d
Current smoker 15348 82 1 Ref. 13 1 Ref.
>0-<15 10444 53 0.95 (0.67-1.34) 7 0.75 (0.30-1.87)
≥15 8657 40 0.91 (0.61-1.37) 3 0.44 (0.12-1.63)
Never smoker 26090 73 0.67 (0.48-0.94) 9 1.63 (0.53-5.01)
p trend, 
excl. never smokers 0.57 0.18
Cont. 
(per 5 yrs), 
former smokers
19102 93 0.98 (0.87-1.11) 10 0.87 (0.58-1.31)
a Additionally adjusted for cigarette smoking duration (years, centered) and cigarette smoking frequency 
(cig/d, centered)
b Additionally adjusted for smoking duration (years, centered)
c Additionally adjusted for smoking frequency (cig/d, centered)




Supplementary Table 1.3 - Sex-adjusted Cox proportional hazard models with age as 
timescale for the association between alcohol and risk of clear-cell Renal Cell Carcinoma 
and papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and cancer, 
1986-2006
clear-cell Renal Cell Carcinoma papillary Renal Cell Carcinoma
Characteristics Subcohort Cases Sex-adjusted Cases Sex-adjusted
person-
years No. HR 95% CI No. HR 95% CI
Alcohol consumption (g/d)
Abstainer 16613 76 1 Ref. 7 1 Ref.
>0-<5 20731 79 0.79 (0.57-1.09) 13 1.37 (0.54-3.47)
≥5-<15 15589 64 0.73 (0.51-1.04) 14 1.37 (0.55-3.44)
≥15-<30 10810 63 0.95 (0.66-1.35) 8 0.91 (0.33-2.53)
≥30 6127 33 0.84 (0.54-1.30) 4 0.74 (0.21-2.61)
p trend 0.66 0.42
Cont. 
(per 5 g/d) 69871 315 0.99 (0.96-1.03) 46 0.96 (0.87-1.05)
Alcohol consumption among stable abstainers/users (g/d) a
Abstainer 12986 57 1 Ref. 7 1 Ref.
>0-<5 11867 46 0.84 (0.56-1.26) 6 0.82 (0.27-2.48)
≥5-<15 9435 42 0.88 (0.58-1.34) 6 0.82 (0.26-2.61)
≥15-<30 5832 38 1.20 (0.77-1.88) 3 0.56 (0.14-2.29)
≥30 3287 20 1.11 (0.64-1.93) 2 0.64 (0.12-3.51)
p trend 0.43 0.46
Cont. 
(per 5 g/d) 43407 203 1.01 (0.97-1.06) 24 0.97 (0.84-1.13)
a Stable abstainers were defined as participants that reported no alcohol consumption 5 years before 
baseline. Stable users were defined as participants who reported that they drank equal amounts of beer 
or other alcoholic beverages 5 years before baseline.




Supplementary Table 1.4 - Sex-adjusted Cox proportional hazard models with age 
as timescale for the association between hypertension and risk of clear-cell Renal Cell 
Carcinoma and papillary Renal Cell Carcinoma in the Netherlands Cohort Study on diet and 
cancer, 1986-2006
clear-cell Renal Cell Carcinoma papillary Renal Cell Carcinoma
Characteristics Subcohort Cases Sex-adjusted Cases Sex-adjusted
person-
years No. HR 95% CI No. HR 95% CI
Self-reported hypertension diagnosis
No 51868 216 1 Ref. 30 1 Ref.
Yes 18002 99 1.37 (1.07-1.76) 16 1.73 (0.94-3.19)
Use of antihypertensive medication
No 56463 235 1 Ref. 35 1 Ref.
Yes 13408 80 1.51 (1.16-1.98) 11 1.43 (0.71-2.86)
Hypertension status & antihypertensive use
No hyp or no 
med 59848 251 1 Ref. 35 1 Ref.
Hyp and med 10023 64 1.61 (1.20-2.15) 11 2.15 (1.09-4.24)




Supplementary Table 2.1 - Sex- and multivariable-adjusted Cox proportional hazard models 
with age as timescale for the association between Body Mass Index (BMI) and risk of Renal 
Cell Carcinoma (RCC) in the Netherlands Cohort Study on diet and cancer, 1986-2006
Renal Cell Carcinoma
Characteristics Cases Subcohort Sex-adjusted Multivariable-adjusteda
No. person-years HR 95% CI HR 95% CI
BMI at baseline (kg/m2)
<23 98 16723 1 Ref. 1 Ref.
23-<25 151 21298 1.09 (0.83-1.43) 1.06 (0.80-1.39)
25-<27 120 16372 1.11 (0.83-1.47) 1.05 (0.78-1.40)
≥27 146 15477 1.56 (1.19-2.05) 1.46 (1.11-1.94)
p trend 0.002 0.009
Cont. (per kg/m2) 515 69871 1.05 (1.02-1.08) 1.04 (1.01-1.07)
BMI at age 20 (kg/m2) b
<20.0 104 15384 1.28 (0.94-1.74) 1.25 (0.92-1.71)
20.0-<21.5 86 14576 1 Ref. 1 Ref.
21.5-<23 109 14558 1.28 (0.95-1.73) 1.29 (0.95-1.75)
≥23 125 15549 1.39 (1.04-1.86) 1.35 (1.00-1.81)
p trend 0.28 0.29
Cont. (per kg/m2) 424 60067 1.03 (0.98-1.07) 1.02 (0.98-1.07)
BMI change since age 20 (kg/m2) c
<1.5 95 14892 1 Ref. 1 Ref.
1.5-<3.5 121 16693 1.13 (0.84-1.52) 1.10 (0.82-1.49)
3.5-<5.5 103 13659 1.27 (0.93-1.74) 1.23 (0.89-1.69)
≥5.5 105 14823 1.30 (0.94-1.80) 1.21 (0.86-1.69)
p trend 0.08 0.21
Cont. (per kg/m2) 424 60067 1.04 (1.01-1.08) 1.03 (0.99-1.07)
Trouser size - Men
<50 44 4745 1.13 (0.74-1.74) 1.14 (0.74-1.75)
50-<52 55 6736 1 Ref. 1 Ref.
52-<54 108 10137 1.30 (0.91-1.84) 1.29 (0.91-1.83)
54-<56 69 5553 1.51 (1.03-2.21) 1.55 (1.05-2.28)
≥56 38 2756 1.67 (1.07-2.62) 1.64 (1.04-2.57)
p trend 0.02 0.02
Cont. (per size) 314 29928 1.06 (1.02-1.10) 1.06 (1.01-1.10)
Corr. BMI/size 0.281
Skirt size - women d
<42 24 7012 0.83 (0.49-1.40) 0.83 (0.49-1.41)
42-<44 39 9372 1 Ref. 1 Ref.
44-<46 43 10272 1.00 (0.64-1.57) 1.00 (0.64-1.57)
46-<48 35 6529 1.30 (0.81-2.09) 1.22 (0.76-1.98)
≥48 33 3774 2.09 (1.28-3.41) 1.96 (1.18-3.27)
p trend 0.001 0.005
Cont. (per size) 174 36958 1.10 (1.04-1.16) 1.09 (1.03-1.15)
Corr. BMI/size 0.771
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered), smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/
current), hypertension status (no/yes), alcohol consumption (g/d, continuous), diabetes (no/yes), 
models included a time-varying covariate for smoking frequency because of a potential violation of the 
proportional hazards assumption
b Analysis with BMI at age 20 have a restricted number of cases due to missing values
c Additionally adjusted for BMI at age 20
d Not adjusted for pipe and/or cigar smoking due to unstable estimates for these confounding factors




Supplementary Table 2.2 - Sex- and multivariable-adjusted Cox proportional hazard models 
with age as timescale for the association between cigarette smoking and risk of Renal Cell 
Carcinoma (RCC) in the Netherlands Cohort Study on diet and cancer, 1986-2006
Renal Cell carcinoma
Characteristics Cases Subcohort Sex-adjusted Multivariable-adjusteda
No. person-years HR 95% CI HR 95% CI
Unadjusted for cigarette smoking frequency and duration
Cigarette smoking status
Never 136 27409 1 Ref. 1 Ref.
Former 219 24499 1.26 (0.98-1.62) 1.21 (0.93-1.57)
Current 160 17963 1.35 (1.04-1.74) 1.47 (1.13-1.91)
p trend 0.03 0.004
Adjusted for cigarette smoking frequency and duration b
Cigarette smoking status
Never 136 27409 1 Ref. 1 Ref.
Former 219 24499 1.26 (0.97-1.64) 1.21 (0.91-1.6)
Current 160 17963 1.35 (1.03-1.77) 1.48 (1.12-1.94)
p trend 0.02 0.006
Exclusively cigarette smoking
Never 123 26090 1 Ref. 1 Ref.
Former 150 19102 1.19 (0.88-1.61) 1.21 (0.89-1.65)
Current 141 15348 1.46 (1.10-1.95) 1.54 (1.15-2.06)
p trend 0.01 0.004
Solely in exclusive cigarette smokers
Smoking frequency c
>0-<20 cig/d 163 21689 1 Ref. 1 Ref.
≥20 cig/d 128 12761 1.16 (0.89-1.51) 1.12 (0.86-1.46)
Cont. (per 5 cig/d), 
former smoker 150 19102 1.07 (0.99-1.17) 1.06 (0.97-1.16)
Cont. (per 5 cig/d), 
current smoker 141 15348 1.07 (0.98-1.17) 1.07 (0.98-1.17)
Smoking duration d
>0-<30 yrs 102 13701 1 Ref. 1 Ref.
≥30 yrs 189 20749 0.92 (0.68-1.25) 0.93 (0.68-1.26)
Cont. (per 5 yrs), 
former smoker 150 19102 1.02 (0.94-1.12) 1.03 (0.94-1.12)
Cont. (per 5 yrs), 
current smoker 141 15348 0.96 (0.86-1.07) 0.96 (0.86-1.07)
Number of years of smoking cessation e
Current smoker 141 15348 1 Ref. 1 Ref.
>0-<15 90 10444 0.92 (0.71-1.2) 0.88 (0.67-1.14)
≥15 60 8657 0.77 (0.56-1.07) 0.74 (0.54-1.03)
Never smoker 123 26090 0.69 (0.53-0.90) 0.66 (0.50-0.86)
p trend, 
excl. never smokers 0.11 0.08
Cont. (per 5 yrs), 
former smokers 150 19102 0.98 (0.89-1.08) 0.97 (0.88-1.07)
a Additionally adjusted for: pipe and/or cigar smoking (never/former/current), Body Mass Index 
(continuous), hypertension status (no/yes), alcohol consumption (g/d, continuous), diabetes (no/yes), 
models included a time-varying covariate for smoking frequency because of a potential violation of the 
proportional hazards assumption
b Additionally adjusted for cigarette smoking duration (years, centered) and cigarette smoking frequency 
(cig/d, centered)
c Additionally adjusted for smoking duration (years, centered)
d Additionally adjusted for smoking frequency (cig/d, centered)




Supplementary Table 2.3 - Sex- and multivariable-adjusted Cox proportional hazard models 
with age as timescale for the association between alcohol and risk of Renal Cell Carcinoma 
(RCC) in the Netherlands Cohort Study on diet and cancer, 1986-2006
Renal Cell Carcinoma
Characteristics Cases Subcohort Sex-adjusted Multivariable-adjusteda
No. person-years HR 95% CI HR 95% CI
Alcohol consumption (g/d)
Abstainer 118 16613 1 Ref. 1 Ref.
>0-<5 135 20731 0.87 (0.67-1.13) 0.87 (0.66-1.13)
≥5-<15 104 15589 0.75 (0.56-0.99) 0.74 (0.56-0.99)
≥15-<30 101 10810 0.95 (0.71-1.28) 0.88 (0.65-1.19)
≥30 57 6127 0.89 (0.63-1.28) 0.82 (0.56-1.18)
p trend 0.63 0.28
Cont. (per 5 g/d) 515 69871 1.00 (0.97-1.03) 0.99 (0.95-1.02)
Alcohol consumption among stable abstainers/users (g/d) b
Abstainer 91 12986 1 Ref. 1 Ref.
>0-<5 73 11867 0.83 (0.60-1.15) 0.84 (0.60-1.16)
≥5-<15 62 9435 0.78 (0.55-1.10) 0.78 (0.54-1.11)
≥15-<30 60 5832 1.14 (0.79-1.65) 1.06 (0.71-1.56)
≥30 31 3287 1.02 (0.64-1.61) 0.92 (0.57-1.5)
p trend 0.63 0.95
Cont. (per 5 g/d) 317 43407 1.01 (0.97-1.05) 0.99 (0.95-1.04)
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered), smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/current), 
hypertension status (no/yes), body mass index (kg/m2, continuous), diabetes (no/yes), models included 
a time-varying covariate for smoking frequency because of a potential violation of the proportional 
hazards assumption
b Stable abstainers were defined as participants that reported no alcohol consumption 5 years before 
baseline. Stable users were defined as participants who reported that they drank equal amounts of beer 
or other alcoholic beverages 5 years before baseline.




Supplementary Table 2.4: Sex- and multivariable-adjusted Cox proportional hazard models 
with age as timescale for the association between hypertension and risk of Renal Cell 
Carcinoma (RCC) in the Netherlands Cohort Study on diet and cancer, 1986-2006
Renal Cell Carcinoma
Characteristics Cases Subcohort Sex-adjusted Multivariable-adjusteda
No. person-years HR 95% CI HR 95% CI
Self-reported hypertension diagnosis
No 354 51868 1 Ref. 1 Ref.
Yes 161 18002 1.38 (1.13-1.69) 1.32 (1.08-1.62)
Use of antihypertensive medication
No 391 56463 1 Ref. 1 Ref.
Yes 124 13408 1.40 (1.12-1.75) 1.20 (0.93-1.54)
Hypertension status & antihypertensive use
No hyp or no med 410 59848 1 Ref. 1 Ref.
Hyp and med 105 10023 1.63 (1.29-2.07) 1.60 (1.12-2.28)
a Additionally adjusted for: smoking status (never/former/current), smoking duration (continuous, 
centered), smoking frequency (continuous, centered), pipe and/or cigar smoking (never/former/
current), alcohol consumption (g/d, continuous), body mass index (kg/m2, continuous), diabetes (no/
yes), models included a time-varying covariate for smoking frequency because of a potential violation 
of the proportional hazards assumption
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We examined the association between kidney stones and renal cell carcinoma (RCC) and 
upper tract urothelial carcinoma (UTUC) risk in the Netherlands Cohort Study on diet and 
cancer. 
Methods
In total, 120,852 participants aged 55-69 completed a self-administered questionnaire on 
diet, medical conditions and other risk factors for cancer at baseline (1986). After 20.3 years 
of cancer follow-up 4352 subcohort members, 544 RCC cases and 140 UTUC cases were 
eligible for case-cohort analysis. Hazard ratios (HR) and 95% confidence intervals (CIs) 
were estimated by multivariable-adjusted proportional hazards models.
Results
Kidney stones were associated with an increased RCC risk (HR: 1.39, 95%CI 1.06-1.85), 
vs. no kidney stones. Kidney stones were associated with an increased risk of papillary RCC 
(HR: 3.08, 95%CI 1.55-6.11), but not clear-cell RCC (HR: 1.14, 95%CI 0.79-1.65). UTUC 
risk was increased for participants with kidney stones (HR: 1.66, 95%CI 1.03-2.68). No 
heterogeneity of associations was found for UTUC in the ureter and renal pelvis. An early 
kidney stone diagnosis (≤40 years) was associated with an increased RCC and UTUC risk, 
compared to later diagnosis. 
Conclusion
Kidney stones were associated with increased papillary RCC risk, but not clear-cell RCC 
risk. No heterogeneity was found for UTUC subtypes.





Kidney stones, a common urological condition, affect five to ten percent of the population 
in Europe and North America 1. Globally, the incidence and prevalence of kidney stones 
have increased over the years and are expected to increase further through the increasing 
prevalence of related medical conditions, such as obesity and diabetes mellitus1, 2. In general, 
kidney stone occurrences increase with age and are more common in men than in women1, 
3. The likelihood of kidney stones decreases with an increased intake of fluids, fruits and 
vegetables. Sodium restriction also reduces the probability for kidney stones3.
Several studies have assessed the relationship between kidney stones and renal cell carcinoma 
(RCC) and upper tract urothelial carcinoma (UTUC)4-6. Recently, a meta-analysis, based on 
eight case-control studies and one retrospective cohort study, found an increased risk of RCC 
and both ureter and renal pelvis cancer in individuals with kidney stones7. Furthermore, 
kidney stones were associated with an increased risk of RCC in males, but not in females. 
Three retrospective cohort studies not included in the aforementioned meta-analysis also 
found an increased risk of renal, ureter, or renal pelvis cancer in patients with urinary tract 
stones8-10.
Increased cancer risks associated with kidney stones are commonly attributed to chronic 
inflammation and infections, which may lead to an altered proliferation in urothelial cells5, 11, 
12. In turn, this process may lead to the development of a tumour. However, this association 
may also be explained by shared risk factors between kidney stones and RCC and UTUC5, 11. 
For example, obesity, diabetes mellitus, and several dietary factors are also associated with 
RCC risk13, 14.
At present, solely case-control and retrospective cohort studies have assessed the relationship 
between kidney stones and RCC and UTUC risk. These study designs tend to be prone to 
information and selection bias, which may affect found associations. In addition, most of 
these studies were limited in their adjustment for confounding factors7. As a result, there 
is uncertainty whether kidney stones or a lifestyle related to kidney stone formation 
are associated with an increased RCC and UTUC risk. In this study, we investigate the 
relationship between self-reported history of kidney stones and the risk of RCC and UTUC in 
the Netherlands Cohort Study (NLCS) on Diet and Cancer. In the NLCS, detailed information 
on risk factors associated with kidney stones, RCC and UTUC has been collected prior to 
cancer development enabling this study to adjust for multiple confounders.
Methods
Study population:
The NLCS is a nation-wide prospective cohort study initiated in September 1986. It included 
58 279 men and 62 573 women aged 55-69 years at baseline. The study design has been 
described in detail elsewhere15. In short, the study is a prospective cohort study initiated to 
investigate the association between diet and the development of cancer. For efficiency in data 
processing and analysis, a case-cohort design was used. A subcohort of 5,000 participants, of 
which 2,411 men and 2,589 women, was randomly sampled from the full cohort at baseline 




At baseline, all participants completed a mailed, self-administered questionnaire on dietary 
habits and other risk factors for cancer. By filling in and returning the baseline questionnaire 
participants agreed to participate in the NLCS. Follow-up for cancer occurrence for all 
participants was conducted by computerised record linkage with the Netherlands Cancer 
Registry (NCR), the Netherlands Pathology Registry (PALGA), and causes of death 
registry maintained by Statistics Netherlands (CBS). In addition, subcohort members were 
followed up biannually for migration and vital status by contacting the participants and the 
municipalities. The completeness of cancer follow-up through record linkage is estimated 
to be at least 96%16. The institutional review boards of the Netherlands Organization for 
Applied Scientific Research TNO (Zeist) and Maastricht University (Maastricht) approved 
the NLCS. The NLCS was conducted in accordance with the Declaration of Helsinki.
In total, 608 RCC cases were identified in the NLCS between 1986 and 2006 (20.3 years). 
Histologically confirmed epithelial RCC cases were eligible for the collection of formalin-
fixed paraffin-embedded (FFPE) tumour tissues. Overall, FFPE tumour tissues were collected 
for 454 (79.8%) of the eligible cases. Tumour histology was revised by two experienced 
pathologists according to the WHO-classification of RCC tumours17. Of the 454 RCC cases 
with available tumour tissue, 366 (80.6%) were clear-cell (cc)RCC cases, 60 (13.2%) papillary 
(p)RCC cases, 15 (3.3%) chromophobe RCC cases, and 13 (2.9%) other or undefined RCC 
cases. Further classification of pRCC cases resulted in 35 (7.7%) type 1 pRCC, 24 (5.3%) 
type 2 pRCC, and 1 (0.2%) undefined pRCC.
Cohort members with prevalent cancer at baseline, except skin cancer, and incomplete or 
inconsistent information on a priori selected confounders were excluded from analyses. Figure 
1 shows the selection and exclusion of participants. In total, 544 RCC cases (International 
Classification of Diseases for Oncology 3 (ICD-O-3) C64.9), 140 UTUC cases, and 4352 
subcohort members were included in this study. Of eligible RCC cases with confirmed 
tumour histology 332 were ccRCC cases and 48 were pRCC cases. Of UTUC cases 86 were 
renal pelvis cancer cases (ICD-O-3 C65.9) and 54 ureter cancer cases (ICD-O-3 C66.9). 
Questionnaire data
All participants completed a mailed, self-administered questionnaire at baseline on dietary 
habits and other risk factors for cancer. The exposure to kidney stones was obtained from the 
question “Has a physician ever diagnosed kidney stones and what was your age at that time?”. 
Participants reported the age at first kidney stone diagnosis in 5-year increments starting 
from “younger than 30”. Information on dietary habits was obtained through a 150-item, 
semi-quantitative food frequency questionnaire (FFQ) focusing on habitual consumption of 
food and beverages during the year preceding baseline. Other risk factors included in the 
questionnaire considered for the association between RCC, UTUC and kidney stones were: 
age at baseline, anthropometry (height and weight), cigarette smoking (status, intensity, and 
duration), medical conditions (hypertension, diabetes mellitus and kidney stones including 
age at first diagnosis in 5-year increments), and the use of diuretic medication.





Cox proportional hazards models were used to estimate age- and sex-adjusted and 
multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs). A priori 
confounders in the multivariable-adjusted model were body mass index (BMI, kg/m2; 
continuous), hypertension (yes/no), smoking status (never, former and current), smoking 
intensity (cig/d, centered; continuous), and smoking duration (years, centered; continuous). 
Potential confounders were added to the multivariable-adjusted model if they affected the 
HR of kidney stones on RCC and UTUC risk for more than 10%. Potential confounders 
considered were diuretic medication use (yes/no), alcohol intake (g/d; continuous), fluid 
intake (liters; continuous), sodium intake (g/d, adjusted for total energy intake by residuals; 
continuous), total energy intake (kcal/d; continuous), fruit intake (g/d; continuous), vegetable 
intake (g/d; continuous) and family history of renal carcinoma (yes/no). None of these 
potential confounders affected the HR of kidney stones on RCC and UTUC risk by more 
than 10% and, therefore, none were included in the final multivariable-adjusted models.
Additionally, the relationship between kidney stones and the risk of histological RCC 
subtypes (ccRCC and pRCC), and UTUC subtypes based on location (renal pelvis cancer and 
ureter cancer) was analysed. Moreover, the association for age of first reported kidney stone 
diagnosis was assessed as the main exposure for RCC and UTUC risk. An age of 40 years 
was determined as cut-off point based on the median age at first kidney stone occurrence.
HRs and 95% CIs were obtained through Cox proportional hazards regression models using 
Stata statistical software: release 14 (StataCorp., 2015, College Station, TX). Person-years 
Figure 1 - Flow diagram of subcohort members and case subjects on whom the analyses were 
based. Abbreviations; RCC = renal cell carcinoma; ccRCC = clear cell renal cell carcinoma; 
pRCC - Papillary renal cell carcinoma; UTUC = upper tract urothelial carcinoma; NCR = 
Netherlands Cancer Registry; PALGA = the Netherlands Pathology Registry. * Histologically 





at risk were calculated from baseline until registration of RCC or UTUC (depending on the 
cancer of interest) or until date of censoring by death, emigration, loss to follow-up or end of 
follow-up, whichever occurred first. During analyses for RCC or UTUC solely the cancer of 
interest was considered as an event and the development of other cancer types did not lead 
to censoring of observations. During analyses with histological RCC subtypes or UTUC 
subtypes based on location as the outcome, the first occurring subtype was considered as the 
time of censoring. The proportional hazards assumption was tested with Scaled Schoenfeld 
residuals and log-log curves18. Age at baseline was included as a time-varying covariate 
due to a violation of this assumption. Additional variance introduced due to the case-cohort 
approach by sampling a subcohort from the cohort was accounted for by use of the Huber-
White sandwich estimator for standard errors, similar to the variance-covariance estimator 
by Barlow19.
Tests for heterogeneity were performed to evaluate differences between histological subtypes 
and different localizations of tumours using the competing risks procedure in Stata. P-values 
were calculated based on a bootstrapping method that was developed for the case-cohort 
design. This procedure has been described in detail elsewhere20, 21.
All tests were performed two-sided and P values <0.05 were considered statistically 
significant.
Results
Subcohort baseline characteristics categorised by history of kidney stones are presented in 
Table 1. In total, 8.4% of the subcohort had a history of kidney stones. In general, baseline 
characteristics for members with a history of kidney stones were similar to members without 
a history of kidney stones. Exceptions included a decreased proportion of current smokers in 
males with kidney stones and an increased fruit and vegetable intake in both men and women 
with kidney stones, when compared to participants without kidney stones in those categories.
Results from age- and sex-adjusted analyses did not differ substantially from the multivariable-
adjusted results. Tables 2 and 3 present the results of the multivariable-adjusted analyses on 
history of kidney stones and age at first diagnosis of kidney stones for RCC and UTUC, 
respectively. In multivariable-adjusted analyses, participants with a history of kidney stones 
had a statistically significantly increased overall RCC risk (Table 2, HR: 1.39, 95% CI 
1.06-1.85) compared to participants without a history of kidney stones. Kidney stones were 
significantly associated to pRCC (HR: 3.08, 95% CI 1.55-6.11), while no association was 
found for ccRCC (HR: 1.14, 95% CI 0.79-1.65). Tests for heterogeneity of associations for 
kidney stones indicated significant differences between ccRCC and pRCC for all participants 
(P=0.001). Type 1 pRCC risk and type 2 pRCC risk did not differ substantially from 
overall pRCC estimates (data not shown). In males, similar findings were obtained for RCC 
overall (HR: 1.42, 95% CI 1.04-1.93), pRCC (HR: 2.37, 95% CI 1.16-4.85) and ccRCC 
(HR: 1.20, 95% CI 0.80-1.81). In females, no statistically significant association was found 
for RCC overall (HR: 1.30, 95% CI 0.68-2.50) and ccRCC (HR: 0.88, 95% CI 0.35-2.22). 
An increased risk of pRCC (HR: 16.37, 95% CI 3.53-75.89) was found for females with a 
history of kidney stones compared to females without kidney stones. However, in females, 
the number of exposed cases was limited.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A history of kidney stones was statistically significantly associated with an increased risk 
of UTUC overall in multivariable-adjusted models (Table 3, HR: 1.66, 95% CI 1.03-2.68). 
Similar estimates were found for specific UTUC localizations, namely the renal pelvis (HR: 
1.76, 95% CI 0.96-3.23) and the ureter (HR: 1.50, 95% CI 0.71-3.18). Tests for heterogeneity 
of associations did not indicate significant differences between cancer of the renal pelvis and 
the ureter (P=0.841). Associations were similar for sex-specific estimates for UTUC overall 
and UTUC localizations. Due to the absence of exposed cases, no analyses on ureter cancer 
were performed in females.
An early diagnosis of kidney stones (<40 years), compared to a later kidney stone diagnosis 
(≥40 years), was statistically significantly associated with an increased overall RCC risk 
(HR: 2.10, 95% CI 1.21-3.65). For histological RCC subtypes a non-statistically significantly 
increased risk was found for both pRCC (HR: 3.52, 95% CI 0.95-13.01) and ccRCC (HR: 
1.43, 95% CI 0.70-2.93). In UTUC analyses, an association was found for age (<40 years) at 
first diagnosis of kidney stones and overall UTUC risk (HR: 1.76, 95% CI 0.69-4.52). While 
no association was found for UTUC localized in the renal pelvis (HR: 1.13, 95% CI 0.30-
4.22), an increased risk of ureter cancer was found (HR: 4.79, 95% CI 0.83-27.71). However, 
the number of participants was limited for this analysis, which reduced the power to find 
statistically significant results. 
Discussion
In this study, an increased RCC and UTUC risk was found for participants with a history 
of kidney stones. Moreover, an increased pRCC risk, but not ccRCC risk, was observed in 
relation to a history of kidney stones. Furthermore, an increased RCC and UTUC risk was 
found for participants with a kidney stone diagnosis before their fortieth birthday. To our 
knowledge, this is the first prospective study to examine the relationship between kidney 
stones and RCC and UTUC risk and the first study to show heterogeneity of associations 
between pRCC and ccRCC.
The present study concurs with previously published studies on the relationship between 
kidney stones and RCC and UTUC risk. In a meta-analysis by Cheungpasitporn et al. an 
overall risk ratio of 1.76 (95% CI 1.24-2.49) was found comparing RCC risk for patients 
with kidney stones to those without kidney stones7. In the same meta-analysis a pooled risk 
ratio of 2.14 (95% CI 1.35-3.40) was found for transitional cell carcinoma, involving the 
ureter and renal pelvis7. Although HR estimates are lower in our study, we found similar 
associations for both RCC and UTUC risk. In addition, Cheungpasitporn et al. found an 
increased RCC risk associated with kidney stones in males, but not females7. In contrast, we 
found no difference between males and females.
To our knowledge, this is the first study to find an increased pRCC risk in participants with 
kidney stones. Nearly half of all pRCC cases in our study could be attributed to kidney 
stones based on the population attributable fraction using a multivariable-adjusted HR 
of 3.08 22. In general, pRCC is a heterogeneous RCC subtype consisting of two distinct 
subtypes characterised by genetic variations in the MET-gene for type 1 pRCC and in 
fumarate hydratase for type 2 pRCC17, 23. Previous studies on kidney stones have often been 
unable to assess the relationship with pRCC, either because pRCC has only been classified 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































as a distinct tumour type since 1996, or because they did not contain information on tumour 
histology24. Our study was able to assess tumour histology through centralised revision by 
two pathologists. Even though pRCC is a very heterogeneous subtype of RCC, we did not 
find differences between type 1 pRCC and type 2 pRCC.
There is uncertainty regarding the biological mechanism that may relate kidney stones to 
kidney cancer. Kidney stones are presumed to cause chronic irritation in the local environment 
of the kidney and ureter5-7. In general, chronic irritation and infection recruit inflammatory 
cells, which secrete cytokines and chemokines. In turn, free radical species from oxygen and 
nitrogen are produced, facilitating the onset of cancer through, among others, increased cell 
proliferation12. However, more insight on the role of kidney stones in this process is needed 
to elucidate the found associations.
Chow et al. found that most renal pelvis and ureter cancers occurred on the same side as 
kidney stone formation, which could indicate that kidney stones are exerting the effect in 
UTUC5. In animal studies, induced stone formation was correlated to the development of 
bladder cancer25, 26. By suppressing stone formation in rats, the effect of kidney stones could 
be attributed to the irritative stimulation by kidney stones, rather than to metabolites of the 
stone inducing factor25. However, both ccRCC and pRCC are thought to originate from the 
proximal convoluted renal tubule23. It is deemed unlikely that stones or stone-forming crystals 
deposit in the proximal convoluted renal tubule. Kidney stones tend to form in locations 
where there is a combination of supersaturation of the urine and where there is a change in 
the luminal diameter of the renal tubules, such as the loop of Henle, the distal tubules and in 
the collecting ducts27. Therefore, urinary solutes or a predisposing lifestyle, rather than actual 
stone formation in the kidney, might play a role in the development of these cancer subtypes. 
In contrast to pRCC, ccRCC risk was not associated with a history of kidney stones in this 
study. In general, genetic susceptibility and the interaction with environmental exposures 
are believed to influence RCC risk28. Hypothetically, tumour development could be related 
to the presence of stone-forming salts in the filtrate of the proximal tubules. The presence of 
these solutes may affect cell metabolism, which could potentially result in the development 
of distinct renal cancer subtypes.
UTUC risk was increased in participants with kidney stones, compared to participants without 
kidney stones, but no difference was found between the localization in the renal pelvis or the 
ureter. In contrast to the proximal tubule, stone formation is common in the renal pelvis and 
ureter, which enables kidney stones to cause chronic irritation and inflammation to urothelial 
cells. In turn, this may explain the increased UTUC risk in relation to kidney stones.
In this study, an age below 40 years at first kidney stone diagnosis was potentially associated 
with an increased RCC and UTUC risk. However, further research on this potential association 
is needed as the number of cases eligible for these analyses was limited. An earlier kidney 
stones diagnosis could provide a longer time period for kidney stones to induce chronic 
irritation to the local environment or for potentially harmful solutes in the urine to have 
a carcinogenic effect. Therefore, the found associations could indicate that the lifestyle of 





The strengths of the present study were the complete follow-up, the extensive information 
on potential confounders and the differentiation between histological subtypes based on the 
centralised revision by experienced pathologists.
However, this study was also subject to limitations. Information on kidney stones was 
retrieved from a self-administered questionnaire at baseline. Consequentially, kidney stone 
occurrences beyond the age at baseline may have been missed for participants with and 
without cancer. However, peak kidney stone incidence is expected at 40 to 49 years of age. 
Therefore, effects on our results are assumed to be limited. Furthermore, information obtained 
through self-reported questionnaires may contain inaccuracies regarding the diagnosis of 
kidney stones. However, the prevalence and incidence of kidney stones were as expected 
in the population and the RCC and UTUC risk was the greatest before 40 years of age1. 
Therefore, we think that our results are generalizable for the population. In this study, we did 
not have information on kidney stone composition, frequency and laterality. This information 
could provide additional insight on the mechanisms behind the found association in future 
studies. Residual confounding could have affected our results. However, as all models were 
extensively adjusted for confounders, we expect this effect to be limited. Lastly, a diagnosis 
of kidney stones may warrant additional surveillance, which could lead to an earlier detection 
of RCC. However, in our study, the average tumour size was larger in cases with a history 
of kidney stones, compared to cases without a history of kidney stones (72 mm vs. 65 mm, 
respectively), which makes bias due to earlier detection unlikely.
In light of the findings of this study, more research is needed to unravel the mechanisms 
behind the relation of kidney stones and RCC and UTUC. Firstly, future studies are required 
to ascertain the relationship between kidney stones and pRCC. Secondly, more studies are 
needed on kidney stone composition, stone laterality and exposure to stone-forming solutes 
to uncover the impact on cell metabolism and cancer development. Lastly, more studies are 
required to get a better insight on sex-specific differences in RCC and UTUC risk as a result 
of kidney stones.
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We investigated the relationship between germline single nucleotide polymorphisms (SNPs) 
in Von Hippel-Lindau (VHL) and Hypoxia-inducible factor 1-alpha (HIF1A), and their gene-
environment and gene-gene interactions, and clear-cell RCC (ccRCC) risk. Furthermore, we 
assessed the relationship between VHL SNPs and VHL promoter methylation. Three VHL 
polymorphisms and one HIF1A polymorphism were genotyped in the Netherlands Cohort 
Study. In 1986, 120,852 participants aged 55-69 completed a self-administered questionnaire 
on diet and lifestyle and toenail clippings were collected. Toenail DNA was genotyped using 
the Sequenom MassARRAY platform. After 20.3 years, 3004 subcohort members and 406 
RCC cases, of which 263 ccRCC cases, were eligible for multivariate case-cohort analyses. 
VHL_rs779805 was associated with RCC (Hazard Ratio (HR) 1.53; 95% Confidence Interval 
(CI) 1.07-2.17) and ccRCC risk (HR 1.88; 95% CI 1.25-2.81). No associations were found 
for other SNPs. Potential gene-environment interactions were found between alcohol 
consumption and selected SNPs. However, none remained statistically significant after 
multiple comparison correction. No gene-gene interactions were observed between VHL and 
HIF1A. VHL promoter methylation was not associated with VHL SNPs. VHL SNPs may 
increase (cc)RCC susceptibility. No associations were found between gene-environment and 
gene-gene interactions and (cc)RCC risk and between VHL promoter methylation and VHL 
SNPs.





Genetic and epigenetic alterations in the Von Hippel-Lindau (VHL) gene are important drivers 
of carcinogenesis in clear-cell renal cell carcinoma (ccRCC)1. For sporadic ccRCC, biallelic 
inactivation of VHL because of rare, but highly penetrant, somatic mutations is relatively 
common2, 3. Previous studies have estimated that 50-82% of patients with sporadic ccRCC 
have a mutation in the VHL gene4-8 The VHL gene encodes the VHL tumor suppressor protein 
(pVHL). Inactivation of pVHL leads to the unchecked accumulation of hypoxia-inducible 
factor 1 alpha (HIF1A), which facilitates oxygen delivery, adaptation to oxygen deprivation 
and angiogenesis1, 9. Therefore, genetic or epigenetic alterations in VHL and HIF1A may lead 
to enhanced cell survival and carcinogenesis.
In contrast to the rare, but highly penetrant, sequence alterations leading to functional VHL 
loss, some germline Single Nucleotide Polymorphisms (SNPs) are highly frequent, but have 
a low penetrance. In general, SNPs account for many different phenotypes as they may alter 
disease susceptibility by affecting the gene’s function10. Genome-wide association studies 
(GWAS) have not found an association with VHL and HIF1A loci11-18. However, candidate 
gene studies have found conflicting evidence on the relationship between VHL SNPs and (cc)
RCC risk, with some studies indicating a positive association19, 20, while others indicate no 
association 21. In previous studies, HIF1A SNPs have been associated with RCC prognosis, 
but not with (cc)RCC development21, 22.
Previous studies have indicated the importance of assessing the interplay between genetic, 
epigenetic and environmental triggers when assessing ccRCC risk. Moore et al. found 
increased promoter hypermethylation in sporadic ccRCC when certain VHL polymorphisms 
were present23. In addition, multiple studies have indicated potential gene-environment 
interactions between germline SNPs and environmental factors in RCC24-28. To our knowledge, 
the relationship between established environmental risk factors associated with RCC risk, 
namely smoking, hypertension, obesity and alcohol consumption29, and VHL and HIF1A 
SNPs remains unstudied.
Therefore, we investigated the relationship between three selected germline VHL SNPs 
and one HIF1A SNP and (cc)RCC risk in the Netherlands Cohort Study on diet and cancer 
(NLCS). In addition, interactions between VHL and HIF1A SNPs and smoking, hypertension, 
body mass index (BMI) and alcohol consumption were studied. Lastly, we investigated the 
association between VHL promoter methylation and VHL SNPs.
Methods:
Study design
The NLCS is a nation-wide prospective cohort study initiated in September 1986 with the 
inclusion of 120,852 participants aged 55-69 years to study the relationship between diet 
and cancer. The study design has been described in detail elsewhere30. In short, a case-cohort 
design was used for efficiency in data processing and follow-up for vital status. Cases were 
derived from the entire cohort, whereas a subcohort of 5000 participants, consisting of 2411 
men and 2589 women, was randomly sampled at baseline to estimate person years at risk for 
the entire cohort. The subcohort was followed up biennially for migration and vital status 




Using the subcohort, person-years at risk were calculated from baseline until registration of 
RCC, or until date of censoring by death, emigration, loss to follow-up or end of follow-up, 
whichever occurred first. Cancer follow-up for the full cohort was conducted by computerized 
record linkage with the Netherlands Cancer Registry (NCR), the Netherlands Pathology 
Registry (PALGA), and causes of death registry maintained by Statistics Netherlands 
(CBS)31. Follow-up for vital status of the subcohort was nearly 100% complete after 20.3 
years. The completeness of cancer follow-up is estimated to be over 96%32.
 
Individuals with prevalent cancer, excluding skin cancer, at baseline were excluded. After 20.3 
years of follow-up, 608 RCC cases were identified (International Classification of Diseases 
for Oncology 3 (ICD-O-3):C64). Histologically confirmed epithelial RCC cases were eligible 
for the collection of formalin-fixed paraffin-embedded (FFPE) tumor tissue. Tumor blocks 
were collected for 454 out of 568 eligible cases (80%). Two experienced pathologists revised 
the tumor histology according to the WHO-classification of RCC tumors33. Based on this 
revision 366 (81%) of the cases with available tumor blocks were classified as ccRCC cases, 
60 (13%) as papillary RCC cases, 15 (3.3%) chromophobe RCC cases, and 13 (2.9%) other 
or undefined RCC cases.
Ethics Statement
Individuals invited to participate in the NLCS received an invitation letter with details on 
the study and the use of their data. In addition, they received the baseline questionnaire, 
which included an envelope for returning toenail clippings. By completing and returning 
the baseline questionnaire, individuals consented to participate in the NLCS (response rate 
35.5%). Individuals were informed about the possibility to end their participation at any time, 
at which point all their data would be removed. All methods were performed in accordance 
with the relevant guidelines and regulations that were applicable at that time (1986). The 
institutional review boards of Maastricht University (Maastricht) and the Netherlands 
Organization for Applied Scientific Research TNO (Zeist) approved the NLCS (February 
2, 1985 and January 6, 1986, respectively). The institutional review board of Maastricht 
University (Maastricht) later re-evaluated the original approval of the study protocol and 
procedures (2010). Based on the re-evaluation the institutional review board amended the 
original approval to include the genotyping of SNPs (April 12, 2010). Participants did not 
provide written informed consent to the sharing of data.
Gene and SNP selection
Genes and SNPs related to RCC risk were selected through literature search. Priority was 
given to SNPs with a MAF ≥ 20% in Caucasians and primers had to be compatible with 
RAAS-pathway SNPs present on the multiplex assay34. Consequently, three VHL SNPs 
(rs779805, rs265318 and rs1642739) and one HIF1A SNP (rs2301111) were selected. All 
included VHL SNPs were selected based on their association with VHL promoter methylation 
in previous research23. The included HIF1A tag-SNP had the MAF of the HIF1A SNPs 
compatible with the assay. 
Tissue collection and DNA isolation
Approximately 90,000 participants provided toenail clippings at baseline, which have been 
shown to be a valid source of DNA for the genotyping of germline genetic variants35. DNA 




was isolated according to the DNA isolation protocol by Cline et al 36. To increase the number 
of cases with available DNA, DNA was isolated from FFPE healthy tissue, as described 
by van Houwelingen et al.37, for 67 RCC cases without toenail clippings. There were no 
substantial quality differences between DNA samples from toenail and FFPE healthy tissue 
34. In total, 3582 (75%) subcohort members and 502 (83%) RCC cases were genotyped. 
SNP genotyping was performed on the Sequenom MassARRAY platform using the iPLEX 
assay (Sequenom Inc., Hamburg, Germany), as described previously34. This method provides 
suitable SNP call rates and reproducibility using toenail DNA35.
 
DNA methylation of the CpG island of the VHL gene promoter region, of which methylation 
has been associated with inhibition of VHL gene expression38, in RCC tumor blocks was 
determined by chemical modification of genomic DNA with sodium bisulfite and subsequent 
methylation-specific PCR analysis (MSP) as previously described elsewhere39-41. MSP 
primer design was based on the MBD-affinity massive parallel sequencing data. Detailed 
information on primer sequences and MSP conditions are available elsewhere24.
Questionnaire information
All participants completed a mailed, self-administered, questionnaire on diet and other 
cancer risk factors for cancer at baseline (1986)42. Information on dietary habits was obtained 
through a 150-item, semi-quantitative food frequency questionnaire (FFQ) focusing on 
habitual consumption of food and beverages during the year preceding baseline.
Cigarette smoking status, frequency and duration were based on self-reported information. 
Participants reported hypertension as diagnosed by a physician, preceding baseline. 
Participants were asked to report the use of any drugs that they used longer than 6 months. 
From this information, the use of antihypertensive medication was extracted. BMI was 
calculated using self-reported height and weight from the baseline questionnaire. Questions 
on beer, red wine, white wine, sherry, fortified wines, liqueur, and liquor were used to assess 
the consumption of alcohol. Participants who consumed alcoholic beverages less than once 
a month were considered non-users. Standard glass sizes were defined as 200 ml for beer, 
105 ml for wine, 80 ml for sherry, and 45 ml for both liqueur and liquor43. These values 
corresponded to 8, 10, 11, 7 and 13 grams of alcohol, respectively. Mean daily alcohol 
consumption was calculated by multiplying the consumption frequency and the standardized 
item unit.
Statistical analyses
Cox proportional hazards models were used to estimate age- and sex-adjusted and 
multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CIs). A priori 
selected covariables in the multivariable-adjusted model were BMI (kg/m2, continuous), 
hypertension (yes,no), cigarette smoking status (never, former, current), intensity (cig/d, 
centered; continuous), duration (years, centered; continuous) and alcohol consumption (g/d, 
continuous).
The most common allele was used as the reference allele. Associations between genotypes 
and RCC and ccRCC risk were assessed using additive and dominant models. Results of 




allele frequencies in the subcohort were tested against departure from the Hardy-Weinberg 
Equilibrium using the Pearson χ2-test, as calculated with the Stata program ‘hwsnp’44. Gene-
environment interactions were tested with the Wald χ2-test. Gene-environment analyses were 
adjusted for multiple comparisons with the adaptive Benjamini-Hochberg false discovery rate 
(FDR) procedure with a q-value threshold of 10%45. Sensitivity analyses were performed to 
explore the impact of using alternative categorizations for BMI (<20 kg/m2, 20-<25 kg/m2, 
25-<30 kg/m2 and 30+ kg/m2), smoking status (never, ever), hypertension (no self-reported 
hypertension or no self-reported antihypertensive medication, hypertension with self-reported 
hypertensive medication) and alcohol consumption (0 g/d, 0.1-4 g/d, 5-14 g/d, 15-29 g/d and 
30+ g/d) when assessing gene-environment interactions. Gene-gene interactions between 
VHL SNPs and the selected HIF1A SNP were tested using the Wald χ2-test. In a case-only 
analysis, the association between VHL SNPs and VHL tumor promoter methylation status 
(methylated, unmethylated) was assessed using multiple logistic regression for both RCC 
and ccRCC.
All analyses were performed using Stata Statistical Software: Release 15 (StataCorp., 
2017, College Station, TX). The proportional hazards assumption was tested using scaled 
Schoenfeld residuals46. A violation of the assumption was apparent for age. Therefore, all 
models were adjusted for age as a time-dependent covariable. With the exception of FDR-
corrected analyses, a p-value <0.05 was considered statistically significant.
Results
After excluding participants with missing values for predefined confounders 3004 subcohort 
members and 406 RCC cases, of which 263 ccRCC cases, were included in the analyses. The 
proportion of men was higher in both RCC and ccRCC cases when compared to the subcohort 
(Table 1). In addition, cases were more often smokers and were more often diagnosed with 
hypertension when compared to the subcohort.
Genotype and allele frequencies for the four selected SNPs in subcohort members of the 
NLCS are presented in Supplementary Table 1. All selected SNPs adhered to the Hardy-
Weinberg Equilibrium. Only VHL_rs779805 had a minor allele frequency (MAF) above 25% 
and is, therefore, assessed primarily using additive models. 
Main SNP effects
In both age- and sex-adjusted analyses and multivariable-adjusted analyses, an association 
with (cc)RCC risk was observed for SNPs in VHL_rs779805, but not for SNPs in VHL_
rs1642739, VHL_rs265318 and HIF1A_rs2301111 (Table 2). In multivariable-adjusted 
analyses individuals carrying the AG (vs. AA) genotype of VHL_rs779805 had a statistically 
significantly increased RCC risk (HR 1.32, 95%CI 1.06-1.66), and the GG (vs. AA) genotype 
was associated with a statistically significantly increased RCC risk (HR 1.53, 95%CI 1.07-
2.17). In addition, a statistically significant per-allele p for trend was observed (p=0.004). In 
multivariable-analyses for ccRCC risk, the AG (vs. AA) genotype for VHL_rs779805 was 
associated with a statistically significantly increased ccRCC risk (HR 1.35, 95% CI 1.02-
1.78), as was the GG (vs. AA) genotype of VHL_rs779805 (HR 1.88, 95%CI 1.25-2.81).




Table 1 - Baseline characteristics of the subcohort and renal cell carcinoma (RCC) and clear 
cell renal cell carcinoma (ccRCC) cases; Netherlands Cohort Study on diet and cancer, 1986-
2006
Baseline characteristics (mean (SD)) Subcohort members RCC ccRCC
Total (n) 3004 406 263
Age (y) 61.3 (4.2) 60.7 (3.9) 60.6 (3.9)
Male sex (%) 49.6 65.8 64.3
Tumor stage (%)a
Stage 1/2 - 49.8 51.0
Stage 3/4 - 38.2 39.5
Undefined - 12.1 9.5
Cigarette smoking status (%)
Never smoker 36.8 26.9 26.6
Former smoker 36.4 43.8 45.3
Current smoker 26.9 29.3 28.1
Smoking intensity (cig/d)b 15.2 (10.2) 17.0 (11.7) 16.2 (10.5)
Smoking duration (y)b 31.5 (12.2) 32.0 (11.6) 31.4 (11.3)
Hypertension (%) 26.4 33.5 33.5
BMI (kg/m2) 25.0 (3.1) 25.4 (3.0) 25.5 (2.9)
Alcohol consumption (g ethanol/d)c 13.7 (15.0) 15.4 (15.3) 14.9 (14.7)
Energy intake (kcal) 1915 (505) 1998 (529) 1994 (517)
Diuretic medication (%) 11.0 14.0 15.2
Antihypertensive medication (%) 20.5 24.6 26.2
The subcohort includes 15 RCC cases, of which 11 ccRCC cases. Solely participants with complete 
information for main exposures are included in this table. SD = Standard deviation, RCC = renal cell 
carcinoma, ccRCC = clear cell renal cell carcinoma, BMI = Body Mass Index.
a According to the TNM version used at time of diagnosis by the Netherlands Cancer registry.
b In former and current smokers only.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In multivariable-adjusted models for RCC risk, potential gene-environment interactions 
were observed between VHL_rs1642739, VHL_rs779805 and HIF1A_rs2301111 SNPs and 
alcohol consumption (Table 3). A weak inverse association between alcohol consumption 
(per 5g/day) and RCC risk was observed in participants carrying the rare genotype for VHL_
rs1642739 and VHL_rs779805, but not in participants carrying the wild-type genotype. For 
carriers of the wild-type HIF1A_rs2301111 genotype a weak inverse association between 
alcohol consumption and RCC risk, but not for individuals carrying the rare genotype. No 
interaction was observed between either of the selected SNPs and self-reported hypertension 
(yes, no), smoking status (never, former, current) and BMI (per kg/m2) for RCC risk. For 
ccRCC, a potential interaction between VHL_rs779805 SNPs and alcohol consumption was 
observed. However, after correction for multiple comparisons using the adaptive Benjamini-
Hochberg method none of the potential gene-environment interactions maintained statistical 
significance45.
In sensitivity analyses, a potential gene-environment interaction was apparent between 
categorized alcohol consumption (0 g/d, 0.1-4 g/d, 5-14 g/d, 15-29 g/d and 30+ g/d) and 
VHL_rs164273 status for ccRCC risk (p=0.009; Supplementary Table 2). The direction of 
associations for VHL_rs779805 was similar to main analyses using alcohol consumption 
(per 5g/day). Sensitivity analyses between smoking status (ever/never), hypertension (no 
self-reported hypertension or no self-reported antihypertensive medication, hypertension 
with self-reported hypertensive medication) and BMI (<20 kg/m2, 20-<25 kg/m2, 25-<30 
kg/m2 and 30+ kg/m2) and SNP status showed similar associations compared to main gene-
environment analyses (Supplementary Table 2). Similar to main analyses, no sensitivity 
analysis remained statistically significant after multiple comparison correction.
Gene-gene interactions
No gene-gene interactions, as tested with the Wald χ2-test, were found between the three 
selected VHL SNPs and HIF1A_rs2301111 for both RCC (p=0.310, p=0.321 and p=0.514 for 
VHL_rs1642739, VHL_rs779805 and VHL_rs265318, respectively) and ccRCC (p=0.762, 
p=0.442 and p=0.978 for VHL_rs1642739, VHL_rs779805 and VHL_rs265318, respectively).
Association between SNPs and VHL promoter methylation status
In total, information on VHL promoter methylation was available from 253 ccRCC cases. 
Among ccRCC cases, 19 (7.5%) participants had a methylated CpG island in the VHL 
promoter region of which 13 had at least one mutant allele for the selected VHL SNPs 
(Supplementary Table 3). VHL promoter methylation was apparent in three, twelve and two 
participants for the rare genotype of VHL_rs1642739 (GG vs. GT+TT), VHL_rs779805 (AA 
vs. AG+GG) and VHL_rs264318 (AA vs. AC+CC), respectively. In multivariable-adjusted 
analyses a non-significant inverse association was observed between both VHL_rs1642739 
(HR 0.45, 95%CI 0.12-1.69) and VHL_rs265318 (HR 0.38, 95%CI 0.07-2.00) and VHL 
promoter methylation in ccRCC cases. No association was observed for the VHL_rs779805 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study, a statistically significantly increased RCC risk was found for individuals that 
carry genotypes with at least one variant allele for the VHL_rs779805 SNP. This association 
was especially pronounced for ccRCC risk. No association was found for VHL_rs164239, 
VHL_rs265318 and HIF1A_rs2301111. After adjustment for multiple comparisons, no 
statistically significant gene-environment interactions were found between the selected SNPs 
and smoking, hypertension, BMI and alcohol for both RCC and ccRCC cases. No gene-gene 
interactions were found between selected VHL SNPs and the HIF1A SNP.
Several studies have assessed the relationship between the VHL_rs779805 SNP and sporadic 
RCC19-21. Lv et al. found an association between the germline SNP VHL_rs779805 and 
RCC risk. Similarly, we found a statistically significant positive trend for the G allele and 
a positive association between the GG genotype for VHL_rs779805 and RCC risk20. The 
aforementioned studies did not report associations between VHL SNPs and ccRCC risk. In our 
study, rare VHL_rs779805 genotypes had a stronger association with ccRCC risk than with 
RCC risk. This might indicate that VHL polymorphisms lead to an increased susceptibility 
for ccRCC in particular. To our knowledge, no other study has investigated the relationship 
between VHL_rs1642739, VHL_rs265318 and HIF1A_rs2301111 and (cc)RCC risk. In this 
study, no association was found between (cc)RCC risk and VHL_rs1642739, VHL_rs265318 
or HIF1A_rs2301111.
Multiple studies have assessed gene-environment interactions in RCC and ccRCC. RCC 
risk has been found to be associated with interactions between alcohol consumption and 
ADH726; sodium and hypertension and AGTR, AGT and ACE34; calcium and vitamin 
D intake and RXRA28; tobacco smoking and NAT2, CYP1A1 and GSTM125; and meat-
cooking mutagens and ITPR2 and EPAS127. To our knowledge, we are the first to study 
gene-environment interactions between the selected VHL and HIF1A SNPs and smoking, 
hypertension, BMI and alcohol consumption. Solely the interaction between VHL_rs779805 
and alcohol consumption was associated with both RCC and ccRCC risk. However, this 
association did not maintain statistical significance after correction for multiple comparisons 
with the adaptive Benjamini-Hochberg method. Dominant models were used for all gene-
environment analyses because of the low MAF of most included SNPs. However, SNPs may 
not have adhered to a dominant model, as there may be differences in disease susceptibility 
between heterozygous and homozygous rare genotypes, as was found for VHL_rs779805 
(Table 2). This exemplifies that our gene-environment analyses may have been hampered by 
the inability to assess interactions per genotype. Further research is needed to ascertain the 
interaction between alcohol and VHL SNP status on (cc)RCC risk.
Disruptions in the VHL tumor suppressor gene are thought to play a role in the constitutive 
activation of hypoxia-inducible factors, as regulated in part by HIF1A, which may lead to 
carcinogenesis1. Therefore, it is plausible for gene-gene interactions to occur. However, in 
this study, we did not find gene-gene interactions between selected VHL and HIF1A SNPs on 
the risk of developing (cc)RCC. 
Previous studies have found a relationship between VHL promoter hypermethylation and 
SNPs in VHL_rs779805 in sporadic ccRCC cases6, 23. Moore et al. also reported a positive 




association between promoter hypermethylation and VHL_rs265318 and VHL_rs1642739. In 
contrast, we found no association between promoter methylation status and VHL_rs779805 
in ccRCC cases. VHL_rs1642739 and VHL_rs265318 seemed inversely associated with VHL 
promoter methylation in ccRCC cases. However, this association was based on a limited 
sample size. While the number of cases with known promoter methylation status was similar 
in size to the study of Moore et al., our study had a smaller proportion of cases with VHL 
promoter methylation (7.5% vs. 9.8%)23. Banks et al. reported an even higher proportion 
of sporadic ccRCC cases with a methylated VHL promoter (20.4%), but had a smaller 
study population6. In general, there are large differences in the proportion of methylated 
VHL promoters per SNP between studies, which may explain these unstable point estimates 
23. Therefore, more research with a larger number of sporadic ccRCC cases is needed to 
elucidate the relationship between VHL promoter methylation and VHL SNPs.
At present, genome-wide association studies (GWAS) have identified multiple novel risk loci 
that may contribute to RCC susceptibility. Interestingly, SNPs in the VHL and HIF1A genes 
have not (yet) been identified as potential risk variants, while there is a biological plausibility 
for the involvement of these genes based on current evidence on the development of RCC2, 9. 
For example, risk loci have been identified in EPAS111, 13, 17, 18, which is known to be involved 
in the VHL-HIF-1 pathway47. While we found no evidence for an association between 
three of our selected SNPs, VHL_rs779805 was associated with an increased risk of RCC. 
This finding was in line with two prior published studies, in which a potential association 
between VHL_rs779805 and RCC risk was found19, 20. While this particular SNP is present on 
commonly used SNP arrays, this SNP remains unidentified in large-scale GWAS studies11-18. 
It is estimated that the currently available risk loci for RCC account for approximately 10% 
of the familial risk for RCC11. Therefore, it may well be possible for minor susceptibility loci 
to remain unidentified in GWAS studies, due to their tendency to convey small-to-moderate 
changes in risk, while major susceptibility loci are detectable in the stringent false discovery 
rate correction criteria of GWAS studies. This could be a reason why SNPs like VHL_
rs779805 may remain unidentified, unless alternative methodologies are employed11. As a 
result, there is ample opportunity to discover new, rarer, RCC risk variants in future research. 
Additional evidence on risk loci from GWAS studies, combined with extensive information 
on direct effects, environmental factors and other potential modulators of disease etiology 
from candidate SNP studies, should lead to new insights into the biology of RCC to further 
the potential for new prevention, early detection and intervention strategies to be employed11.
This study also has several strengths. Strengths of this study were the detailed questionnaire 
information, the long duration and the histological revision of RCC cases by two experienced 
pathologists. Furthermore, cases in our study were obtained prospectively from a population 
of 120,852 men and women from 204 Dutch municipalities. Combined with the completeness 
of follow-up, we assume that these cases are a representative of kidney cancer cases in the 
Netherlands at the time.
In conclusion, this study confirmed the association between germline SNP VHL_rs779805 
with RCC risk. In addition, a slightly stronger association for ccRCC was found compared 
to RCC. Potential gene-environment interactions were found between alcohol and VHL 




comparisons. No gene-gene interactions were observed between the VHL and HIF1A SNPs. 
Lastly, tumor promoter methylation was not significantly associated with VHL SNPs.
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Supplementary Table 3 - Case-only analysis on the association between VHL promoter 
methylation status and VHL SNP status, the Netherlands Cohort Study on Diet and Cancer, 
1986-2006.






Methylated Unmethylated ORa (95% CI) ORb (95% CI)
Clear-cell renal cell carcinoma
VHL_rs1642739
GG 16 169 1 1
GT+TT 3 65 0.48 (0.14-1.73) 0.45 (0.12-1.69)
VHL_rs779805
AA 7 88 1 1
AG+GG 12 146 1.02 (0.38-2.70) 0.99 (0.37-2.69)
VHL_rs265318
AA 17 183 1 1
AC+CC 2 51 0.42 (0.09-1.87) 0.38 (0.07-2.00)
Total number of SNPs present
None 6 85 1 1
1 or more 13 150 1.20 (0.43-3.36) 1.13 (0.39-3.29)
a Models adjusted for age (y, continuous) and sex (man/woman)
b Models adjusted for age (y, continuous), sex (man/woman), hypertension (yes/no), smoking status 
(never, former, current), smoking duration (y, centered), smoking intensity (cig/d, centered), BMI (kg/
m2, continuous) and alcohol intake (g ethanol/d, continuous)
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In this chapter, the main findings of the chapters in this thesis will be discussed. Subsequently, 
we will critically reflect on methodological considerations and the strengths and weaknesses 
that may have impacted the findings in this thesis. Furthermore, we will discuss the impact 
of the main findings. Moreover, we will discuss suggestions for future research. Lastly, we 
make concluding remarks regarding the work presented in this thesis and the current research 
in renal cell carcinoma (RCC).
Summary of the main findings:
In this thesis, we assessed whether various environmental and genetic risk factors are 
differentially associated with the risk of specific subgroups of renal cell carcinoma. In 
chapter 2, we observed that the association between type 2 diabetes mellitus and Renal Cell 
Carcinoma (RCC) risk is present in women, but not in men. Upon further analysis, individuals 
who reported the use of anti-diabetic medication, in particular insulin and its analogues, had 
an increased risk of RCC (chapter 2). Furthermore, we found evidence for heterogeneity of 
associations regarding body mass index (BMI) and the risk of clear cell RCC (ccRCC) and 
papillary RCC (pRCC), as BMI was associated positively with ccRCC risk, but inversely 
with pRCC risk (chapter 3). No clear evidence was found for heterogeneity of associations 
regarding the association between cigarette smoking, hypertension and antihypertensives, 
and alcohol consumption and the risk of ccRCC and pRCC. In chapter 4, we investigated the 
association between a history of kidney stones and the development of RCC and upper tract 
urothelial carcinoma (UTUC). Having a history of kidney stones was associated with both an 
increased RCC and UTUC risk. Having a younger age, before 40 years of age, at first diagnosis 
of kidney stones increased these risks, when compared to a later diagnosis. In particular, 
there was a potential heterogeneity of associations as having a history of kidney stones was 
associated with an increased pRCC risk, but not with clear cell RCC risk. No heterogeneity 
of associations was observed between kidney stones and different UTUC localisations. In 
chapter 5 we investigated the role of some selected germline single nucleotide polymorphisms 
(SNPs) in VHL and HIF1A on (cc)RCC risk. Overall, VHL_rs779805 was associated with the 
risk of RCC overall and ccRCC, while no associations were found for two other VHL SNPs 
and a HIF1A SNP. In addition, we assessed gene-environment and gene-gene interactions for 
these VHL and HIF1A SNPs. There was a potential gene-environment interaction between 
alcohol consumption and VHL_rs1642739, VHL_rs779805 and HIF1A_rs2301111 in RCC, 
but these interactions did not maintain statistical significance after correcting for the false 
discovery rate. No gene-gene interactions were found between the selected SNPs. Finally, we 
used targeted sequencing to examine the association between somatic mutations in the seven 
most frequently mutated genes in ccRCC, namely VHL, PBRM1, SETD2, BAP1, MTOR, 
KDM5C and TP53, and ccRCC-specific survival (chapter 6). Mutations in VHL and PBRM1 
were associated with ccRCC-specific survival, regardless of co-occurrence. However, these 
results did not maintain statistical significance after multiple testing correction.
Methodological considerations
The use of observational and molecular data, as included in this thesis, may introduce various 
sources of bias, which may have influenced the validity of our findings. This section will 
highlight and discuss various methodological strengths and limitations, and the influences 






There were several important strengths regarding the analyses in this thesis, including the 
longitudinal study design, the availability of extensive confounder information, and the 
completeness of follow-up. Compared to case-control studies, the more commonly employed 
observational study designs in RCC research, prospective cohort studies have a reduced risk of 
information and selection bias. This, because the exposure information has been determined 
prior to the assessment of the outcome and all participants were at risk of developing the 
disease upon inclusion in our longitudinal study. Moreover, in the Netherlands Cohort Study 
on diet and cancer (NLCS) extensive information was available on potential confounding 
factors, which enabled us to extensively adjust for confounders in our analyses. Lastly, the 
completeness of follow-up for cancer incidence through record linkage is estimated to be 
over 96%1. 
Use of the self-administered baseline questionnaire
A methodological consideration that should be taken into account when interpreting the 
analyses presented in this thesis is the use of exposure data obtained through the use of a self-
administered baseline questionnaire. These data were used in chapter 2 through chapter 5 
to determine the exposure to various risk factors, including among others cigarette smoking, 
body mass index, hypertension, alcohol consumption, diabetes mellitus and kidney stones. 
A limitation is the absence of repeated measurements of exposure status during follow-up 
due to the design of the NLCS. Therefore, we need to consider two factors. Namely the 
potential for misclassification of exposures through self-report and the potential for change 
in exposure status in the period beyond baseline.
The misclassification of exposures may have occurred as the baseline questionnaire was based 
on self-report without additional verification of exposure. Therefore, the misclassification 
of exposure status may be a potential source of information bias. An advantage is the 
prospective nature of the Netherlands Cohort Study in which the participants were all at risk 
of developing cancer at the onset of the study. As such, it is unlikely that information bias 
has occurred, as a systematic difference in the accuracy of reported information between 
the randomly selected subcohort and participants who developed renal cell cancer is not 
expected. However, non-differential misclassification may have occurred. In general, non-
differential misclassification most likely leads to the attenuation of results towards the null 
for binary exposures2. In the case of non-binary exposures, or upon collapsing continuous 
exposure data into categorical data, the effects of the misclassification of exposures is more 
difficult to predict2.
Moreover, the measurement of exposure data at one point in time may be a source of 
potential bias, as we do not have information on the change in exposures beyond the baseline 
measurement. We believe that the participants in the age group as targeted in the NLCS, may 
have had relatively stable lifestyle habits over a period of at least 5 years after completing 
the baseline questionnaire, as reflected during reproducibility studies regarding the food 
frequency questionnaire (FFQ) included in the NLCS questionnaire3, 4. However, there is a 
possibility that participants may have changed their habits at some point or that they may have 
been diagnosed with medical conditions during follow-up. To gain more insight into this, we 




for the main risk factors derived from the baseline questionnaire in this thesis. Regarding 
(cigarette) smoking, we would expect that the proportion of never smokers would not be 
heavily affected, as very few people start smoking at older ages5. On the other hand, based 
on information from a Dutch study investigating the change in lifestyle habits, we expect 
that approximately 8%-12% of the individuals classified as current smokers at baseline may 
have quit smoking during follow-up5. This may have led to an underestimation of the effect 
of cigarette smoking on RCC subtypes in our study. Moreover, BMI may also have varied 
over time beyond baseline. The subcohort of the NLCS has reported their body weight (kg) 
at three separate occasions at baseline in 1986 and during follow-up in 1992, and 20006, 7. 
In addition, the self-reported height was available from the baseline questionnaire in 1986. 
Using this information, the change of BMI until 14 years of follow-up could be determined. 
BMI did not increase over time in men, but increased slightly over time in women (0.2 
kg/m2 and 0.4 kg/m2 from baseline to 6 and 14 years of follow-up, respectively)7. Based 
on these small increases in women, we expect that the associations for BMI should not 
have been affected by changes in BMI beyond baseline. Moreover, sharp increases in the 
prevalence of hypertension and hypertension with anti-hypertensive medication at older 
ages have been observed after repeated measurements in two cohorts5, 8. The prevalence 
of hypertension was found to increase with more than 20% in both men and women aged 
50-59 years over a period of 11 years5. Increases were also observed for individuals with 
hypertension who used antihypertensive medication in Germany, these increases were the 
largest in age categories of 55-64 years (29%) and 65-74 years (22%) over a follow-up period 
of 9 years on average8. Based on these changes over time, we assume that similar trends 
may have occurred in the NLCS, which would likely lead to an attenuation of results in 
our analyses, in particular due to changes in hypertension status in the younger age groups. 
In the NLCS, questions were included in the baseline questionnaire to detect differences 
over time with regards to the consumption of alcohol before baseline. This information was 
used to assess whether individuals were stable alcohol users or abstainers during the 5-year 
period preceding baseline and separate analyses have been performed using this information. 
However, this does not provide information on the change in alcohol consumption during 
follow-up. As elderly tend to experience more severe and more prolonged effects of drinking 
alcohol, they may potentially reduce their consumption at older ages9. Such an effect was 
observed in a 20-year follow-up of a community sample from the United States, in which 
a reduction was observed in both the proportion of alcohol consumers and the frequency of 
consumption10. Another study, which showed similar trends, indicated that the consumption 
of lower quantities (one drink) increased with old age11. In light of these studies, the true 
(inverse) association between alcohol consumption and RCC risk may in reality be stronger 
than the association observed in our study, as individuals potentially decreased their alcohol 
consumption over time and more often consumed less alcohol than what they reported in 
the baseline questionnaire. We also used information on the self-reported history of kidney 
stones as diagnosed by a physician from the baseline questionnaire. In general, as the passing 
of a kidney stone generally is a memorable event, we expect that the reporting of kidney 
stones was accurate. In addition, the peak incidence of kidney stones is at 45-49 years of 
age, with the incidence decreasing after 55-59 years12. Noteworthy however, is the rise in 
kidney stone prevalence over the years, which may indicate that the increased occurrence 
of comorbidities implicated in kidney stone formation (among others, diabetes mellitus and 





follow-up. The diagnosis of kidney stones during follow-up likely indicates that the true 
effect of kidney stones on RCC development is larger than observed in our study. Regarding 
the ascertainment of diabetes mellitus in our cohort, we expect that more participants may 
have been diagnosed with type 2 diabetes mellitus during follow-up. In the years beyond 
baseline, there was a greater alertness regarding diabetes mellitus as a public health problem, 
largely due to the implementation of the Standard Diabetes Mellitus Type II in 1988, which 
contained guidelines on diagnosis, treatment and support of diabetes patients13. Furthermore, 
the Hoorn study which assessed the diabetes status of 2472 individuals aged 50-75 years 
in the Dutch town of Hoorn in the period 1989-1992 indicated that approximately 50% of 
all patients with diabetes were undiagnosed14. This, combined with the increased alertness 
for diabetes mellitus, increases the likelihood that additional diagnoses will have been 
made during follow-up by general practitioners. Furthermore, an increase in prevalence of 
approximately 75% was observed in the time-period 1991-2000 in men, and 25% in women 
in the Netherlands15. This change may largely be attributed to changes in the prevalence of 
risk factors for diabetes mellitus in the Netherlands (among others obesity, physical inactivity 
and smoking)15. In the period beyond 1999, changes have been made in the diagnostic criteria 
for diabetes mellitus, which may have contributed to a rise in prevalence beyond 199915. 
Although the effects of this change will likely be small, as this affects only the last 7 years 
of follow-up. Overall, it is likely that the prevalence of diagnosed diabetes mellitus will 
also have increased during follow-up in our cohort, which will most likely have led to the 
underestimation of effects in the relationship between type 2 diabetes mellitus and RCC in 
our study.
Selection bias in the collection and sequencing of tumour blocks
Analyses using the NLCS data are generally unlikely to be influenced by selection bias, as 
participants who reported cancer at baseline were excluded from the analyses and the loss 
to follow-up was limited. However, selection bias may have occurred during the collection 
of tumour blocks of RCC cases, during the selection of samples with sufficiently available 
isolated DNA for performing targeted sequencing and the selection of samples as a result of 
the quality of sequencing as described in chapter 616.
The completeness of follow-up for cancer in the NLCS was high through the use of record 
linkage with the Netherlands Cancer Registry (NCR), the Dutch Pathology Registry 
(PALGA) and Statistics Netherlands (CBS). Two studies assessing the coverage of the 
NCR have indicated coverage rates of 96% in the Limburg region and in Rotterdam (upon 
restriction to pathology-confirmed cancers)19, 20. In the NLCS, at the onset of the study (1987) 
the coverage by the NCR alone was 89%1. Supplementing with information from PALGA 
helped attain a coverage of 98.5%, and in 1988 the proportion of cancer cases that could be 
retrieved through the combined efforts of the NCR and PALGA was 100%1. These findings 
highlight the completeness of cancer follow-up in our study and as a result the accuracy of 
the estimated person-time at risk was high. Therefore, we estimate that selection bias by loss 
to follow-up was minimal. 
The potential for selection bias related to the collection of tumour blocks has been described 
in previous publications within the NLCS17, 18. In total, formalin-fixed paraffin-embedded 




able to be collected (80%) from ~50 pathology laboratories throughout the Netherlands. Some 
reasons for the unavailability of tumour blocks were the absence of tumour material during 
the collection process (e.g. stage IV tumours are often not excised), the inability to send the 
tumour tissue by pathology laboratories and the incomplete linkage with the Dutch Pathology 
Registry (PALGA), in particular for cases before 199117, 18. One method to assess whether 
selection bias has occurred due to sample loss is comparing whether exposures are related to 
the presence or absence of tumour blocks16. There were no differences on various exposure 
factors including, among others, age, sex, BMI, smoking, alcohol intake and hypertension 
between incident RCC cases with and without successful collection of tumour blocks17. In 
addition to this, due to the exceptionally high retrieval of tumour material (80%), we consider 
the potential of selection bias regarding the collection of RCC tumour blocks to be low17.
From the available ccRCC tumour blocks (n=366) tumour DNA from 252 ccRCC cases 
was selected for targeted sequencing as described in chapter 6. This selection was based 
on the availability of sufficient DNA required for sequencing and the presence of DNA 
fragments of at least 200 base pairs based on a DNA ladder. This selection was important as 
severely fragmented DNA, which is a common occurrence in routinely archived formalin-
fixed paraffin-embedded (FFPE) tissue, is less suitable for sequencing. After sequencing, 121 
samples had an average unique read depth of at least 20x for six out of seven selected genes. 
To assess the potential of selection bias we assessed whether there were differences based 
on the distribution of clinical characteristics (i.e. age at diagnosis, sex, tumour grade, tumour 
stage and tumour size) between all ccRCC cases with available tumour blocks (n=266), 
cases eligible for targeted DNA sequencing (n=252) and samples included in the prognostic 
analyses in chapter 6 (n=121). We assessed clinical characteristics, instead of environmental 
exposures as we did for the assessment of selection bias based on tumour collection, because 
these clinical characteristics may be associated with the prognosis of ccRCC, which was 
the outcome under study. In addition, these variables were available for all tumour blocks, 
based on the histological revision by two genitourinary pathologists. We did not observe 
clear differences between the distribution of clinical characteristics between these different 
selection steps. Therefore, we also consider the potential of selection bias to be low regarding 
the selection and inclusion of samples for targeted sequencing.
Histologic revision and the potential for misclassification of tumours
The classification of collected FFPE tumour material was performed by centralised revision 
of haematoxylin and eosin (HE)-stained slides by two experienced genitourinary pathologists 
based on the WHO-classification of tumours of 200421. Based on this revision of tumour 
material of 454 RCC cases, 366 (80.6%) were clear-cell (cc)RCC cases, 60 (13.2%) papillary 
(p)RCC cases, 15 (3.3%) chromophobe RCC cases, and 13 (2.9%) other or undefined RCC 
cases. The collection and histological revision of tumour samples is a unique asset of the 
NLCS, which provides a means to investigate relationship between different histologic 
entities and the aetiology and prognosis of cancer. In addition, the centralised revision by 
two genitourinary pathologists allows for a more accurate representation of tumour histology, 
as large differences may be expected if the histologic revision was based on information as 
entered in the NCR or derived from separate pathologists at the ~50 laboratories of tumour 





However, due to recent advances and changes in the classification of RCC tumours there 
are potential differences in tumour classification that may be present if the tumour blocks 
would be revised using present day classification systems. These advances include the 
emergence and ascertainment of new renal entities in the time-period after the pathological 
revision in the NLCS was performed22, 23. These newly described emerging renal tumour 
entities are relatively rare, compared to ccRCC and pRCC, with the estimated occurrence 
per subtype ranging from <1% to 4% of all (adult) RCCs24. Of these new entities, clear cell 
papillary RCC (ccpRCC) is the most frequent entity, with an occurrence of approximately 
3-4%24, 25. Noteworthy for ccpRCC is the overlap in morphological features with low-grade 
ccRCC and pRCC, which increases the difficulty to accurately distinguish this subtype24, 
26. Therefore, histological confirmation of ccpRCC often necessitates the assessment of 
immunohistochemical characteristics for accurate classification24. As these subtypes were 
not yet included as major subtypes in the WHO classification in 2004, and the methods of 
accurately assessing these subtypes were yet to be standardised, these new subtypes were 
not included in our classification21. As a result, our histologic classification likely contains 
ccpRCC cases that were categorised as either ccRCC or pRCC. It is likely, as indicated in 
this thesis, that different renal entities possess different aetiologies. Therefore, the presence of 
ccpRCC cases in subgroups categorised as ccRCC or pRCC may have distorted our results. 
We estimate that the effect of this difference in classification would be most pronounced in 
pRCC cases as these were limited in number in our analyses and, in turn, the misclassification 
of cases could then have a larger effect. However, based on the rare occurrence of these new 
entities, when compared to the main histological subtypes, we estimate that the impact of this 
potential difference in classification will have been limited.
In addition to changes in the histological classification of tumours, changes have also been 
made in the UICC TNM classification of malignant tumours during the follow-up period of 
the NLCS. These changes have been integrated in the Netherlands Cancer Registry (NCR) 
during the follow-up. The most impactful changes were alterations made in the classification 
between T1 and T2 regarding the tumour size, with the original cut-off between ‘small’ and 
‘large’ tumours, used by the NCR until 1988 (TNM: third edition27), <2.5 and ≥ 2.5 cm used 
by the NCR until 1998 (TNM: fourth edition28 through the 2nd revision of the fourth edition29), 
and a cut-off threshold between T1 and T2 at 7 cm in the time-period beyond that (TNM: fifth 
edition and up30, 31). In addition, different versions were not comparable regarding the lymph 
node involvement and changes have been made regarding the classification of the number and 
dimension of involved lymph nodes, with increasing strictness across later versions27-31. To 
remedy potential differences in classification over time, an older tumour grade classification 
(Fuhrman grading system) and all tumours in the NLCS were recoded according to the 
third edition of the TNM classification, as used in chapter 627. To remedy the differences in 
T-stage, we adjusted all our models that included tumour stage with tumour size.
Considerations in molecular (epidemiologic) research
Molecular research is a rapidly evolving field in which new revolutionary technologies 
are introduced in quick successions to uncover new genetic markers for disease32. Indeed, 
with the use of sophisticated next generation sequencing technologies and the continuous 
reduction of sequencing costs ample opportunities exist to unravel the biological complexities 




ranging from the identification of variants in candidate-genes to the use of next-generation 
sequencing techniques (NGS).
The detection of potential risk loci in RCC for the study of gene-environment interactions
In present day cancer research, the identification of novel risk loci is largely driven by the use 
of genome-wide association studies (GWAS). In these GWAS studies hundreds of thousands 
of Single Nucleotide Polymorphisms are tested for associations in an agnostic manner after 
which stringent genome-wide significance p-value thresholds are applied. As a result, only 
the most consistently and (relatively) strongly associated SNPs are maintained with odds 
ratios ranging from 1.1-1.4 in RCC33-40. At present, at least 13 autosomal risk loci have been 
described in the development of RCC and at least 2 sex-specific loci have been reported33-40. 
The GWAS approach stands in strong contrast to the use of a more traditional candidate gene 
approach, in which often specific pathways of interest are analysed in a hypothesis-driven 
manner, with specific associations between genes and the environment in mind41. With the 
advent of GWAS studies, due to the increased availability of SNP-chips and the limited 
power and low replicability of the often smaller candidate gene studies, the candidate gene 
study has taken a backseat in genetic research with some researchers even hinting at the 
obsoleteness of candidate gene studies in genetic research42. However, these GWAS studies 
do not come without risks either, as there are some methodological considerations that need 
to be made. Firstly, genetic traits identified in large GWAS studies are often determined 
based on linkage disequilibrium in the genome, which is the non-random linkage of genetic 
variants that are inherited together, indicating that a variant or a linked non-measured variant 
is associated in an independent model on disease outcome. As a result, it is often difficult 
to draw clear inferences from the findings in GWAS to make the step from sequence to 
consequence and from risk locus to involved gene43. In that sense, there is a niche opportunity 
for candidate gene studies to assess risk polymorphisms at a deeper level, when compared 
to GWAS studies. In candidate gene studies, as performed in chapter 5, it is important to 
critically assess potential polymorphisms based on a priori hypotheses. In the research 
described in this thesis, three SNPs in VHL were selected based on their association with 
either RCC risk or VHL promoter methylation in prior research44, 45. In addition, one HIF1A 
tag-SNP was included to investigate the potential for gene-environment interactions between 
SNPs in HIF1A and RCC, as the VHL/HIF-pathway is known to be involved in the aetiology 
of RCC46. Indeed, in chapter 5, an association was found between one of the included VHL 
SNPs and (cc)RCC risk in our models. While this SNP is readily available on commonly 
employed SNP assays used in GWAS studies, it has not yet been detected as a potential risk 
locus in GWAS studies, even though it has been consistently detected in multiple candidate 
gene studies44, 47-49. This indicates that candidate gene studies can still be relevant for the 
detection of plausible risk loci, and that risk loci should not solely stem from findings 
from large GWAS studies50. However, before performing a candidate gene study, serious 
considerations need to be made. First and foremost, sample sizes and biological plausibility 
should be critically assessed to be able to detect the presence of the relative small increases 
in risk conveyed by SNPs in relevant areas of the genome. Furthermore, information on 
the biological plausibility can be derived from either mechanistic hypotheses due to the 
involvement of a key pathway in tumourigenesis, or it could stem from novel regions of 
interest as detected in GWAS studies to try and pinpoint risk SNPs in potential functional 





criticisms of candidate gene studies is the non-replication of results, which is often thought to 
be attributed to population stratification52. Therefore, candidate gene studies should focus on 
extensive validation of detected associations in separate studies and populations to increase 
the reproducibility. In addition, even though often few candidate SNPs are tested, candidate 
gene studies require the implementation of false discovery rate procedures as there is a 
considerable risk of false discoveries. While genome-wide significance p-values are often 
too stringent, other techniques such as the (adaptive) Benjamini-Hochberg method provide a 
valid method for controlling false discoveries in candidate gene studies53. Upon taking these 
factors into account a niche might be created for candidate gene studies to provide valuable 
insights alongside the evidence generated by genome-wide association studies.
The selection and use of (NGS) techniques in this thesis
There are several NGS-based techniques available for the use in molecular research. In 
chapter 6 of this thesis we describe a study in which a target panel of the coding regions of 
42 genes was sequenced using a targeted sequencing approach. This approach was chosen 
to optimize the number of samples available for analysis, taking into account the costs when 
compared to whole genome sequencing (WGS) and whole exome sequencing (WES). In 
addition, the currently employed targeted sequencing panel enabled us to focus on setting 
variant call thresholds, to reduce the time needed to interpret the data, and it allowed for the 
visual verification of mutations in regions of interest. More comprehensive techniques, such 
as WES and WGS, result in long lists of variants with (yet) unknown significance54. As a 
result, the clinical relevance of these results will be difficult to assess. Therefore, we believe 
the chosen method was the most feasible, taking into account the means available at the onset 
of this study.
At the onset of this study, we focused on the sequencing of 32 of the most frequently mutated 
genes in ccRCC, supplemented with 10 genes associated with the VHL/HIF pathway and the 
P13K/AKT/MTOR pathway in ccRCC55-57. The original aim of this research was to assess 
somatic mutations, pathways and clustered analyses. However, because of the limited number 
of samples with sufficient sequencing quality (n=121), related power issues when assessing 
genes with a lower mutation prevalence (<5%), we restricted the analyses as presented in 
chapter 6 to the seven most frequently mutated genes in ccRCC (i.e. VHL, PBRM1, SETD2, 
BAP1, MTOR and TP53)55, 56. 
Suggestions and potential pitfalls for the use of sequencing data in large cohort studies
The collection and storage of fresh-frozen tissue, which is considered to be the standard 
for use in NGS, is often not feasible in large cohort studies due to the difficulty in logistics 
and costs of storage. Therefore, routinely archived FFPE tissue, as was collected in the 
NLCS, might pose an alternative to fresh-frozen samples, when taking into account the easy 
handling, long-term cheap storage and accessibility. While the fixation delay, the fixation 
process, tissue preparation, paraffin embedding and archival storage are known to contribute 
to DNA fragmentation, cross-linking and chemical modification of FFPE tissue-derived 
DNA, FFPE tissue derived DNA can provide valuable information regarding mutations 
in tumour DNA58. Unfortunately, the aforementioned factors will likely have biased the 
DNA quality of samples in this thesis, as we were not able to discern between pathology 




analyses. Therefore, selective drop out of samples may have occurred during the sequencing 
process based on differences in practices and guidelines between pathology laboratories. In 
addition, fixation and storage practices in Dutch pathology laboratories may have changed 
over time and small variations in fixation protocols may have led to differences in quality and 
quantity of isolated DNA59. 
While we were unable to assess the fixation practices in the NLCS, we did use the available 
information on the date of diagnosis and the date of DNA isolation to obtain information 
on the storage duration of FFPE blocks. In addition, we had information on the DNA stock 
concentration after DNA isolation, DNA fragment length as determined by a DNA ladder, 
and the estimated percentage of tumour tissue per tumour block. We used this information 
to assess which of these factors may have contributed to the quality of sequencing, 
operationalised as average read depth, of the 252 samples sequenced in the NLCS. Overall, 
we observed that samples with a longer storage duration as a FFPE block, a lower DNA 
stock concentration and higher fragmentation prior to sequencing had a lower average read 
depth. No direct association was observed between the percentage of tumour content and 
average read depth. Consequently, we noted that samples that had sufficient DNA quality 
to be included in analyses in this thesis had a shorter storage duration, a higher stock DNA 
concentration and a longer fragment length prior to sequencing. Two previous studies have 
found similar evidence regarding the association between storage duration and the reduction 
of sequencing quality58, while other studies found that storage up to 12 and 18 years only had 
a minor impact on the sequencing quality60, 61. Secondly, the long-term storage of DNA may 
negatively impact the stability and degradation of DNA when stored in low concentration62. 
This could explain the reduced sequencing quality observed in samples with reduced 
DNA stock concentrations during storage. However, it is important to note that the input 
quantity of DNA for sequencing was standardised for all samples under study. Lastly, DNA 
fragmentation is a substantial and well-documented problem in FFPE samples63, 64. Therefore, 
assessing which samples have limited DNA fragmentation prior to sequencing is valuable 
when selecting which samples to sequence as NGS fails more often when DNA is extracted 
from old FFPE samples58. 
While these findings by themselves do not completely pinpoint the reason why a large 
proportion of samples have dropped out in our study, they still may hold great value for 
future large scale cohort studies willing to obtain DNA from samples to manage expectations 
and to assess potential measures to counteract the temporal changes in the sample DNA. In 
general, FFPE tissue has been indicated as a source of robust data with comparable results 
to fresh-frozen tissue61, 65, 66. Findings reported in this thesis indicate that extensive quality 
control prior to sequencing may provide valuable opportunities for enhancing NGS results 






The selection of variant calling thresholds
In the sequencing process, various decisions have been made to optimise the variant calling 
process of the NGS data. Firstly, two variant callers, namely Freebayes and HaplotypeCaller 
from the Genome Analysis Toolkit (GATK), were employed to detect single nucleotide 
variants, insertions and deletions in our study. One limiting factor in this study was the 
absence of matching normal tissue to the tumour tissue, which increased the difficulty in 
the identification of true somatic mutations. To increase the likelihood of detecting somatic 
mutations, variants with a population-based frequency over 1% were filtered out. As it is 
likely that common population-specific variants were still present, we excluded variants that 
were present in more than four samples. FFPE tissue is also known to contain random C>T 
and G>A sequence artifacts67. By using a molecular barcoding-based method, which enabled 
us to detect unique sequencing reads, we likely reduced the likelihood that we detected these 
random artifacts as a major clone in our analyses67. In addition, we have assessed various 
methods of denoting which variants were major clones in our dataset and should be maintained 
for analysis, including changing the threshold regarding the mutant read frequency, minimum 
alternate reads and the required number of reads needed to call mutations. Major clones were 
defined as variants that were likely to be present in the majority of tumour cells. Due to the 
varying read depth between samples in our studies setting robust thresholds often led to the 
over- or insensitivity of the detection of variants in our study. As a result, gene mutation 
percentages were highly variable depending on the chosen thresholds. Therefore, a per sample 
proportional mutant read frequency approach was employed, in which the somatic variant 
with the highest mutation read frequency within the 42 included genes was called as a major 
clone. Subsequently, variants with a mutant read frequency ≥50% of the highest mutant read 
frequency seen for that sample and with at least four alternate reads were also detected as 
major clone variants. This also provided a method to deal with samples with a heterogeneous 
tumour content, which normally require adjusted variant detection limits depending on the 
tumour content percentage68. There are some limitations to the use of this method. Firstly, 
this method assumes that the coverage for all included regions is sufficiently high to reliably 
call mutations. Therefore, samples and target regions that did not function properly were 
assessed and excluded prior to the application of this method. Secondly, the assumption is 
made that at least one mutation is present in the 42 included genes under study, after earlier 
exclusion steps, which is then assessed as a major clone for that sample, unless no mutation 
is found with an alternative read frequency of at least four. Overall, the overall gene mutation 
frequency for the 121 samples were slightly lower compared to the TCGA and COSMIC 
databases as depicted in Table 1, except for KDM5C, which was slightly higher. Likely we 
were conservative in the calling of mutations, which is also exemplified in the lower variant 
calling rate with the currently employed method compared to prior studies in the NLCS18, 69. 
This may in part be attributable to the focus on major clones in this study, while other studies 
often included all detectable variants. Considering these factors, it is likely that the mutation 
percentages are lower than if we had decided to be less conservative with our variant calling. 




Table 1 - Comparison in gene mutation frequencies between the NLCS, the TCGA and 
COSMIC
NLCS TCGA (PanCancer)a,70 COSMIC
b, 56
VHL 37% 41% 52%
PBRM1 22% 38% 30%
SETD2 12% 12% 13%
KDM5C 12% 5% 7%
BAP1 6% 10% 13%
MTOR 3% 8% 7%
TP53 3% 3% 7%
a Kidney Renal Clear Cell Carcinoma (TCGA), PanCancer Atlas – samples with mutation data – 
accessed 02-July-2020 through cbioportal.org71, 72
b accessed 02 July-2020 through https://cancer.sanger.ac.uk/cosmic
The potential impact of intratumour heterogeneity
At the time of the collection of tumour blocks, one tumour block was collected per case 
for the isolation of DNA. Therefore, the results derived from our sequencing efforts reflect 
the occurrence of mutations in one tumour block. However, in present day research there 
is more attention for the potential intratumour heterogeneity in cancer, in which different 
mutations are found in different segments of the tumour, or in our case, within one tumour 
block. In general, tumours evolve into multiple genetically distinct subclones, which follow 
a branched evolution reflecting the tumour’s life history73. Mutations that are present in 
all tumour cells generally reflect mutations that have been acquired in the beginning of 
tumourigenesis. These major somatic mutations are thought to either be drivers or initiators 
of the process of tumourigenesis, or they may be passenger mutations that were already 
present in the cell prior to the transformation into a malignant cell73. In studies in ccRCC, 
inactivation of the VHL tumour suppressor gene and loss of heterozygosity at chromosome 
3p were seen as truncal early events74, 75. In addition, PBRM1 was also commonly observed 
as a truncal driver mutation in ccRCC74. Other common mutations in expected driver genes 
in ccRCC, such as BAP1, PTEN, PIK3CA, SETD2 and TP53, are often subclonal and play a 
role in progression of the tumour74. Of interest is the parallel evolution occurring in different 
subclones of SETD2, BAP1, KDM5C, ARID1A and PBRM1. These genes are recognised as 
chromatin modifiers, regulators of genomic architecture and DNA accessibility, which are 
important for gene expression and DNA damage repair, and have been consistently detected 
in subgroups of cases in single-sample analyses of ccRCC75, 76. Aside from the mechanical 
and clinical implications of these genes in tumour progression, this may also be an important 
consideration for the results of this thesis. As we only assessed one tumour block from our 
patients, we may only have a limited insight in the overall mutational profile of these patients. 
While it is likely that we have observed the most important driver mutations, as we commonly 
observed mutations in VHL and PBRM1, we were only able to detect mutations that were 
present in the specific area of origin of the tumour block. Resultingly, it is likely that we may 
not have been able to detect the full spectrum of mutations present in the (complete) tumour 
in our sequencing results. A solution to this, would be to introduce multiregional sampling, 
or alternatively, to collect multiple tumour blocks75, 77. Unfortunately, this is generally not 





selection tumour blocks or regarding the logistics and planning for the sampling of multiple 
areas in the tumour. In hindsight, an alternative could have been to collect and histologically 
revise multiple tumour blocks per individual. In turn, the tumour block with the highest 
tumour grade should then have been selected for sequencing, as tumour grade has been 
associated with mutational load in studies on intratumour heterogeneity75, 78. In addition, this 
allows for the identification of mutations in the most aggressive tumour cells. Potentially, this 
could have provided us with a more complete overview of the mutational burden for ccRCC 
in the tumours of the included samples. Future studies should ideally include protocols for 
multiregional sampling to provide crucial insights in the aetiology and prognosis of ccRCC, 
to assess tumour progression and to obtain a more complete snapshot of the mutational 
profile of the tumour.
Implications of the findings of this thesis
One of the aims of this thesis was to identify whether various environmental risk factors are 
differentially associated with the risk of renal cell carcinoma and its subtypes. With regards 
to environmental risk factors, we observed a potential heterogeneity of associations for 
BMI across ccRCC and pRCC risk. In the study detailed in chapter 3, BMI was positively 
associated with the risk of ccRCC, but inversely with pRCC risk. No clear heterogeneity 
of associations was found for cigarette smoking, alcohol consumption, hypertension 
and antihypertensive medication. The consistent reports of heterogeneity for BMI across 
ccRCC and pRCC risk may provide an indication of etiologic differences across RCC 
subtypes79-81. Until recently, from the other investigated risk factors, solely specific subtypes 
of antihypertensive medication have been heterogeneously associated across histological 
subtypes in other studies82. While we did assess the use of antihypertensive medication in 
our study, for which we observed no heterogeneity, we were unable to look into detail at the 
different types of antihypertensive medication due to power considerations and due to the use 
of different types of antihypertensive medication at the time. As a result, we were not able to 
validate these findings regarding specific types of antihypertensive medication. In a recently 
published study, which investigated the prevalence of cigarette smoking among patients with 
different histologic RCC subtypes, a higher prevalence of smoking was observed in pRCC, 
compared to ccRCC, although the difference was relatively small83. The extremely high 
sample size, due to the use of population-based cancer registries, may in part explain why 
this study was able to find differences in smoking status, while other smaller studies did not 
observe such heterogeneity.
These studies may act as a starting point to unravel differences in the mechanisms that 
influence the risk of specific RCC subtypes. There is a constant further sophistication in the 
classification of subtypes in RCC. Recent research has highlighted that there is a potential 
molecular subtyping present in ccRCC, designated as ccA and ccB, as originally described 
by Brannon et al.84. Of particular interest is the new finding that ccA risk may even be more 
strongly associated with BMI, when compared to ccB85. Moreover, the subclassification of 
pRCC into type 1 and type 2 in aetiology research may also provide worthwhile avenues for 
the detection of more specific aetiologic relationships in subtypes of RCC in future research. 
Papillary RCC is of particular interest, as type 1 and type 2 pRCC, also possess a distinct 
genomic profile. Type 1 pRCC more often features MET alterations, either through mutations 




heterogeneous genomic profile, as it tends to have alterations in FH, CDKN2A, TFE, TFEB, 
SETD2, BAP1 and PBRM1 genes86. Based on these differences, these pRCC subtypes could 
possess different mechanisms for developing cancer, and may as a result also be differentially 
associated with aetiologic risk factors. Unfortunately, in our studies, we were unable to 
discriminate between pRCC type 1 and type 2, even though the classification information 
was readily available, due to the limited number of pRCC cases in our study. These novel 
findings, combined with the evidence described in this thesis, highlight that the aetiology of 
ccRCC and pRCC is even more complex than previously understood.
While there is great focus on the established risk factors for RCC, other potential risk factors 
for RCC are still relatively poorly understood. In particular, evidence from large prospective 
cohort studies regarding these risk factors is lacking or needs confirmation. Therefore, we 
studied two potential risk factors of interest in this dissertation, namely type 2 diabetes 
mellitus (chapter 2) and the history of kidney stones (chapter 4).
In chapter 2, we assessed the association between type 2 diabetes mellitus and RCC. We 
were able to confirm associations, as described in the Nurses’ Health Study and the Health 
Professionals Follow-up Study87, as the association between type 2 diabetes mellitus and 
RCC was present in women, but not in men. We also assessed the relationship between RCC 
and antidiabetic medication and observed that individuals with type 2 diabetes mellitus who 
used insulin or analogues had a strongly increased risk compared to individuals without type 
2 diabetes mellitus. However, we need to be reserved and cautious when interpreting these 
results. As a result of the increasing stratification of subgroups and the further specification 
of exposures the number of cases in subgroups has become increasingly low, and effect 
estimates have become increasingly imprecise. Therefore, we hope that future studies are 
able to further discern this relationship as the relationship between anti-diabetic medication, 
in particularly metformin, and cancer has been a source of debate in cancer research. Based 
on the evidence from the Nurses’ Health Study and the Health Professionals Follow-up study, 
which found similar relationships regarding the association between type 2 diabetes mellitus 
and renal cell cancer, we might need to revisit the relationship between diabetes mellitus 
and its medication and the risk of RCC and its subtypes with the use of modern methods to 
ascertain the status of diabetes mellitus87. In addition, there is a sense of urgency with regards 
to untangling this relationship, as the worldwide prevalence of diabetes is projected to keep 
increasing in the coming 25 years88.
 
In chapter 4, we describe the association between the history of kidney stones and 
the occurrence of RCC and UTUC. At the time of publication, solely case-control and 
retrospective cohort studies had described this relationship, as detailed in the extensive meta-
analysis by Cheungpasitporn et al.89. In addition, there were few new studies investigating 
this relationship as eight out of nine studies included in the meta-analysis were published 
before the year 2000, and only three retrospective cohort studies were published after the 
publication of the meta-analysis on this relationship89-91. The analysis in the NLCS was able 
to describe new evidence on the relationship between kidney stones and RCC and UTUC 
risk. Most interestingly, we observed a heterogeneity of associations regarding the history of 
kidney stones and ccRCC and pRCC risk that had not been described before, namely kidney 





finding needs further confirmation, as both these histologic subtypes are thought to stem 
from the proximal convoluted tubule92. At this location it is thought to be unlikely for kidney 
stones to form93, 94. Therefore, the difference in these subtypes might imply that not the kidney 
stone formation, but another factor correlated with kidney stones may be associated with the 
difference in aetiology of RCC subtypes. In this research, we did not have information on 
the type(s) of kidney stones and the recurrence of kidney stones. Potentially, the association 
between different kidney stone types and the risk of ccRCC and pRCC may provide additional 
insights on the influence of specific components on the development of these subtypes. 
Hopefully, this may help elucidate the mechanisms behind this peculiar finding. In addition, 
information on the recurrences of kidney stones could provide interesting evidence as the 
results detailed an increased RCC risk at earlier ages of first kidney stone. Potentially, the 
earlier age at first kidney stone could be an indicator of having a longer period with recurrent 
stones. Aside from the effects of stone formation, tumour development could also be related 
to the presence of stone-forming salts and the interaction with fluids. Previous research in 
the NLCS has indicated that the interaction between sodium and fluid was associated with 
RCC aetiology, which are both important factors for the development of kidney stones95. 
Therefore, while the reason behind the heterogeneous association between kidney stones and 
RCC subtypes is unclear, it may provide a starting point for future research.
In chapter 5, we confirmed the association between one VHL SNP and (cc)RCC risk. VHL_
rs779805, while not (yet) discovered in large GWAS studies in RCC, has been associated 
with RCC risk in multiple candidate-gene studies47, 48. In addition, we observed that this 
risk was increased in ccRCC, when compared to overall RCC. While there is a clear link 
between the presence of mutations and epigenetic alterations in VHL for the risk of ccRCC, 
these findings also indicate that a smaller and more frequently occurring polymorphism in 
VHL may increase the susceptibility to ccRCC. In our study, we were not able to discern any 
clear gene-environment and gene-gene interactions. Moreover, based on earlier publications 
on VHL polymorphisms, we had expectations that there may be a possible link between 
tumour-specific VHL promoter methylation and the occurrence of VHL SNPs44. However, 
we did not observe an association between VHL SNPs and VHL promoter methylation in 
our study. Furthermore, various gene-environment interactions have been observed in (cc)
RCC96-100. We hypothesised that there might be potential for interaction between the most 
common risk factors for RCC and SNPs in the VHL/HIF-pathway. However, we observed no 
clear indication that there is a role of environmental factors in increasing or decreasing the 
susceptibility for ccRCC in the presence of VHL or HIF1A SNPs.
To assess high-risk alterations to the DNA, we used NGS to sequence a panel of frequently 
mutated genes in ccRCC (chapter 6). Determining the prognostic relevance of the seven 
most frequently mutated genes in ccRCC is a daunting task. There is a need for detailed 
clinical information, long-term follow-up data and the availability of either tumour material 
or isolated tumour DNA. In this dissertation, we describe the favourable association in 
individuals with VHL and PBRM1 mutations with ccRCC-specific survival, when compared 
to individuals without mutations in VHL and PBRM1. Evidence on the association between 
VHL mutations and ccRCC-specific survival is inconsistent, as studies have reported both a 
better101 and a worse ccRCC-specific survival associated with VHL mutations102. In addition, 




indicate the difficulty of discerning the influence of these mutations on ccRCC prognosis. 
The association of overall survival with PBRM1 mutations has been described in a large 
retrospective study within Memorial Sloan Kettering Cancer Center103, but not clearly with 
cause-specific survival using earlier Memorial Sloan Kettering Cancer Center and TCGA 
data101, 104, 105. These findings indicate the need for new large-scale studies to create additional 
insight into these relationships, as the current evidence is not sufficient to be able to provide 
unambiguous recommendations to the clinic regarding the prognosis of tumours based on 
their molecular make-up.
At present, the bulk of the evidence regarding the association between somatic mutations 
and the prognosis of ccRCC is often obtained using large databases, such as the TCGA and 
COSMIC. While many reasons support the use of such elaborate programmes, there may be 
some intrinsic factors that may affect the generalizability of results. Most importantly, when 
assessing the TCGA-KIRC classification (n=537) in the NIH Genomic Data Commons the 
source of samples is dominated by three large centres, namely the Memorial Sloan Kettering 
Cancer Center (26%), the University of Pittsburgh (20%), and the MD Anderson Cancer 
Center (13%)55, 106. As younger patients are more likely to be treated and included in research 
in these centres, this may affect the clinical characteristics and the treatments received of the 
population in this database107. Therefore, results and mutation rates as found in these initiatives 
are potentially driven by cases coming from these large specialised U.S. cancer and academic 
institutes, potentially affecting the genetic profile observed in ccRCC. In addition, these 
patients may also have received different treatments, when compared to other institutions, 
as these institutes are counted among the best hospitals for cancer in the U.S. and are more 
prone to use cutting-edge therapies. Potentially, this may affect outcomes when assessing the 
relationship between mutations and prognosis. Therefore, assessing the prognostic value of 
somatic mutations in an independent cohort may provide valuable information. In addition, 
novel research on samples from new large-scale studies might aid in getting a clearer view of 
the genomic characterisation of ccRCC, as there are some deviations, as indicated by table 1, 
in mutation rates between large databases for some of the most frequently mutated genes in 
ccRCC. This is exemplified in currently published studies in which a large variability in the 
proportion of ccRCC cases with VHL mutations is detected (17-95%)108.
Recommendations for future research
The results in this thesis indicate that there is potential for heterogeneity in the aetiology 
between RCC subtypes, in particular for BMI and kidney stones. While the current evidence 
has been consistent across studies, more studies are needed to further solidify the evidence. In 
addition, more research is needed to be able to adequately assess potential aetiologic factors 
taking into account the different RCC subtypes. Potentially, the effect of these risk factors may 
have been distorted by the inclusion of different RCC subtypes in analyses on overall RCC 
in past research. While the number of cases in individual studies for pRCC, chromophobe 
RCC and other more infrequent subtypes are in general very limited, large collaborations 
or the presentation of results for use in large meta-analyses may help circumvent this 
methodological problem. At present, little is known about the exact mechanisms how, and 
why these aetiologic factors lead to differences in the risk of histologic subtypes of RCC. In 
the past, attempts have been made to tie various risk factors together with the most common 





hypoxia109. However, a clear causal link between risk factors, hypoxia and RCC has not yet 
been described, aside from the involvement of the VHL/HIF pathway.
To create more insight into these mechanisms, future RCC research should focus on 
combining information from lifestyle and medical conditions, somatic mutations and 
epigenetic alterations. Assessing the co-occurrence of these factors requires methods that are 
able to agnostically assess combinations between environmental and genetic risk factors. At 
present, so-called mutographs are employed to assess the interplay between risk factors and 
alterations in the DNA, as described in the paper by Alexandrov et al.110. Using this method, 
unique mutational signatures are created to detect potential exposures to mutagens. With 
the help of specific mutational patterns, it may be possible to pinpoint the effect a specific 
exposure or activity exerts on the genome111. At present, more than 70 signatures have been 
identified in cancer, which have been associated with various proposed aetiologies including 
processes related to, among others, tobacco smoking and alcohol consumption110. In addition, 
signatures have been found that were specific to kidney papillary cancers110. However, 
the majority of mutational signatures remain of unknown cause110. In future research, 
underlying processes or tumour subtypes may be uncovered by assessing tumour profiles 
using more accurate exposure information or more elaborate mathematical approaches to 
derive the origin of mutations. Furthermore, future studies may also be able to use clustering 
techniques to determine common co-occurrences of mutations, copy number variations and 
variations in expression, as described in Begg et al.112. Methods like these may be able to 
detect combinations of aetiologic factors for cancer or specific cancer subtypes that would 
not readily be detected using more traditional methods. Unfortunately, the use of these 
mutographs and clustering techniques was beyond the scope of this thesis due to the need of 
more extensive genomic information than what is currently available within the Netherlands 
Cohort Study on diet and cancer (NLCS).
Concluding remarks
Renal cell carcinoma is complex due to the great amount of heterogeneity present between 
histologic subtypes. Continuous efforts are made to detail the underlying pathology with 
regards to risk factors, subtype classification and genetic alterations. Only by striving 
to classify renal cell carcinoma as accurately as possible can we get more insight on the 
mechanisms that drive this cancer. This will require epidemiologists to be highly adaptable 
to the continuously changing classifications or to critically assess the magnitude of these 
alterations on the results if older classifications are used.
The subclassification of renal cell carcinoma is not without problems. With continuously 
changing classifications and new insights on the genetic and histologic characteristics 
of RCC it is difficult to stay up-to-date with the present status of RCC research in large 
prospective cohort studies. Which often necessitates falling back on older classification 
systems to unify the available data collected over long follow-up durations. In addition, the 
constant stratification of subtypes in RCC leads to a decrease of power in analyses, which 
leads to difficulties in obtaining consistent results. Therefore, transparency in results and the 
combined effort of multiple research teams is required to enable future researchers to place 




With this dissertation, I hope to contribute by providing insight and critical considerations in 
the field of renal cell carcinoma research. In short, we observed heterogeneity of associations 
between ccRCC and pRCC regarding BMI and kidney stones. In addition, we confirmed 
findings regarding the association between kidney stones and type 2 diabetes mellitus with 
RCC. Furthermore, we observed differences in ccRCC risk between individuals with a VHL 
SNP. Lastly, using targeted sequencing, we observed that cases with mutations in VHL and 
PBRM1 had a better prognosis, when compared to cases without mutations in these genes. 
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The aetiology of RCC is still poorly understood. Although multiple risk factors have been 
investigated in relation to the risk of renal cell carcinoma (RCC), few risk factors have 
consistently been associated with RCC. In addition, there has been little attention for potential 
heterogeneity of associations across RCC subtypes. In the past, studies primarily focused on 
overall RCC. In recent years more attention has been given to associations between risk 
factors and distinct histological subtypes of RCC. Due to their distinct clinical, pathological 
and genetic makeup, it has been hypothesized that these histological subtypes may be 
differentially associated with risk factors. In turn, these differences may also contribute to a 
difference in aetiology across histological subtypes. Overall, more studies are needed on risk 
factors to unravel these relationships and to get a clearer view on the aetiology of RCC and 
its most common histological subtypes clear-cell RCC (ccRCC) and papillary RCC (pRCC).
All studies within this thesis were conducted using information obtained through the 
Netherlands Cohort Study on diet and cancer (NLCS). The NLCS was initiated in September 
1986 with the inclusion of 120,852 men and women aged 55-69 years. Information on 
dietary habits and other risk factors for cancer, such as lifestyle factors, medical conditions 
and anthropometry, were collected through a mailed, self-administered questionnaire. In 
addition to the questionnaire, approximately 90,000 participants provided toenail clippings. 
Follow-up for cancer occurrence was performed for all participants through computerized 
record linkage with the Netherlands Cancer Registry (NCR), the Dutch pathology registry 
(PALGA), and the causes of death registry maintained by Statistics Netherlands (CBS). 
During 20.3 years of follow-up 608 RCC cases were identified. For 454 RCC cases, formalin-
fixed paraffin-embedded (FFPE) tumour tissue could be collected and was available for the 
revision of tumour histology by two experienced pathologists. Of these 454 RCC cases, 366 
were classified as ccRCC cases, 60 as pRCC cases, and 28 as other or undefined RCC cases. 
DNA Isolated from FFPE healthy tissue and from provided toenail clippings was used for 
genotyping germline single nucleotide variants. In addition, DNA was isolated from collected 
FFPE tumour blocks for the identification of somatic mutations.
In chapter 2 of this thesis, we focused on the relationship between type 2 diabetes mellitus 
and the risk of RCC. We observed that type 2 diabetes was moderately associated with an 
increased RCC risk. In particular, we observed that female participants with type 2 diabetes 
had a more strongly elevated RCC risk, while this association was not present in men. 
Furthermore, we investigated the use of anti-diabetic medication and RCC risk. We observed 
that individuals with type 2 diabetes who reported the use of insulin had an increased risk of 
RCC, when compared to participants without type 2 diabetes. However, the number of people 
in this particular analysis was quite small, which might influence the accuracy of this result.
In chapter 3 we analysed whether there was a difference in association between established 
modifiable risk factors for RCC and the development of the two most common histological 
subtypes of RCC. To this end, we focused on the heterogeneity between body mass index 
(BMI), cigarette smoking, alcohol consumption and hypertension across ccRCC and pRCC 
risk. We observed a potential aetiologic heterogeneity regarding the association for BMI. 





finding was of great interest as BMI has been indicated as a potential source of aetiologic 
heterogeneity in prior studies on RCC subtypes. Furthermore, no clear and consistent 
indications were found for other sources of heterogeneity of associations regarding the risk 
of RCC subtypes.
In the analyses presented in chapter 4, we observed a relationship between the self-reported 
history of kidney stones and the development of RCC and upper tract urothelial carcinoma 
(UTUC). In particular, the risk of kidney stones was associated with an increased risk of 
papillary RCC, but not ccRCC. No heterogeneity of associations was found between kidney 
stones and UTUC in the ureter and renal pelvis. These findings raise questions regarding 
the mechanisms by which kidney stones may increase the risk of RCC, as the general 
hypothesis that kidney stones cause chronic inflammation and infection which may lead to 
the development of a tumour would not explain the observed differences in risk between 
ccRCC and pRCC.
Genetic alterations in the VHL/HIF pathway have been found to be important drivers of 
carcinogenesis in ccRCC. Therefore, we investigated the role of three candidate Single 
Nucleotide Polymorphisms (SNPs) in VHL and one SNP in HIF1A on the risk of developing 
(cc)RCC, their potential for interplay with the environment and with each other, and the 
relationship between VHL SNPs and VHL promoter methylation (chapter 5). One VHL SNP, 
VHL_rs779805, was associated with an increased RCC risk. No associations were observed 
for the three other SNPs. In addition, no clear interactions were found between the four 
selected SNPs and environmental factors after adjusting for multiple testing. Neither did we 
observe interactions between the SNPs. Lastly, we observed no associations between the 
selected VHL SNPs and VHL promoter methylation.
For the analyses presented in chapter 6 of this thesis we performed targeted sequencing on 
DNA isolated from tumour blocks of 252 ccRCC cases. Using this sequencing information, 
we created a seven-gene mutational profile, based on the seven genes with the highest reported 
mutation frequencies in ccRCC, to identify somatic alterations that alter the prognosis of 
ccRCC. This panel included VHL, PBRM1, SETD2, BAP1, MTOR, KDM5C, and TP53. 
Overall, 110 cases were eligible for these analyses. Individuals with mutations in VHL and 
PBRM1 had a more favourable ccRCC-specific survival, compared to individuals without 
mutations in these genes. However, this association did not maintain statistical significance 
after correction for multiple testing. The reasons for this potential association remain poorly 
understood. However, both VHL and PBRM1 have been implicated as important drivers in 
the early events of ccRCC development. 
In conclusion, taking into account various methodological considerations detailed in chapter 
7, this thesis highlights the importance of further subclassification of renal cancers by 
histopathological features and molecular characteristics for both aetiology and progression. 
This subclassification, however, does not come without compromise and will require great 
adaptability by epidemiological researchers. In the future, large-scale efforts will be required 
to be able to accurately and consistently assess the role of risk factors on the aetiology of 





Nog steeds is er weinig inzicht in de etiologie van het niercelcarcinoom (RCC). Hoewel 
verscheidene risicofactoren onderzocht zijn in relatie tot het risico op RCC, zijn er nog altijd 
weinig risicofactoren consistent in verband gebracht met RCC. Bovendien is er tot op heden 
weinig aandacht voor de mogelijke heterogeniteit van associaties met de verschillende RCC-
subtypen. In het verleden waren onderzoeken voornamelijk gericht op RCC in zijn geheel. De 
laatste jaren is echter meer aandacht besteed aan de specifieke associaties tussen risicofactoren 
en verschillende histologische subtypen van RCC. Verondersteld wordt dat deze subtypen 
mogelijk verschillend geassocieerd kunnen zijn met diverse risicofactoren vanwege de 
verschillende klinische, pathologische en genetische samenstelling. Deze verschillen kunnen 
op hun beurt ook bijdragen aan een verschil in oorzaken tussen histologische subtypen. Er 
is meer data nodig om deze relaties te ontrafelen en om een duidelijker beeld te krijgen van 
de etiologie van het RCC en de meest voorkomende histologische subtypen van het RCC, 
namelijk heldercellig RCC (ccRCC) en papillair RCC (pRCC).
De onderzoeken in dit proefschrift zijn allemaal uitgevoerd met behulp van informatie 
verkregen uit de Nederlandse Cohortstudie naar voeding en kanker (NLCS). De NLCS is in 
september 1986 gestart met de inclusie van 120.852 mannen en vrouwen die op dat moment 
55-69 jaar oud waren. Door middel van een zelf in te vullen vragenlijst werd informatie 
verzameld over voedingsgewoonten en andere risicofactoren voor kanker, waaronder 
leefstijlfactoren, medische aandoeningen en antropometrie. Daarnaast leverden ongeveer 
90.000 deelnemers teennagelknipsels aan. Met behulp van een koppeling met de Nederlandse 
Kankerregistratie (NKR), het Nederlandse pathologieregister (PALGA) en de registratie 
van doodsoorzaken, zoals bijgehouden door het Centraal Bureau voor de Statistiek (CBS), 
werd geregistreerd welke deelnemers, gedurende de studieperiode van meer dan 20 jaar, 
nierkanker ontwikkelden. In totaal werden gedurende de studieperiode 608 RCC-gevallen 
geïdentificeerd. Van454 RCC-gevallen kon formaline-gefixeerd paraffine-ingebed (FFPE) 
tumorweefsel worden verzameld. Dit FFPE-weefsel kon gebruikt worden voor de herziening 
van de tumorhistologie (subclassificatie) door twee ervaren uropathologen. Van deze 454 
RCC-gevallen werden 366 RCC-gevallen geclassificeerd als ccRCC, 60 als pRCC en 28 als 
andere of niet-gedefinieerde RCC. Daarnaast werd DNA geïsoleerd uit gezond FFPE-weefsel 
en uit de verstrekte teennagelknipsels voor het genotyperen van kiembaan mutaties en werd 
DNA geïsoleerd uit verzamelde FFPE-tumorblokken voor de identificatie van somatische 
mutaties.
In hoofdstuk 2 van dit proefschrift hebben we gefocust op de relatie tussen diabetes mellitus 
type 2 en het risico op RCC. We zagen dat diabetes type 2 geassocieerd was met een licht 
verhoogd risico op het krijgen van RCC. We zagen in het bijzonder dat vrouwelijke deelnemers 
met diabetes type 2 een sterker verhoogd RCC-risico hadden, terwijl deze associatie niet 
aanwezig was bij mannen. Verder onderzochten we het gebruik van antidiabetica en het 
RCC-risico. We stelden vast dat personen met diabetes type 2 die aangaven dat ze insuline 
gebruikten een verhoogd risico hadden op het krijgen van RCC, in vergelijking met 
deelnemers zonder diabetes type 2. Het aantal mensen in deze specifieke analyse was echter 





In hoofdstuk 3 hebben we onderzocht of er een verschil was in het verband tussen bekende 
beïnvloedbare risicofactoren voor RCC en de ontwikkeling van de twee meest voorkomende 
histologische subtypes van RCC. Daartoe hebben we ons gericht op de heterogeniteit tussen 
body mass index (BMI), het roken van sigaretten, alcoholgebruik en hypertensie op het 
ccRCC- en pRCC-risico. We constateerden een mogelijke etiologische heterogeniteit met de 
associatie voor BMI. BMI was namelijk geassocieerd met een verhoogd risico op ccRCC, 
maar omgekeerd geassocieerd met het risico op het krijgen van pRCC. Deze bevinding 
kwam overeen met eerdere onderzoeken naar RCC-subtypen, waarin BMI ook als mogelijke 
bron van etiologische heterogeniteit werd geduid. Voor andere risicofactoren werden geen 
duidelijke of consistente aanwijzingen gevonden voor heterogeniteit met betrekking tot het 
risico van RCC-subtypen.
In de analyses die beschreven staan in hoofdstuk 4 hebben we een relatie gevonden 
tussen de zelf-gerapporteerde geschiedenis van nierstenen en de ontwikkeling van RCC en 
urotheelcarcinoom van de bovenste urinewegen (UTUC). In het bijzonder was het risico op 
nierstenen geassocieerd met een verhoogd risico op pRCC, maar niet op het ccRCC-risico. 
Tussen nierstenen en UTUC in de urineleider en het nierbekken werd geen heterogeniteit 
van associaties gevonden. Deze bevindingen roepen vragen op over het onderliggende 
mechanisme waarmee nierstenen het risico op RCC verhogen. De algemene hypothese die 
beschrijft dat nierstenen chronische ontstekingen en infecties veroorzaken die vervolgens 
kunnen leiden tot de ontwikkeling van een tumor, zou vanwege deze bevindingen geen 
passende verklaring zijn voor de waargenomen verschillen in het risico tussen ccRCC en 
pRCC.
Op basis van eerder gepubliceerde artikelen blijken genetische veranderingen in het VHL/HIF-
systeem belangrijke beïnvloedende factoren van carcinogenese bij ccRCC te zijn. Daarom 
onderzochten we de rol van drie veelvoorkomende enkelvoudige basenpaarveranderingen 
(single nucleotide polymorphisms; SNP’s) in VHL en één SNP in HIF1A op het risico van 
het ontwikkelen van (cc)RCC (hoofdstuk 5). Daarnaast onderzochten we de interactie van 
deze SNPs met verscheidene omgevingsfactoren en met elkaar. Tevens onderzochten we de 
relatie tussen de VHL SNPs en VHL promotor methylering. Eén VHL SNP, namelijk VHL_
rs779805, was geassocieerd met een verhoogd (cc)RCC-risico. Er werden geen associaties 
waargenomen voor de drie andere SNP’s. Bovendien werden geen duidelijke interacties 
gevonden tussen de vier geselecteerde SNP’s en omgevingsfactoren na het uitvoeren van 
een correctie voor meervoudig toetsen. Evenmin hebben we interacties tussen de SNP’s 
waargenomen. Ten slotte, namen we ook geen associaties waar tussen de geïncludeerde VHL 
SNP’s en VHL-promotormethylering.
Voor de analyses in hoofdstuk 6 van dit proefschrift hebben we een gerichte nucleotide 
volgorde bepaling (targeted sequencing) uitgevoerd op DNA geïsoleerd uit tumorblokken 
van 252 ccRCC gevallen. Met behulp van deze sequentie informatie hebben we een 
mutatieprofiel gemaakt, welke gebaseerd is op de zeven genen (VHL, PBRM1, SETD2, BAP1, 
MTOR, KDM5C en TP53) met de hoogst gerapporteerde mutatiefrequenties in ccRCC. Op 
deze manier wilden wij somatische veranderingen identificeren die mogelijk de prognose van 
ccRCC beïnvloeden. In totaal kwamen 110 cases in aanmerking voor onze analyses. Uit de 




overleving hadden in vergelijking met cases zonder mutaties in deze genen. Deze associatie 
verloor echter de statistische significantie na correctie voor meervoudig toetsen. De redenen 
voor het verband van deze genen met een verbeterde ccRCC-overleving blijft onduidelijk. 
Uit eerdere studies is echter gebleken dat zowel VHL als PBRM1 betrokken zijn bij de initiële 
ccRCC-ontwikkeling. Verder onderzoek is nodig om te zien of deze genen ook een rol spelen 
bij de prognose van ccRCC.
Rekening houdend met verschillende methodologische overwegingen, zoals beschreven 
in hoofdstuk 7, benadrukt dit proefschrift het belang van verdere subclassificatie van 
nierkanker op basis van histopathologische kenmerken en moleculaire karakteristieken voor 
zowel de etiologie als de progressie van nierkanker. Verdere subclassificatie komt echter 
niet zonder compromis en vereist een groot aanpassingsvermogen van epidemiologische 
onderzoekers. Naar verwachting zal in de toekomst grootschalig onderzoek nodig zijn om 
de rol van risicofactoren op de etiologie van histologische subtypen van RCC nauwkeurig en 






In this chapter I will discuss the scientific and social impact that the research described in this 
dissertation has provided in the short-term and could provide in the long-term. Furthermore, 
we will detail how the results were disseminated during the PhD trajectory. Additionally, we 
put the results of this thesis into a broader perspective by highlighting the potential impact 
of this dissertation for researchers, clinicians and policymakers in a public health setting and 
patient care.
The dissemination of results during the PhD trajectory
During the PhD trajectory various means were employed to disseminate the study results to a 
broad audience, including researchers and clinicians from multiple disciplines.
Firstly, study findings were published in various international scientific journals, as detailed 
in the beginning of each chapter of this dissertation. Secondly, our scientific findings were 
presented at various conferences and symposia for audiences with a broad background. For 
example, in 2017 and 2019, our scientific results were presented at the Dutch Epidemiological 
Conference (WEON), which is generally attended by epidemiologists from various research 
backgrounds. In addition, our research was presented at science days and research meetings 
in Maastricht thereby sharing the results to multidisciplinary audiences with a broad 
clinical and/or healthcare background. Thirdly, scientific results were presented targeted 
to specific audiences relevant to the scientific work. For instance, considerations regarding 
the feasibility of the use of formalin-fixed paraffin embedded (FFPE) tumour material were 
presented at the 4th International Molecular Pathological Epidemiology (MPE) Meeting 
(Boston, USA) in 2018. At this conference, an international audience from diverse fields 
gathered for discussions on the topic of MPE. This event proved to be a key opportunity to 
discuss our insights into factors affecting the quality of sequencing when using routinely 
archived FFPE material with experts in the field of DNA sequencing. During this meeting, 
we realized that the use of FFPE tissue for sequencing wasn’t as clear-cut as we expected 
and that various research groups were experiencing similar difficulties in maintaining a 
high sequencing quality needed in research. By sharing our first-hand experiences from the 
Netherlands Cohort Study on diet and cancer (NLCS), we hopefully gave other researchers 
insights on what to account for when using routinely archived FFPE tumour material that 
has been stored for extended periods of time. Hopefully, this may lead to a reduction in 
research waste, as researchers may be more inclined to account for sample characteristics 
(i.e. storage duration and DNA concentration) during DNA isolation and work-up that could 
lead to reduced sequencing yields. To further the dissemination of these insights, appendix 2 
has been added to chapter 5 in this dissertation. Moreover, factors influencing the quality of 
sequencing were presented to pathologists at the Maastricht Pathology Meeting (Maastricht, 
the Netherlands) in 2018, which was a joint effort from the British Division of the International 
Academy of Pathology (BDIAP), the Pathological Society of Great Britain & Ireland and 
the Dutch Society for Pathology (NVVP). During this meeting questions were addressed 
on what factors pathologists, among others, should be aware of to maintain sufficient data 
quality for sequencing. Sharing these insights could be useful for expectations management 
in the case researchers want to use routinely archived FFPE tumour material which has been 
stored in suboptimal conditions for a prolonged period of time. Lastly, these insights could 





optimize the collection and storage of (FFPE) tumour tissue.
Lastly, our research on the association between kidney stones and renal cell carcinoma 
(RCC) and upper tract urothelial carcinoma (UTUC) was picked up by international press, 
which enabled our research to reach a broad audience beyond the scientific community. 
Furthermore, the article was featured on online websites specialized in clinical research, 
which may hopefully have led to additional awareness around the potential link between 
kidney stones and RCC and UTUC and its subtypes in clinicians and other health care 
professionals.
Future impact of the generated knowledge
The findings presented in this dissertation may also have various scientific and social 
implications in the (nearby) future. In addition, several challenges for research are brought 
up by the research presented in this dissertation that researchers should be aware of in the 
field of RCC research.
Determinants for renal cell carcinoma
One of the primary aims of this dissertation was to assess risk factors for RCC and its 
subtypes. Two potential risk factors which are highly prevalent in the population, namely 
type 2 diabetes mellitus and kidney stones, which as of yet are not considered established 
risk factors for RCC, were observed to be associated with an increased risk of RCC in the 
Netherlands Cohort Study on diet and cancer. 
The study on type 2 diabetes mellitus described in this dissertation reinforces recent evidence 
from the Nurses’ Health Study and the Health Professionals Follow Up Study that diabetes 
mellitus is associated with RCC specifically in women, but not in men1. From a scientific 
perspective, this observation could be of great importance for finding clues for unravelling 
factors that contribute to the development of RCC. In a similar vein, the observed association 
between anti-diabetic medication use and the risk of RCC may prove to be an interesting 
observation for future research. Anti-diabetic medication has often been a source for heated 
debate in the scientific community. This is, in part, due to the inconsistent associations 
between anti-diabetic medication and the risk of various cancers2, 3. The information regarding 
the effect of these types of medication on the risk of kidney cancer remains limited from 
observational studies2. Hopefully, other largescale prospective cohorts will find opportunities 
to look into replication of these findings, as these observed results in our study do not yet 
suffice as conclusive evidence due to underlying methodological constraints.
The current evidence on the association between kidney stones and RCC is slightly stronger, 
although mainly supported by evidence from retrospective cohort studies or case-control 
studies. As a result of a meta-analysis by Cheungpasitporn et al., kidney stones have been 
featured on Wolters Kluwer UpToDate as a risk factor for RCC, enabling physicians to easily 
access information on the role of this risk factor in RCC4, 5. Interestingly, the majority of 
studies featured in the aforementioned meta-analysis were published between 1984-19974. 
Resultingly, no evidence is available regarding associations between kidney stones and 
specific RCC tumor entities. Therefore, if clinicians are inclined to look for more information 
on kidney stones and the relationship with RCC subtypes, they are likely to end up with the 
data from our study, being the first to report on the heterogeneity of associations regarding 
kidney stones across ccRCC and pRCC risk. This heterogeneity of associations is of particular 




disconnect between the location where kidney stones form and the location where ccRCC 
and pRCC develop. This finding may therefore provide a lead for delving deeper into the 
characteristics and mechanisms resulting in the association between kidney stones and RCC 
subtypes for future research.
An increased awareness by both clinicians, policy makers and patients for (lesser known) 
risk factors for RCC and its subtypes may contribute to improved individual healthcare in the 
future. With increased awareness clinicians may be better equipped to provide advice targeted 
to the characteristics of the patient. As many of the risk factors for RCC are shared with other 
important comorbidities that tend to severely effect the quality of life, these advices may 
improve the overall health of patients. Furthermore, policy makers and health professionals 
may include these risk factors in guidelines and factsheets to aid in the education of clinicians, 
patients and researchers.
Heterogeneous associations for histologic subtypes of RCC
In recent years more attention has been brought to the associations between risk factors 
and the risk of specific histological subtypes of RCC. These histological subtypes may be 
differentially associated to risk factors due to their distinct clinical, pathological and genetic 
makeup. Information on the association between risk factors and specific subtypes of RCC is 
crucial as potential differences in association can add noise when trying to assess aetiological 
relationships. For instance, if a risk factor is only associated to a specific histologic subtype of 
RCC, no clear or conclusive evidence may be found if studies are performed in a population 
with varying tumour histologic subtypes. Therefore, the observed differences across the risk 
of ccRCC and pRCC regarding the history of kidney stones and body mass index (BMI) may 
help elucidate differences in aetiology and differences in aetiological mechanisms involved 
between subtypes. At present, new entities are continuously described and incorporated in 
the WHO classification for tumours. Therefore, more research is needed to establish whether 
different entities possess different aetiologic mechanisms. 
Even though established risk factors convey additional risks for RCC it remains hard to 
translate these findings into direct changes in prevention strategies for health policy makers. 
Population screening, for instance, is not a feasible strategy at this point in time. One of the 
primary barriers to population screening for RCC is the relatively low prevalence of RCC. It 
is estimated that by screening 1,000 asymptomatic individuals from the general population 
using ultrasound only one or two cases of RCC will be detected6. An employable strategy 
to resolve this problem is by creating prediction models for targeted screening of high-risk 
populations. However, as (modifiable) risk factors for RCC, including smoking, obesity, 
hypertension, kidney stones and diabetes mellitus, only translate into moderate risk increases 
and since they are not specific for RCC, these factors are unlikely to be suitable for use in risk 
prediction models6. Resultingly, more evidence is needed on the aetiology of RCC to make 
risk estimations more accurate. Hopefully, this will enable us to detect RCC in earlier stages 
in future times and, in turn, reduce mortality rates of RCC. 
For clinicians and general practitioners it remains of great importance to actively promote 
healthy lifestyles as the reduction of the prevalence of obesity, smoking and hypertension 
in the general population may pose viable strategies to the reduction of the burden of RCC. 





Prevalence) indicates that more than 20% of the RCC cases in Europe can be attributed to 
obesity7. Furthermore, tobacco smoking also heavily contributes to the burden of kidney 
cancer8. More information is needed to get more accurate estimations on the burden of RCC 
attributed to hypertension, diabetes mellitus and kidney stones. To this end, more information 
is needed on the direct mechanisms by which these risk factors are associated to RCC. An 
example is inconclusive evidence regarding the role of anti-hypertensive medication on the 
risk of RCC. Insights in such factors may then open new avenues for prevention strategies 
against renal cancer in the general population.
In the past, strategies have been made to create risk profiles of patients who developed (cc)
RCC9. In general, the focus in these methods relies on clinical characteristics to create a 
prognostic index. Based on the predicted prognosis of these patients, different systemic 
therapies are recommended. These models could also benefit from additional prognostic 
variables such as molecular testing. For instance, in this dissertation (chapter 6) we reported 
that patients with ccRCC had a better prognosis if they had VHL or PBRM1 mutations, when 
compared to patients without these mutations. Insights like these, combined with detailed 
clinical information may be used in the future to predict the prognosis of (cc)RCC in patients 
or to recommend treatments with higher rates of success. 
One important sidenote regarding this observed association is that the analyses in this 
dissertation were based on a mostly treatment-naïve population. This may provide indications 
of how ccRCC progresses without the effect of interventions beyond surgical resection. 
Nowadays, this information is hard to obtain, as patients tend to receive various forms of 
treatment (a.o surgical resection, targeted therapy and/or immunotherapy). Hopefully, 
the information on gene profiles described in this thesis may provide useful information 
for researchers and clinicians who are looking to further incorporate mutational profiles in 
prognostic indices. Hopefully, in the future extensive tailored treatment strategies will become 
available for the treatment of RCC depending on the genotypic and phenotypic features of the 
tumour. Having clearer information regarding more optimal treatment strategies for patients 
by incorporating prognostic features may aid clinicians in providing better patient care in the 
future, which may reduce the health care burden of RCC.
Conclusion
In this dissertation we have included several studies that highlight aetiological and prognostic 
mechanisms for the risk of RCC and its subtypes. To disseminate this evidence to the right 
audiences and to increase the impact of this work, several strategies were employed to share 
these results with researchers, clinicians and general audiences. While most results are not 
directly suited for inclusion in adjustments to current healthcare, they may provide crucial 
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Gedurende de afgelopen vier jaren heb ik veel verschillende mensen mogen ontmoeten en 
met veel geweldige mensen samen mogen werken. Door jullie allen heb ik gedurende de 
afgelopen jaren een behoorlijke groei op professioneel als persoonlijk vlak door kunnen en 
mogen maken. In dit hoofdstuk wil ik graag enkele personen of groepen even uitlichten om 
in het bijzonder te bedanken.
Allereerst wil ik natuurlijk mijn promotieteam bedanken. 
Leo, ik heb ontzettend genoten van onze samenwerking. Ik heb veel geleerd van de kalme 
en weldoordachte wijze waarmee jij (epidemiologische) vraagstukken aanpakt. Bij jou kon 
ik niet alleen altijd terecht voor een technische of vakinhoudelijke vraag, maar ook voor het 
over en weer kaatsen van ideeën. Gelukkig hebben we gedurende de afgelopen jaren geleerd 
om al deze creativiteit te bundelen en om zo (enigszins) gestructureerd onze vraagstukken 
aan te pakken. Dat was tijdens onze eerste overleggen wel anders. Uiteindelijk denk ik dat 
we wel 3 á 4 boekjes met ideeën hadden kunnen vullen... Verder wil ik je ook bedanken voor 
alle kansen en mogelijkheden die je me geboden hebt. Voor mijn gevoel heb ik bij jou vanaf 
mijn eerste dag als PhD alle kansen gekregen die jij me kon bieden. Door jouw aanpak en 
goede begeleiding ben ik de afgelopen jaren niet alleen flink gegroeid als epidemioloog, maar 
ook als persoon.
Piet, bedankt het vertrouwen in mij. Jouw scherpe blik en kritische vragen gaven vaak een 
nieuwe impuls aan ons onderzoek. Ook jouw tijdsmanagement bleek van groot belang 
gedurende mijn promotietraject waar jij op de juiste momenten aan de rem durfde te trekken, 
danwel randzaken durfde weg te halen. Tevens wil ik je bedanken voor de kans om mijn 
onderzoek uit te voeren binnen de NLCS. Zonder jou was dit niet mogelijk geweest.
Klaas, jij hebt mij veel inzicht geboden in de wereld van genetica, sequencing en labwerk, 
waar ik als relatieve leek instapte aan het begin van dit promotietraject. Met jouw Groningse 
nuchterheid wist je me de belangrijkste concepten van genetica en sequencing in rap tempo 
helder uit te leggen, zodat we snel theorie en praktijk konden combineren binnen onze 
samenwerking. Zowel tijdens mijn bezoekjes aan Groningen, als tijdens het schrijven van de 
stukken voor dit boekje, maakte je altijd tijd vrij om te zorgen dat alles in orde kwam.
Verder zou ik ook graag mijn dank uit willen spreken voor de leden van de 
beoordelingscommissie: Prof. dr. Jeroen Kooman, Prof. dr. Axel zur Hausen, Prof. dr. Bart 
Kiemeney, Prof. dr. Peter Mulders, en Prof. dr. Frans Ramaekers voor de tijd en moeite die 
jullie gestoken hebben in het beoordelen van dit proefschrift.
Ook wil ik alle co-auteurs bedanken voor jullie waardevolle inzichten, kritische remarks en 
vooral de prettige samenwerking. In particular, I would like to mention Ferronika, thank you 
for your effort on the Maastricht/Groningen project (depending where you’re doing your 
PhD!) and thank you for the good times when I was visiting Groningen. I am glad we were 
able to include our interesting paper in our dissertations.





geroepen werd. Het informele karakter en het overmatige enthousiasme tijdens de overleggen, 
presentaties en het delen van hersenspinsels was altijd een ideale broedvijver voor nieuwe 
ideeën, artikelen en samenwerkingen. In het bijzonder wil ik Manon, Kim en Maureen,  als 
aanschuivers van het eerste uur, bedanken voor de frisse en reeële blik. Andere Kim (haha), 
bedankt dat jij het aandurfde om het stokje van mij over te nemen. Dit is met alle schema’s, 
annuleringen, etcetera, een behoorlijk uitdagende taak. Adriaan, bedankt voor de peptalk op 
het PathSoc en MPE congres. Selena en Iryna, hopelijk kunnen we in de toekomst nog veel 
mooie inzichten halen uit het revisie-project! Jaleesa... zelfs als ik paniekerig aangestuifd 
kwam, wist jij de kalmte te bewaren. Bedankt voor al je werk met de GENRE series en het 
overzicht dat je meermaals kon bieden.
Ik wil ook alle collega’s van de NLCS bedanken. Middels jullie inzichten en kennis heb ik 
ontzettend veel geleerd. Al jullie projecten, ideeën en bezigheden blijven mij intrigeren en 
laten mij duizelen over alle mogelijkheden.
Verder wil ik ook alle collega’s van de vakgroep epidemiologie bedanken. Jullie hebben er 
voor gezorgd dat ik net iets vaker koffie wilde halen, zodat ik de kans had om iemand tegen 
te komen voor een praatje bij het koffiezetapparaat of bij een toevallig openstaande, danwel 
openslaande deur. Bedankt voor jullie collegialiteit, ondersteuning en belangstelling die ik 
heb ervaren in alle jaren dat ik op de vakgroep rondzwierf. Ook wil ik mijn waardering 
uitspreken voor jullie inzet voor het onderwijs. Voor jullie studenten gaan jullie allemaal 
door het vuur. 
Ook al was ik niet vaak zo’n binnenloper, toch wil ik graag in het bijzonder ook Yvonne 
Leenders, Mariëlle, Petra, Conny, Irma en Yvonne (van den Bergh) bedanken voor al jullie 
hulp als ik dan toch een prangende vraag had of ondersteuning vanuit de vakgroep nodig 
had. Jolanda, bedankt voor het inplannen van mijn niet-altijd-driemaandelijkse afspraken 
met Piet en Leo. Ook wil ik je bedanken voor de geweldige verjaardags-plakaten die je 
gemaakt hebt in de afgelopen jaren (zowel voor mij als voor collega’s). Zelfs al was het 
onderwerp voor jou wereldvreemd, jij kwam altijd aanzetten met schitterende, doch relevante 
kunstwerken. Harry en Jos, jullie stonden altijd paraat om mij uit de brand te helpen. Jos, 
jouw aanpakkersmentaliteit en enorme collegialiteit heeft me ontzettend geholpen in de 
laatste jaren. Van een spontaan verdwenen beeldscherm tot een trage computer, jij wist 
altijd met een passende oplossing te komen. Harry, de rust en kalmte waarmee jij problemen 
oplost, zelfs als ik niet helemaal begreep wat er uiteindelijk aan de hand was, is van niet te 
onderschatten waarde. En als laatste Matty, bedankt dat je altijd een luisterend oor bood en 
naar mogelijkheden zocht om net iets meer te kunnen bieden. Daarnaast ontzettend bedankt 
voor al je hulp in de afgelopen periode, het heeft mij veel stress gescheeld wetende dat ik op 
jou kon vertrouwen.
Christel en Martien, ik herinner me de dag dat ik kwam solliciteren voor de HSRM nog als 
gisteren. Christel, zoals altijd, kwebbelend over van alles en nog wat en Martien pijnzend 
over de materie. Dat beeld is zeker blijven hangen gedurende de laatste jaren. Christel, 
bedankt voor alle momenten dat ik bij jou binnen kon lopen of dat je jezelf naar de verste 
uithoek van Deb bewoog. Voor je verhuizing op Deb had ik altijd een goed excuus om naar de 
‘Gym’ te gaan, al kon dat zelfs spontaan veranderen in een korte excursie rond het gebouw. 




je voor iedereen de tijd nam. Wat heb ik genoten van de epistels die je op de mail zette over 
de taken, zodat ik altijd goed voorbereid en vol vertrouwen aan het onderwijs kon beginnen.
Eline en Colinda, jullie brok aan ervaring en open deuren heb ik altijd immens gewaardeerd. 
Eline, jij bent altijd bereid om nog een extra taak, een extra meeting of een extra 
vrijdagmiddagborrel (VrijMiBo) in te plannen. Jij was nooit te flauw om iets voor me uit 
te zoeken of even met me mee te denken. Ook was je een gewillig slachtoffer voor al mijn 
VrijMiBo Photoshop kunsten en (onsuccesvolle) airfryer verkooppraatjes, dank! Colinda, ik 
denk met veel plezier terug aan onze reis naar Boston waar we naast een toffe MPE meeting 
ook overal ongepland wat later aankwamen omdat we (te) lang hadden gekletst in onze air-
BnB. Dit was echter niet verbazingwekkend, want ook op Deb hebben we genoeg lange, 
maar vooral goede gesprekken gevoerd over allerlei onderwerpen. Bedankt voor al jullie 
inzichten, ik heb ontzettend veel van jullie geleerd.
(Oud) Epi-aio’s, waar moet ik beginnen. Broodjeslunches, Fast-Food Friday, VrijMiBo’s, 
Noro-lunches gevolgd door een heus epidemiologisch onderzoek, journal clubs, rondjes 
(snel)wandelen, carnaval, congressen en symposia, het is eigenlijk te veel om hier allemaal 
op te noemen. Maar het belangrijkste bij al deze dingen is dat jullie nooit te flauw waren om 
de deur wagenwijd open te zetten om te helpen bij vragen, even een praatje te maken, of een 
keer in die verre uithoek van Deb te kijken of er toch nog iemand zat. Ook al voelt het raar 
om te vertrekken vanachter een computerscherm, ik waardeer het ontzettend dat we toch nog 
ZOOM-borrels hebben kunnen organiseren. De laatste borrel in het park maakt het dan nog 
net iets specialer.
Dan wil ik ook nog even de mensen op ‘de serieuze kamer’ bedanken voor de geweldige tijd 
die ik de afgelopen jaren heb gehad. Lloyd en Lisette, wat heb ik het naar mijn zin gehad bij 
ons op de kamer en ik hoop dat ik jullie de afgelopen jaren niet te veel afgeleid heb. Maar naar 
mijn idee heb ik daarvoor toch voldoende gecompenseerd door het halen van koffie en thee. 
Lloyd, als stamhoofd was jij altijd de oude wijsgeer van de kamer. Met jouw methodische 
en analytische aanpak wist jij altijd snel tot de kern van het probleem te komen, zelfs als dit 
los stond van wetenschappelijke problemen. Ik denk met veel plezier terug aan alle vrijdagen 
waar jij bewust bus na bus miste om toch nog even de belangrijke dingen in het leven door te 
spreken. Mogelijk kan je de banen van de bureaustoelen nog in de vloerbedekking zien staan. 
Lisette, kamelenkoningin, jij was vaak een bron van inspiratie voor mij als ik jou zag knallen 
achter die miniscule schermpjes. Als jij je zinnen op iets zet dan gaat het ook gebeuren, maar 
altijd in een positieve zin. Jij bent denk ik het schoolvoorbeeld van schijn bedriegt, en dan 
heb ik het niet over imposter-syndroom. Over de jaren bleef je me verbazen met verhalen 
over whiskeyproeverijen en de meest smerige gangsterrap die ik in eerste instantie nooit bij 
jou geplaatst zou hebben. 
Natuurlijk wil ik ook graag mijn vrienden bedanken voor jullie steun en belangstelling, maar 
vooral ook voor de (luchtige) ontspanning gedurende de afgelopen vier jaar. Sam en Chris, 
onze dagen en avondjes gevuld met verhitte discussies over vanalles en nog wat, heerlijke 
muziek van Vet-Relaxte-Deephouse tot Maasjes-finest en intensieve spellen waren voor mij 
altijd ‘five-out-of-five’! Ook wil ik jullie ontzettend bedanken voor alle momenten waar jullie 





een totaal andere invalshoek kwamen. Hoewel het lijkt dat we in de toekomst een andere 
aanpak moeten vinden voor onze chillsessies, hoop ik wel dat we deze avondjes gewoon door 
kunnen zetten. Ik wil daarnaast natuurlijk ook de ‘Bison Boys’ bedanken. Jullie wisten vaak 
mijn gedachten te verzetten als het even (te) druk werd of als er belangrijke keuzes gemaakt 
moesten worden. Hopelijk kunnen we binnenkort weer met zijn allen bij elkaar komen.
Frits, als ware epidemiologiehotline was jij altijd bereid om even te sparren over nieuwe 
ideeën en toffe analyses, maar ook over dingen zoals de beste wetenschappelijke-SPAM 
mails van de week of de slechtste epi grappen. Ik vraag me nog geregeld af hoe het bij jou 
in het Japanse ruimteprogramma verlopen is. Helaas is onze vriendschap nog steeds niet 
in een co-auteurschap vastgelegd, maar wat niet is, kan nog komen. De toekomst is soms 
onzekerder dan het breedste betrouwbaarheidsinterval.
Stella en Daan, samen hebben we GW en de HSRM doorlopen. Als ik de goudgele tijden bij 
M.S.V. Santé vergelijk met de koffiebruine tijden van nu dan kom ik tot de pijnlijke realisatie 
dat we toch echt wel degelijk geworden zijn. Met alle life-events die er op het moment nog 
aan zitten te komen zal dat alleen nog maar erger worden. Tsja, het is nog altijd flink wennen 
om mijn eigen agenda bij te moeten houden, want volgens mij ben ik meestal de bottleneck 
bij het plannen van onze avondjes! Ik zal alvast wat vrije avondjes inplannen!
(Schoon)familie, bedankt dat jullie altijd vol interesse naar mijn verhalen luisterden. Ook al 
waren de verhalen en onderwerpen jullie vaak wereldvreemd, toch kon ik rekenen op jullie 
ongebreidelde aandacht. Als ik er even doorheen zat of als het even tegenzat kon ik ook altijd 
op jullie geruststelling en steun rekenen. Als ik boos was, waren jullie boos mét mij, als ik blij 
was, vierden jullie het met me mee, terecht of onterecht, no questions asked. Dank hiervoor, 
jullie weten maar half wat het voor mij betekent.
Pap en Mam, jullie hebben mij altijd geleerd dat ik mijn dromen na moet jagen, zolang ik 
maar gelukkig ben. Of dat nu betekent dat ik putjesschepper, minister president of dan toch 
epidemioloog wil worden, jullie staan onvoorwaardelijk achter mij. Ook zorgen jullie er 
altijd voor dat ik in het weekend de mogelijkheid heb om mijn hoofd even helemaal leeg te 
maken in het zand van Budel. Helaas betekende dit vaak dat jullie zelf in de kou stonden te 
vernikkelen. Sas, Hans en Luka, wat hebben jullie het goed voor elkaar. Hoewel mijn werk 
vaak maar een vreemde wereld is voor jullie, luisterden jullie altijd naar mijn verhalen als 
we met zijn allen thuis waren en stelden jullie altijd vragen uit oprechte interesse, bedankt. 
Natuurlijk hoop ik dat Luka later, mogelijk door een klein beetje stimulans van Ome Jeroen, 
een succesvol kernfysicus wordt.
Lieve Minke, Baas, Miep, als het in mijn hoofd even te druk wordt dan ben jij er altijd om 
mij er weer uit te halen. Met jouw zachte karakter, inlevingsgevoel en zorgzaamheid kan ik 
me dan ook geen betere vriendin wensen. Met plezier denk ik terug aan al onze avondjes 
rustig op de bank of lachend/schreeuwend (afhankelijk van wie er wint) tijdens al onze 
bordspelletjes. Samen met jou voelt echt als samen. Ik kan dan ook niet wachten om te zien 
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